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ABSTRACT 
 
 
Constitutive phosphorylation of protein kinase B (AKT) is a common feature of prostate 
cancer caused by genetic alteration in phosphoinositide-3-kinase (PI3K) or the 
phosphatase and tensin homolog (PTEN) gene and is associated with poor prognosis. 
Suppression of the AKT signalling pathway in cancer cells carrying genetic alterations in 
PI3K or PTEN has proven to be a challenge. This is due to several factors such as 
existence of a negative feedback loop on AKT, compensation from other oncogenic 
pathways including extracellular signal-regulated kinase (ERK) and potential involvement  
by the androgen receptor (AR) to evade androgen dependence.   
 
Understanding and identifying novel therapeutic targets in prostate cancer may assist in the 
development of strategies to treat prostate cancers with aberrant AKT activation. It has 
been shown that cytosolic phospholipase A2α (cPLA2α) is important for the proliferation 
of PTEN-null prostate cancer cells. cPLA2α is responsible for production of arachidonic 
acid (AA), the precursor of eicosanoids, which can stimulate cell proliferation. The 
mechanisms of how cPLA2α action affects proliferation of prostate cancer cells is unclear. 
To investigate this mechanism, this thesis aims to determine the role of cPLA2α in AKT, 
ERK and AR signaling in PTEN-null/mutated prostate cancer cells. 
 
Chapter 3 describes the effect of overexpression of cPLA2α in a prostate cancer cell line 
LNCaP, with PTEN mutation, on AKT, ERK and AR activation and/or expression. Under 
a tetracycline-inducible expression system, cPLA2α overexpression, coupled with 
ix 
 
increased activity, led to an increase in phosphorylation of AKT. Phosphorylation of 
GSK3β, a target of AKT, and cyclin D1 levels were also increased. However, no 
significant increase was observed for ERK and AR. cPLA2α overexpression and activation 
did not cause  an increase in cell proliferation.  
 
In Chapter 4, the importance of endogenous cPLA2α expression and activation in PTEN-
null prostate cancer cells were examined using siRNA. cPLA2α silencing decreased pAKT, 
pGSK3β and cyclin D1 levels in both PC-3 (PTEN deletion) and LNCaP cells. 
Additionally, silencing of cPLA2α decreased pERK and AR protein levels while total AKT 
and ERK were unchanged. The inhibitory effect of cPLA2α silencing on pAKT, pERK and 
AR were enhanced under epidermal growth factor (EGF)-stimulated conditions. In terms 
of cell proliferation, cPLA2α silencing significantly reduced proliferation of PC-3 and 
LNCaP cells compared with control. The population of G2M cells in siRNA-treated cells 
was significantly decreased while G0/G1populations increased. The effect of cPLA2α on 
these proliferative pathways may be through an EGF receptor, which may activate 
PI3K/AKT and ERK.   
 
In Chapter 5, I examined the role of AA and its metabolites in mediating  cPLA2α action 
on AKT, ERK and AR. The inhibitory effect of cPLA2α siRNA on pAKT and AR protein 
levels was reduced by the addition of AA, which can increase PC-3 and LNCaP cell 
proliferation. AA alone can increase pAKT, pERK and AR level in both cell lines. 
Analysis of hydroxyeicosatetraenoic (HETE) levels following AA addition showed a 
prominent increase in 5-HETE in PC-3 and LNCaP cells. Inhibition of 5-HETE synthesis 
x 
 
abrogated the stimulatory effect of AA on pAKT, pERK and AR levels. This suggests that 
cPLA2α action on AKT, ERK and AR is likely through AA and 5-HETE. 
 
In summary, the studies presented in this thesis demonstrate an important role for cPLA2α 
in sustaining AKT, ERK and AR signaling in PTEN-null/mutated prostate cancer cells and 
provide a potential molecular target for treating prostate cancer with constitutive 
phosphorylation of AKT. 
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1.1 Introduction to prostate cancer (PC) 
PC is one of the most common cancers. The incidence of PC varies 50-fold world-wide (1) 
and is most common in Western countries and least common in South-east Asia (2). In 
Western countries it is the second most commonly diagnosed cancer – after skin cancer – and 
in terms of cancer-related deaths, exceeded only by lung cancer (3; 4). In recent years, PC 
mortality rates have declined in many developed countries, including Australia (5), possibly 
due to the prevalence of screening assays such as prostate-specific antigen (PSA) testing (5; 
6). Presently in Australia, there are about 20,000 new incidences and 3,300 mortalities from 
PC per year. 
 
1.1.1 Prostate anatomy and pathology 
The prostate gland is the size and shape of a walnut and consists of both glandular and 
muscular tissues (7). Located under the bladder and in front of the rectum, the prostate gland 
surrounds the urethra and the two ejaculatory ducts. It consists of a capsule and numerous 
partitions. The main function of the prostate is to store and secrete a fluid which nourishes 
and protects sperms, and carries them during the male orgasm. Prostate fluid constitutes 10–
30% of the volume of seminal fluid (8). 
 
The prostate gland has four distinct glandular zones: peripheral zone; central zone; transition 
zone; and anterior fibromuscular zone (9). The peripheral zone surrounds the anterior urethra 
and is the origin of 64% of prostate cancers; the central zone surrounds the ejaculatory ducts 
and is responsible for about 3% of prostate cancers; the transition zone surrounds the 
proximal urethra and is where approximately 34% of prostate cancers originate (10). The 
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anterior fibromuscular zone does not contain epithelial structures, thus it is not affected by 
adenocarcinoma (10).  
 
1.2 Phosphoinositide-3-kinase (PI3K) / protein kinase B (AKT) / phosphatase and tensin 
homolog (PTEN) pathway 
1.2.1 Overview 
The phosphoinositide-3-kinase / protein kinase B (PI3K/AKT) pathway is one of the major 
signalling pathways, regulating diverse cellular processes (11). It is highly conserved in 
eukaryotes and its activation is tightly controlled via a multistep process (12). PI3K/AKT 
kinases themselves act as major switches conveying signals from transmembrane receptor 
tyrosine kinases (RTKs), which are activated by binding of extracellular ligands such as 
growth factors, hormones and insulin (11). 
 
PI3K is a lipid-modifying enzyme that catalyses conversion of phosphatidylinoistol-4,5-
biphosphate (PIP2) into -3,4,5-triphosphate (PIP3) at the cell membrane (11). As the extra 
phosphate is added at the ‘3’ position in the ring, it is named PI3-kinase (13). PIP3, once 
produced, acts as a docking site for activation of AKT by other phosphoinositide-dependent 
kinases (PDKs) (14).  
 
The AKT kinase phosphorylates a wide range of downstream targets, leading to increased 
proliferation, survival, and cell size. AKT also influences the cellular response to nutrient 
availability, intermediary metabolism, angiogenesis and metastasis (14).  
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1.2.2 Mitogenic signals for PI3K activation 
Activation of PI3K is initiated by extracellular stimuli binding to RTK. These extracellular 
stimuli include growth-related factors (such as epidermal growth factor (EGF); platelet-
derived growth factor (PDGF); vascular endothelial growth factor (VEGF) or metabolism-
related factors such as insulin and insulin-like growth factor (IGF) (13). Ligand binding to the 
RTK monomer leads to receptor dimerisation. The dimerisation allows for the cytoplasmic 
portion of the receptor to trans-phosphorylate a tyrosine residue on its partner (15). This 
activated form of RTK is then able to activate PI3K directly or through recruitment of 
adaptor molecules, such as insulin receptor substrate protein (IRS) or Grb-2 associated binder  
proteins (16). 
 
1.2.3 Activation of PI3K, PIP3 and AKT and dephosphorylation 
PI3K is a heterodimeric protein with two subunits: p85 (regulatory subunit) and p110 
(catalytic subunit). Several isoforms of both subunits exit, although more for p110 than p85 
(11). The p85 subunit is a regulatory element that inhibits and stabilises the p110 subunit. It 
contains a Src-Homology 2 (SH2) domain, which has affinity to RTK to bring PI3K into 
contact (17). Phosphorylation at tyrosine (Tyr) and threonine (Thr) residues of the p85 
subunit (18; 19) leads to a conformational change and thereby releases the inhibitory effect 
on the p110 subunit. The catalytic p110 subunit then turns PIP2 into PIP3 (20). The PIP3 
serves as a docking site for AKT kinase to stay at the membrane through binding to its 
pleckstrin homology (PH) domain (12). This ‘docking’ method allows AKT to be brought in 
close proximity to other regulatory molecules. 
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Activation of AKT is a multistep process (21), and is important for its wide range of 
downstream targets. The complexity of its activation and deactivation is shown in the number 
of kinases and phosphatases involved in conveying its signal by phosphorylation and 
dephosphorylation. RTK and PI3K activation create a build-up of PIP3. Attraction of AKT to 
the increased PIP3 allows for a subsequent two-step phosphorylation process at the membrane 
region. The first phosphorylation (at Thr
308
) by PDK1 (also with PH domain) (22) induces a 
conformational change to its structure (23) and increases activity (24). This change allows a 
second phosphorylation of AKT (Ser
473
) by mTOR Complex 2 (mTORC2) (23). Thus, AKT 
is fully activated and can depart from the membrane to phosphorylate its target proteins. 
 
Phosphorylation on both Thr
308
 and Ser
473
 brings a synergistic boost to AKT function and 
under this state AKT activity is the highest (14; 25). Mutational studies using 308D/473D 
AKT demonstrated an activity increase up to 40-fold compared with unstimulated wildtype 
(24). Both phosphorylations are required for maximum output, although single 
phosphorylation at either site still offers partial improvement to AKT activity and can exist 
independently (24). In addition, the two phosphorylation sites have their distinct purposes – 
Thr
308
 is essential for functioning of the catalytic domain and formation of the active site (26); 
and Ser
473
 broadens substrate scope to include FOXO transcription factors and proline-rich 
AKT substrate (PRAS40), which are not phosphorylated in the absence of Ser
473
 
phosphorylation (27). Interestingly, one study demonstrated that only phosphorylation at 
Thr
308
 (by PDK1) is necessary for full activation and that subsequent phosphorylation at 
Ser
473
 can be achieved by AKT itself (28).  
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Although it is unclear which site is more important for AKT function, Ser
473
 has been studied 
pathologically. Ser
473
 phosphorylation is involved in a negative feedback loop due to mTOR 
inhibition in cancer cells (29). This loop renders inhibition by rapamycin somewhat 
ineffective (explained in more detail below). Further, about 45% of PC cases have increased 
levels of pAKT at Ser
473
, which correlates positively with disease severity (14; 30-32).  
 
1.2.4 Suppression of signalling by PTEN, PP2A and PHLPP 
AKT activation is tightly controlled by counteraction of PTEN (33), protein phosphatase 2A 
(PP2A) (34-36), and pleckstrin homology domain leucine-rich repeat protein phosphatase 
(PHLPP) (37). Being a lipid phosphatase, PTEN is expressed ubiquitously to catalyse the 
hydrolysis of PIP3 back to PIP2 (16). This process counters PI3K action by reducing the 
source of AKT membrane binding and activation. PTEN is the cell’s most effective method 
of turning off AKT while also playing some part in the role of membrane remodelling (38; 
39). 
 
Apart from PTEN, AKT activation may also be controlled by phosphatases. PP2A is found to 
dephosphorylate AKT at Thr
308
 (40). The B55α regulatory subunit of PP2A preferentially 
targets the PP2A holoenzyme to dephosphorylate AKT at Thr
308
 rather than Ser
473
 both in 
cells and in the cell-free system (41). This selective targeting can be inhibited by IEX-1, an 
early gene product with proliferative and survival activities, in an ERK-dependent manner 
(42). Two other phosphatases, PHLPP1 and PHLPP2, selectively dephosphorylate AKT at 
Ser
473
 (37; 43). PHLPP also contains a PH domain, allowing it to migrate to a membrane 
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region to find substrates. Both PP2A and PHLPP1/2 are effective at reducing AKT signalling 
and cell proliferation (37; 41; 43). 
 
The PI3K-AKT Pathway
 
 
Figure 1.1 PI3K/AKT signalling pathway overview. Simplified diagram showing methods of AKT 
phosphorylation and dephosphorylation. Illustration prepared by Soma Vignarajan, a fellow PhD 
student. 
 
1.2.5 Downstream signalling by AKT 
The targets of AKT signalling include a number of cellular molecules that cover a large 
spectrum of functions, ranging from control of cell proliferation and survival to modulation 
of intermediary metabolism and angiogenesis. The complete list of AKT targets is unknown 
but most substrates share the consensus sequence for AKT phosphorylation, RXRXXS/T (14). 
The direct targets of AKT that will affect a single or multiple pathways are (11; 14; 40): 
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- GSK3β (for cyclin D1 phosphorylation and degradation; AKT inactively 
phosphorylates GSK3β to increase the cell cycle) 
- AS160 (for increased GLUT4 translocation and glucose uptake)  
- PRAS40 (required for mTORC1 formation, increases protein translation and 
enhance cell growth)  
- BAD (for reduced Apoptosis by preventing dimerisation with Bcl-XL/Bcl-2) 
- MDM2 (for inhibition of p53 in DNA repair) 
 
The major effects of AKT signalling pass down to increase cell proliferation, cell cycle, 
protein synthesis and survival and reduce apoptosis. 
 
1.2.5.1 Pro-proliferation signals 
AKT is able to phosphorylate multiple substrates to increase proliferation. Phosphorylation of 
GSK3β by AKT prevents the degradation of cyclin D1, which is critical for complexing with 
CDK4 and CDK6 during the cell cycle G1/S transition (44). Phosphorylation by AKT of p21 
and p27 on a site close to their nuclear localisation signal prevents these cell cycle inhibitors 
from entering the nucleus (45). Phosphorylated p27 binds to 14.3.3 scaffold protein and is 
retained in the cytoplasm (46). 
 
1.2.5.2 Increased protein synthesis 
AKT increases protein synthesis by phosphorylation of two substrates: tuberous sclerosis 
complex 1 and 2 (TSC1/2) and proline-rich AKT substrate 1 (PRAS40). Phosphorylation of 
TSC2 disrupts its interaction with TSC1 and destabilises the inhibition of the protein Ras 
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homolog enriched in brain (Rheb) (47; 48). Accumulation of free Rheb leads to activation of 
the mammalian target of rapamycin mTOR complex 1 (mTORC1). Further, AKT 
phosphorylates PRAS40, a component of mTORC1, to relieve the PRAS40 inhibitory effect 
on mTORC1 (16). Activated mTORC1 is able to phosphorylate: (i) p70 S6 kinase, which 
targets S6 ribosomal protein (49); and (ii) eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP), the inhibitory binding partner of eIF4E (50). Phosphorylation of both 
these molecules result in increased protein synthesis (51). 
 
1.2.5.3 GSK3β and metabolism 
AKT affects cell metabolism by increasing glycogen synthesis and cellular glucose uptake. 
GSK3β, the direct target of AKT, is involved in cell metabolism apart from the cell cycle. 
Inhibition of GSK3β by AKT leads to increased glycogen synthesis (52). Secondly, AKT has 
been found to mediate insulin-stimulated glucose transport: AKT phosphorylation of GLUT1 
and GLUT4 leads to increased translocation of glucose through the membrane (53). 
Additionally, AKT phosphorylates the AKT substrate of 160 kDa (AS160) in adipocytes to 
aid the GLUT translocation process (54). Thus, the rate of glucose uptake is increased.  
 
1.2.5.4 Survival signals 
AKT signalling prevents apoptosis and increases survival signal. AKT phosphorylates BAD, 
the pro-apoptotic protein from the Bcl-2 family. Phosphorylated BAD binds to protein 14-3-3 
and is prevented from heterodimerising with Bcl-XL/Bcl-2 to initiate apoptosis (55; 56). 
AKT also prevents apoptosis by inactivation phosphorylation on pro-caspase 9 (57) and 
activation phosphorylation on PED/PEA15, a cytosolic inhibitor of caspase-3 (58). Further, 
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AKT phosphorylation of p21 prevents its nuclear entry, thus abrogating its apoptosis 
signalling through apoptosis signal-regulating kinase 1 (59). In parallel, AKT could also 
activate NF-κB via phosphorylation of IκB kinase, thus resulting in transcription of pro-
survival genes (14; 60). Finally, AKT can also prevent p53-mediated apoptosis by mouse 
double minute 2 homolog (MDM2) phosphorylation, which then complexes with p53 for 
ubiquination and degradation (61).  
 
1.2.6 The PI3K/AKT pathway in PC 
The PI3K/AKT pathway is one of the most prevalent pathways deregulated in cancer, 
including PC (11; 20). Due to the pro-proliferative nature of PI3K/AKT signaling, mutations 
in this pathway are more likely to result in cancer. Studies have shown over 43% of prostate 
cancers have either a gain of function mutation in PI3K (the oncogene) or a loss of function 
mutation in PTEN (tumour suppressor) (11). Thus, effective inhibition of the PI3K/AKT 
pathway is important in therapeutic treatment of PC.  
 
Many epidemiological studies have linked cancer and metabolic disorders such as diabetes 
(62-64). Cancer cells are often glucose-dependent due to increased need for cellular building 
blocks. Hence, increases in insulin and IGF favours tumour growth by stimulating 
proliferation and survival (e.g., via insulin receptors and insulin receptor substrates) (65). 
However, constitutive activation of PI3K/AKT no longer requires insulin regulation and thus 
renders cancer cells resistant to dietary restrictions (66) and cells proceed to proliferate under 
high or low nutrient conditions. Therefore, PI3K plays an important role in balancing 
metabolism and cell proliferation and the underpins both metabolic disorders and cancer (65). 
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1.2.7 Increased activation of PI3K 
Deregulation of the PI3K/AKT pathway can result from mutations in PI3K, making PI3K 
hyperactive. Mutations in PIK3CA, the gene for the p110α subunit is most common relative 
to other PI3K subunits (67). Somatic mutations on Glu
542
, Glu
545
 and His
1047
 have been found 
to be the most common in cancer (11; 67). These mutations, which account for up to 80% of 
PIK3CA mutations (68), increase PI3K activity and lead to growth factor-independent 
activation of AKT (67; 69-71). The Glu
545Lys mutation, for example, disrupts the 
inhibitory interaction with the p85-SH2 domain, and increases kinase activity of the p110 
subunit (72). Constitutive activation of PI3K creates an endless supply of PIP3, the docking 
molecule for AKT before its activation. Thus, there are more PIP3 molecules present and 
AKT signalling is increased. 
 
1.2.8 Loss of PTEN 
Mutations in PTEN are far more common than in PI3K for PC. Inherited PTEN mutations 
cause cancer predisposition and are associated with a wide and diverse clinical spectrum of 
disorders, collectively known as PTEN hamartoma tumour syndromes, which are 
characterised by the development of benign tumours (73). PC cells with genetic mutations 
resulting in a frameshift (e.g., LNCaP) (74) or gene deletion (PC-3) (75) render the PTEN 
protein inactive or absent. Consequently, any build-up of PIP3 cannot be converted back to 
PIP2, leading to constitutive AKT activation. Further, the location of PTEN is at chromosome 
10q23.3, a region that frequently shows loss of heterozygosity (LOH). The rate of LOH for 
PTEN is significantly high for PC with some studies showing as high as 49% (76-78). As 
PTEN is haplo-insufficient (79), losing a single copy of PTEN is often enough to result in 
cancer (79) as it provides a high selective advantage.  
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Other mechanisms of PTEN inactivation exist. For example, PTEN may be inactivated by 
promoter mutations or methylation and silencing of the PTEN promoter (80-82). Post-
translational PTEN phosphorylation (by GSK3β) on its C-terminal tail, may stabilise PTEN 
but reduce its activity towards PIP3 (80). In addition, reactive oxygen species (ROS) from 
arachidonic acid (AA) metabolism is also known to inactivate PTEN (83). Reactive oxygen 
species (ROS) is found to oxidise C124 of the PTEN catalytic domain and inactivate it by 
creating an intramolecular disulfide bond (84). Further, ROS is a by-product of AA catalysis 
by the cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, which are overexpressed in 
inflammation and during multistage tumour progression (85). This process is greatly 
enhanced in PC as the rate of eicosanoid synthesis in tumours is much higher than benign 
tissues (86). Taken together, PTEN inactivation in PC is common due to a variety of 
mechanisms.  
 
1.2.9 Methods of PI3K/AKT inhibition 
It has been suggested that tumours with increased AKT activation (e.g., from PIK3CA 
mutations) will indeed be addicted to PI3K as the primary source of growth, proliferation and 
survival signalling. Accordingly, new methods for PI3K/AKT inhibition are constantly being 
developed and tested (87). Key signalling molecules such as RTK, P110α or mammalian 
target of rapamycin (mTOR) are frequently targeted. RTK inhibitors such as Tarceva 
(epidermal growth factor receptor (EGFR) inhibitor) and Imatinib (PDGF inhibitor), achieve 
their antitumor effects at least in part by shutting off upstream signalling to the PI3K/AKT 
pathway (14). However, the efficacy of upstream inhibitors could be hampered by activating 
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mutations or gene amplifications in downstream signalling components or by the loss of 
PTEN. 
 
On the level of PI3K, inhibitors such as LY2940002 and wortmannin have been used 
extensively in research and have shown antitumour activities in PTEN-null or PI3K-
overexpressing cells (88). Since PI3K is highly pleiotropic, administration of PI3K inhibitors 
would be associated with high toxicities. In addition, these drugs also exhibit off-target 
effects such as inhibition of PI3K-related kinases such as ATM and ATR (essential for DNA 
repair) (89).  
 
Drugs for downstream signalling targets are also available. For example, rapamycin, the 
inhibitor of mTOR, has been considered for cancer treatment (90; 91). Rapamycin is effective 
in mTORC1 inhibition and increases the sensitivity of PTEN-deficient glioblastoma cell lines 
to erlotinib, a RTK inhibitor, to induce growth arrest (92). However, the therapeutic effect of 
rapamycin is diminished over time due to the abolishment of a negative feedback loop as 
described in the next section. 
 
1.2.10 Resistance to insulin regulation and negative feedback loop 
Although the PI3K/AKT pathway presents obvious targets for therapeutic intervention, the 
complexities in signalling regulation pose substantial challenges in therapeutic design (16). 
While inhibition of downstream effectors of AKT (e.g., rapamycin or RAD001) may seem 
effective, the process is complicated by a negative feedback loop on upstream AKT (93). 
While mTORC1 is inactive, its target S6 kinase is inactivated. S6 kinase serves as a negative 
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regulator of PI3K through phosphorylation and inhibition of IRS1 (94). IRS1 is recruited by 
RTK to activate PI3K (16). In this instance, mTOR inhibition results in increased PI3K 
signalling and AKT activation. AKT controls a host of substrates independent of mTOR 
signalling that may contribute strongly to oncogenesis. Thus, growth inhibition is 
compromised.  
 
1.2.11 Compensation mechanism in other signalling pathways 
Existing pathways inside the cell sometimes overlap or interact with each other. This 
horizontal effect between pathways is apparent when the inhibition of one pathway leads to 
upregulation of other pro-proliferative pathways. There is accumulating evidence that the 
Ras/Raf/ mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase 
(ERK) and PI3K/AKT pathways may cooperate to promote the survival of transformed cells 
and resistance to therapy (95-97). One study reported that tumour cell biopsies obtained from 
patients treated with the mTOR inhibitor RAD001 displayed activation of ERK (98). Similar 
events were observed in a breast cancer cell model (97; 98). Others have demonstrated that, 
in a PTEN-deficient transgenic PC model, co-inhibition of ERK1/2 (by PD0325190) and 
mTOR (by rapamycin) had synergistic effects in vitro and in vivo (99). This phenomenon was 
proposed to be due to a S6 kinase /PI3K/AKT/mTOR-dependent pathway (97; 100). 
Exposure of cancer cells to mTORC1 inhibition results in release of a S6 kinase-related 
‘brake’ on Ras (and also on PI3K, from a negative feedback loop) (98). Inhibition of this 
ERK compensation in addition to mTOR shows an increase in apoptosis in animal studies, 
although this was not clearly evident in PC cells (98). 
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Interactions between PI3K/AKT and other pathways exist in PC. Androgen receptor (AR) is 
known to be regulated by PTEN in prostate cells (101). The interaction between PTEN and 
AR inhibits the AR nuclear translocation and promotes AR protein degradation that results in 
the suppression of AR transactivation and induction of apoptosis (101). As PTEN is often 
absent in PC and that AR is often overexpressed, this mechanism of control is lost. This is an 
example where deregulation in PI3K/AKT upregulats growth signalling in another pathway 
in PC.   
 
1.3 Ras/Raf/MEK/ERK pathway 
1.3.1 Overview 
The Ras/Raf/MEK/ERK pathway is a part of the of MAPK pathway and is common amongst 
all mammals (102; 103). ERK, one of four major groups of MAPKs (ERKs, p38MAPKs, c-
Jun NH2-terminal kinases and ERK5 or BMK) (103; 104), has been established as a major 
participant in the regulation of cell cycle progression, apoptosis and differentiation (105), but 
when improperly activated, it contributes to malignant transformation. The 
Ras/Raf/MEK/ERK pathway is regulated by multiple members of the kinase, transcription 
factor, apoptotic regulator and caspase activator families, which can be activated or 
inactivated by protein phosphorylation (95). Abnormal activation of this pathway occurs in 
human cancer due to mutations at upstream membrane receptors, Ras and Raf, as well as 
genes in other pathways (e.g., PI3K/AKT), which can influence Raf activity. Nearly 50% of 
human cancers have alterations in the Ras/Raf/MEK/ERK pathway or in components of Ras 
effector pathways that may lead to increased ERK activity (106). The pathway also 
influences chemotherapeutic drug resistance as ectopic activation of Raf induces drug 
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resistance in breast cancer cells (95). Due to the above reasons, the Ras/Raf/MEK/ERK 
pathway is an important pathway for therapeutic targeting in cancer treatment.  
 
Figure 1.2 Flow chart of the Ras/Raf/MEK/ERK pathway (107). 
 
1.3.2 Mechanism of EGFR, Ras, Raf, MEK and ERK activation 
The Ras/Raf/MEK/ERK signalling cascade is activated by a wide variety of receptors 
involved in growth and differentiation including RTK, G-protein coupled receptors (GPCR), 
integrin and ion channels. Specific components of the cascade vary greatly among different 
stimuli, but the architecture of the pathway usually includes a set of adaptor proteins linking 
the receptor to a guanine nucleotide exchange factor (GEF) and transducing the signal to the 
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small GTP-binding Ras. For instance (in Figure 1.2), EGFR, activated by EGF binding, 
recruits the adaptor growth factor receptor bound protein-2 (Grb2). Grb2 binds to EGFR 
through its SH2 domain, which binds to the phosphotyrosine residues of the activated 
receptor (108). Grb2 then recruits the protein SOS (a GEF) through its double SH3 domain 
(108). The docking of the Grb2-SOS complex on EGFR activates SOS and allows it to 
catalyse the removal of GDP on Ras with a GTP (109). Ras-GTP is the active form of Ras 
and may bind to Raf to activate Raf’s kinase activity (110). Activated RAF kinase 
phosphorylates and activates MEK (MEK1 and MEK2), which in turn phosphorylates and 
activates ERK (ERK1 and ERK2) (95).  
 
1.3.3 Downstream signalling by ERK 
ERK1 and ERK2 are 44 and 42 kDa Ser/Thr kinases (as are Raf and MEK) and are positively 
regulated by MEK1 and MEK2 (95). Activated ERK has over a hundred known targets (95). 
ERK can enter the nucleus and directly phosphorylate many transcription factors, including 
Ets-1, c-Jun and c-Myc (95). ERK can also activate transcription factors indirectly. For 
example, ERK phosphorylates and activates the 90 kDa ribosomal S6 kinase (p90Rsk), which 
then leads to the activation of the transcription factor cAMP response element-binding 
protein (105); ERK can also activate NF-κB through phosphorylation of IκB kinase (111; 
112). By altering the levels and activities of transcription factors, ERK leads to altered 
transcription of genes that are important for the cell cycle.  
 
18 
 
1.3.4 Deregulation of Ras/Raf/MEK/ERK signalling 
As mentioned previously, mutations in the upstream receptor, Ras or Raf, are frequent causes 
of increased Ras/Raf/MEK/ERK signalling. Gene amplification of Ras and activating 
mutations can be as high as 30% of some cancers (113; 114). Point mutations on Ras may 
occur in codons 12, 13, 59 and 61 (105). These mutations result in the constitutive activation 
of the protein so it no longer requires a ligand for activation. Other mutations may activate 
Ras by negating the GTPase activity stimulated by the regulatory partner GTPase-activating 
protein (GAP). This increases the half-life of Ras-GTP (115).  
 
Next, mutations in B-Raf, an isoform of Raf, have been found in about 7% of cancers (116; 
117). Mutations such as Val
600Glu (the most common) (116) results in hyperactive B-Raf, 
as if phosphorylated, and locks it in the active configuration (118). In this setting, B-Raf 
targeting of MEK is increased, leading to increased signalling.  
 
1.3.5 Ras/Raf/MEK/ERK pathway in prostate cancer 
Increased expression/activation of the Ras/Raf/MEK/ERK pathway has been associated with 
advanced PC, hormonal independence and a poor prognosis (119-123). Additionally, 
Ras/Raf/MEK/ERK signalling is also implicated in PC progression by making AR 
hypersensitive to androgens (121). 
 
Prostate cancers commonly have PI3K/AKT activation and there have been evidences of 
cross-talk or shared jurisdiction between PI3K/AKT and the Ras/Raf/MEK/ERK pathway. 
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1. The two pathways may control similar downstream targets. For example, activated 
AKT phosphorylate caspase 9 and BAD prevent apoptosis, but ERK may also 
achieve this through direct phosphorylation (on caspase 9) (124) or through its 
downstream effector p90Rsk (on BAD) (57; 95; 125). Thus, the two pathways 
share a common survival mechanism.  
2. AKT can also enhance MDM2-mediated ubiquitination of p53, which interacts 
with Ras/Raf/MEK/ERK on two levels. On one hand, p53 upregulates expression 
of phosphatases such as MKP1, PAC1 and DUSP5 (126-129) and these negatively 
regulate ERK and other MAPKs (130) in response to different stressful stimuli to 
lead to cell cycle arrest and apoptosis. On the other hand, induced expressions of 
p53 lead to activation of MEK and ERK, but not p38 (131). In this setting, p53 
upregulates heparin-binding epidermal growth factor-like growth factor (HB-
EGF), which (through EGFR) leads to both ERK/MAPK and PI3K/AKT 
activation to prevent cells from oxidative damage-induced apoptosis (130). 
Further, this p53-MAPK signalling can even activate cyclooxygenase-2 (COX2) 
for increased cell survival (132).  
3. AKT may downregulate Ras/Raf/MEK/ERK signalling. Activated AKT mediates 
the inactivation of Raf, e.g., B-Raf (by AKT-related kinase SGK) or c-Raf, 
another type of Raf, by phosphorylation of Ser
259
 (95).  
 
The above mentioned bring some complexity to the cross-talk between the two pathways. 
However, the third point above is true in PTEN-null cell lines (LNCaP and PC-3), as they 
express low, but detectable, levels of activated ERK (95; 133; 134). Despite this, there exists 
a compensation mechanism between the two pathways. Indeed, down-regulation of 
PI3K/AKT would remove the negative regulation of Raf and p53. Additionally, inhibition of 
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PI3K/AKT (such as rapamycin) leads to activation of upstream AKT and Ras through S6 
Kinase and IRS1 (97; 100). Thus, this horizontal compensation mechanism may be the key to 
ERK activation (during PI3K/AKT inhibition) to increase survival. Further, recent evidence 
has highlighted that mTOR can also be activated by Ras/Raf/MEK/ERK (135; 136) and this 
solidifies the notion of cross-regulation. Taken together, these offer rationale for co-targeting 
of both signalling pathways for treatment of PC.  
 
1.4 Androgen receptor pathway 
1.4.1 Overview  
The AR pathway mediates a wide range of developmental and physiological responses 
important in male sexual differentiation, maintenance of spermatogenesis and male hormones 
(137). The pathway initiates when steroidal androgens, testosterone or its metabolite 5-alpha-
dihydrotestosterone (DHT) binds to AR (138; 139), a nuclear receptor (140) normally 
sequestered into the cytoplasm (141). Upon activation, AR translocates from the cytoplasm to 
the nucleus and regulates gene expression of androgen-regulated genes (140).  
 
1.4.2 Structure and function of androgen receptor 
The AR protein is composed of four functional domains: (i) an N-terminus regulatory domain; 
(ii) a DNA-binding domain (DBD); (iii) a hinge region; and (iv) a ligand-binding domain 
(LBD) (142). Each domain has a distinct role in the function and regulation of AR. The N-
terminus regulatory domain encodes transcriptional activation function and homopolymeric 
polyglutamine (CAG) and polyglycine (GCC) repeats (143). The DBD encodes two zinc 
fingers essential for androgen response element (ARE) recognition and the hinge region 
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contains a nuclear localisation signal that directs the AR into the nucleus (144). The LBD is 
responsible for conformational change and optimal transcriptional activation function (TAF-1) 
upon ligand binding (144).  
 
Prior to activation, the unbound AR in the cytoplasm is stabilised by forming a complex with 
heat-shock protein (HSP) 90 (142; 145). This complex is regulated by histone deacetylase 6 
(HDAC6), which deacetylases HSP90 for AR maturation (146; 147). Androgen binding 
induces AR dissociation from HSPs and causes AR dimerisation, phosphorylation and 
nuclear translocalisation. The activated AR then interacts with AREs to recruit co-regulators, 
forming of a preinitiation complex, and ultimately transcriptional activation of androgen-
regulated genes (148). 
 
 
Figure 1.3 AR activation in normal androgen-dependent prostate cancer and reactivation after 
androgen deprivation therapy. Modified from Figure 1 in (149). 
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1.4.3 Androgen receptor in prostate cancer 
AR signalling is able to increase expression of genes for cell cycle and proliferation and is 
required for PC growth and survival (142; 150-153). While localised cases of PC may be 
treated with prostatectomy and irradiation, once metastasised, androgen ablation therapy 
becomes the mainstay of treatment options (142). Such hormone therapies remove androgen 
signalling by surgical or medical castration (with leutenising hormone releasing hormone 
agonists and oral anti-androgen) (142). Castration induces apoptosis in the majority of PC 
cells, which translates clinically to improvement in cancer-related symptoms and lowering of 
AR-regulated genes, including prostate specific antigen (PSA).  
 
Although PC is initially androgen dependent, over time and/or during the course of treatment, 
it progresses into androgen-independent PC (AIPC), through a mix of molecular and cellular 
changes. Growth then becomes viable despite low serum testosterone levels and eventually 
these PC cells stop responding to hormone therapy. After this stage treatment options become 
limited to suboptimal chemotherapeutic measures, allowing limited lifespans (1–2 years) 
(142; 154). 
 
1.4.4 Increased androgen receptor activation 
Deregulation of the AR pathway leads to increased transcription, cell proliferation and 
prostate carcinogenesis (144; 150; 155). Increased AR signalling can result from mutations, 
changes to coactivators and corepressors of AR. Studies show up to 50% of prostate tumours 
have AR mutations, including those that are hormone naïve and AIPC (156-158). Mutations 
in AR coding sequence may lead to increased AR activity. Significant AR mutations found in 
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tumours include Thr
877Ser, Thr877Ala, His874Tyr, Val715Met, Leu701His, 
Thr
877Ala and Tyr741Cys (155; 156; 159-162). These mutations generally transform AR 
to become ‘super receptors’, which respond to a wider variety of agonists at lower 
concentrations. For example, the point-mutation Thr
877Ala in the AR gene of the hormone-
binding domain in LNCaP cell line and other tumour samples allows activation by 
progesterone, estradiol, cyproterone acetate and the anti-androgens, anandron, and 
hydroxyflutamide (163). Protein structural analysis shows some mutations in the ligand-
binding pocket codons 670–678, 701–730, and 874–910 (164; 165) loosen the ligand 
specificity while other mutations (e.g., in codon 874–910 (165)) change the interaction 
between various components of the AR transcriptional complex in favour of growth. 
 
1.4.5 Increase in prostate-specific antigen 
The gene kallikrein-3 is a target of AR and is one of the genes elevated under AR signalling 
(160; 166). The gene encodes PSA, a glycoprotein enzyme, which is secreted by the 
epithelial cells of the prostate gland. PSA is normally present in small quantities in serum of 
healthy men but often elevated in PC. Disruption of the prostate epithelium by inflammation 
or benign prostatic hyperplasia leads to diffusion of PSA into surrounding tissue, and causes 
elevated blood levels of PSA (167). PSA has been suggested as a marker for PC screening in 
the past (168) and although this method may be riddled with false positives it is still a useful 
method for PC risk-stratification and combinatorial screening (169; 170). 
 
PSA remains present in prostate cells after they become malignant and serum PSA levels may 
rise as PC cell numbers increase. A vast majority of men treated with androgen deprivation 
24 
 
therapy show reduced serum PSA, an evidence of improvement (149). However, as PC 
progresses to AIPC, AR signalling becomes reactivated and cells resume expression of AR-
regulated genes, which may include PSA (171-174).  
 
1.4.6 Progression to androgen independence by androgen receptor overexpression 
Following hormone therapy, prostate tumours undergo molecular or cellular changes to 
overcome androgen deprivation. AR protein is present in all stages of PC regardless of stage, 
grade or whether androgen-dependent or not (175). Thus, androgen independence often 
results from mutations leading to hyperactive AR or an increase in AR expression. 
 
The level of AR is an important factor in androgen independence. Studies suggest increased 
that AR expression allows a mechanism to utilise low levels of androgen, following 
castration and hormone ablation therapy (149; 176). Increased AR mRNA can be due to gene 
amplification and is reported in 25–30% of AIPC cases by several studies (171; 177-179). In 
addition, AIPC resumes the expression of multiple AR regulated genes (e.g., PSA), indicating 
reactivation of AR transcriptional activity (149). Importantly, studies using PC cell lines and 
xenografts similarly show that progression to AIPC is associated with high levels of AR and 
resumed expression of androgen-regulated genes (180-182). Moreover, AR down-regulation 
in cell lines at this AIPC stage (by siRNA or other methods) can suppress tumour growth, 
indicating that AR continues to provide critical functions (176; 182; 183). Thus, the level of 
AR is important for its signalling, particularly for AIPC, and should be considered in PC 
treatments. 
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1.5 Arachidonic acid pathway 
1.5.1 Overview 
AA is a member of the ω-6 poly-unsaturated fatty acids and is the precursor to downstream 
eicosanoids. As a long chain fatty acid, AA normally resides in the phospholipid pool of the 
bilipid membrane. Free AA is metabolised by COX and LOX enzymes to form eicosanoids, 
which primarily stimulate inflammatory response (184). In addition to inflammation, AA and 
its metabolites have been shown to affect a wide array of biological functions. In particular, 
its role in promoting cancer proliferation has been under increasing focus in recent decades 
(184-186). 
 
The majority of AA remains esterified in membrane phospholipids at the sn-2 position and 
can be released following phospholipase A2 (PLA2) cleavage in response to a number of 
stimuli such as cytokines, growth factors and hormones (187; 188). AA-containing 
phospholipid, when cleaved by PLA2 releases AA and lysophospholipid. Once released, free 
AA can be metabolised or reinserted into the membrane. In addition to release from 
glycerophospholipids, free AA can also be generated from degradation of 
arachidonoylethanolamide via enzymatic action [182]. 
 
Inflammatory eicosanoids influence several important biological processes in cancer 
progression, such as inflammation, cell proliferation and tumorigenesis (189; 190) including 
in PC (86; 191). Therefore, inhibition of the AA pathway has been an attractive target for 
chemotherapeutic manipulation in PC. 
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1.5.2 PLA2 enzymes 
Phospholipases are important for regulation of membrane phospholipids and the cellular 
processes initiated by their catalytic products, which include inflammation. PLA2 are a family 
of enzymes that recognises the sn-2 acyl bond of phospholipids and catalyses the hydrolysis 
of this bond to produce a free AA and a lysophospholipid (192; 193). PLA2 respond to 
increases in cytokines, growth factors and Ca
2+
 by migration to the membrane region and 
increase in activity. They are central to the maintenance and turnover of membrane 
phospholipids and have also been acknowledged for their pathological role in the 
inflammation pathway (194). 
 
PLA2 are a family of enzymes with over 20 members identified in mammals (195-197). The 
family can be divided into four classes on the basis of their amino acid sequence homology. 
Many forms of PLA2 are differentially expressed in a tissue-, species- and/or genotype-
specific manner (195; 198). 
 
1.5.3 Cytosolic phospholipase A2 alpha (cPLA2α) 
Of all the PLA2s, the cPLA2 is perhaps the most studied. Much research in the field has 
focused on cPLA2 because of its central role in the initiation of AA metabolism (199-201). 
cPLA2 cleaves at the sn-2 position of membrane glycerophospholipids. As a major source 
of AA release, cPLA2 preferentially targets AA-containing glycerophospholipids, which 
contain head groups of ethanolamine, serine, inositol and choline. Stimulation of cells with 
agents that mobilise intracellular calcium and/or promote the phosphorylation of cPLA2 
leads to: (i) translocation of the enzyme from the cytosol to the cell membrane, Golgi 
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apparatus, endoplasmic reticulum and perinuclear membranes where it may associate with the 
glycerol phospholipid to access AA; and (ii) a change in conformation due to 
phosphorylation, which gains increased phospholipid binding affinity and AA release (202; 
203). cPLA2 has attracted considerable attention as a potential therapeutic target for 
treatment of inflammation and cancer (134; 204). Although ubiquitously expressed, cPLA2 
knockout models exhibited a relatively normal phenotype. However, when an inflammation-
related pathological process is introduced to cPLA2 knockout animals, there is a difference 
between wildtype and cPLA2 knockouts (205). 
 
1.5.4 cPLA2α structure 
The cPLA2 coding region is located at chromosome 1q25 and is encoded by a 3.4 kb mRNA 
(849 amino acid peptide length). Its promoter region contains AP1, PEA3 and NF-kB coding 
sequence (206). cPLA2 is highly conserved, sharing over 95% amino acid identity between 
human and mouse. The homologues in chickens, zebra fish and xenopus share over 80% 
amino acid identity with human. The cPLA2 has an N-terminal C2 domain and a C-terminal 
catalytic domain linked by a short and flexible peptide (Figure 1.4). 
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Figure 1.4 cPLA2 structure in Rasmol. Ca2+ (red), C2 domain (yellow), catalytic domain (green) 
and a short and flexible peptide (purple). 
 
1.5.4.1 C2 domain   
Interactions between cPLA2 and membrane lipids occurs through the C2 domain, which 
consists of an eight-stranded antiparallel sandwich. Calcium binding to the C2 domain 
through Asp and Asn residues promotes association of hydrophobic residues with membrane 
phosphatidylcholine. This brings the catalytic subunit close to the membrane bilayer, 
allowing enzymatic activity to take place.  
 
1.5.4.2 Catalytic domain  
The cPLA2 active site is a strictly conserved DYAD composed of a serine (Ser
228
) and an 
aspartic acid (Asp
549
). A conserved Arginine (Arg
200
) is also required for activity. The 
Ser/Asp active site of cPLA2 lies in a deep funnel lined by hydrophobic residues, which 
confers the preference for AA-containing phospholipid (207). Changes in amino acid residues 
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in the funnel in other cPLA2s may account for decreased AA specificity and differences in 
sensitivity to some cPLA2 inhibitors.  
 
In addition to the C2 domain, cPLA2 also contains several conserved serine residues as 
phosphorylation sites for further regulation. Ser
505
 is the most studied and recognised site for 
phosphorylation, followed by Ser
515
 and Ser
727
. Although phosphorylation is not entirely 
necessary, each of these sites has been shown to augment cPLA2 activity to a different 
degree (208-210). Multiple kinases are responsible for phosphorylation of these sites, such as 
MAPK (Ser
505
) and MNK kinase (Ser
515
), which suggest differential regulation of cPLA2 
depending on the route of the signalling process (209; 210).  
 
1.5.5 cPLA2 biochemical and biological function 
cPLA2 produces free AA and lysophospholipids, contributes to the production of 
eicosanoids and platelet activating factors, and possesses lysophospholipase and transacylase 
activities (although these activities are relatively low compared to its primary AA-producing 
activity) (211).  
 
1.5.5.1 Production of AA, providing substrates for eicosanoid and platelet activating 
factor (PAF) production 
cPLA2 is the only PLA2 that displays a high preference for AA and has been deemed the 
rate-limiting step in eicosanoid synthesis (192). Free AA is rapidly oxidised by COX, LOX 
and P450-dependent epoxygenase to produce prostaglandins, HETE and EET respectively. 
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These eicosanoids regulate inflammation and promote mitogenic and angiogenic signals by 
binding to GPCRs, such as the prostanoid receptor, and induce downstream signalling. The 
other product of cPLA2 action, lysophospholipid, is the precursor of PAF and has been 
shown to induce its own biological activities through GPCR (212). Both of these enzymatic 
products have their importance in pathological settings of inflammation and cancer. Thus, 
targeting of cPLA2 offers an attractive option in treatment of PC.  
 
1.5.6 cPLA2 and its native inhibitor in prostate cancer  
Expression and activation of cPLA2 have been associated with cancer pathogenesis in 
several cancer cell types. Proliferation of PC cells is also dependent on the activation and 
expression of cPLA2 (134; 204; 213).  
 
Annexin 1 and 2 (ANX1/2) are natural inhibitors of PLA2 and expressed in normal prostate 
epithelia. Previous studies (214; 215) have demonstrated that ANX2 was absent in 31/31 
randomly selected PC cases with a Gleason score range of 3–9 (214). In benign prostatic 
hyperplasia, ANX2 is expressed in the same location as in a normal prostate, with 
comparable intensity. 65% of prostatic intraepithelial neoplasia (PIN), the precursor of PC, 
also showed a loss of ANX2 expression, suggesting that loss of ANX2 could be an early 
event (214).   
 
Southern blot using genomic DNA from paired PC tissue-derived and blood-derived genomic 
DNA from the same PC patients showed no gross deletion of the ANX2 gene in either cell 
type (214). Hypermethylation is believed to be the cause of loss of ANX2, as sequence 
31 
 
analysis showed a CpG island spanning the promoter, first exon and intron of the gene. 
Further, treatment of the ANX2 negative PC cell line LNCaP with a demethylation agent 
reactivated ANX2 expression, suggesting that methylation is associated with ANX2 silencing 
in PC (214). 
 
Restoration of ANX2 inhibited the migration of the transfected LNCaP cells (216). The effect 
on cell proliferation is uncertain. No change in cell proliferation was reported after restoration 
of ANX2 in the same cell line (216). Since immunohistochemical staining for ANX2 is a 
consistent and reliable marker of prostatic neoplasia, a potential utility as a diagnostic aid in 
PC histopathology has been suggested (217). The silencing of ANX1 (218) and ANX7 (219) 
in PC have also been reported, although the loss of ANX7 appears to occur in later stages of 
the disease (214).  
 
1.5.7 PLA2 expression in prostate cancer tissues  
Studies show that secreted PLA2 (sPLA2)-IIA is detectable in the prostate and in seminal 
plasma (220). One study showed an increase in mRNA level in eight PC specimens (221). 
Finally, an increase in sPLA2-IIA protein levels in PC tissues and the enhanced sPLA2-IIA 
expression have been shown to be inversely related to 5-year patient survival (222; 223).  
 
The significance of cPLA2 in PC comes into light as it is found to be downstream of sPLA2-
IIA signalling. Previous studies demonstrated that sPLA2 signals through cPLA2 in 
inflammation in PC cells (213). The increase in sPLA2 activity led to increased cPLA2 
phosphorylation. In addition, cPLA2 phosphorylation, thereby activation, is higher in PC 
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than benign prostates. Further, this activation is yet higher after patients had undergone 
androgen ablation therapy (204). This gives evidence that cPLA2 expression and activation 
is strongly correlated to PC progression and possibly its proliferation. Thus, reduction to 
cPLA2 expression or retardation to its activity remains a possible option for treatment of 
advanced PC.  
 
1.5.8 Eicosanoid-producing enzyme 5-LOX 
1.5.8.1 LOX structure, function and metabolites 
LOX proteins are about 75-80 kDa (224) with a small N-terminal domain and a large 
catalytic domain. LOX are activated when a nonheme iron of the C-terminal domain is 
oxidised to the active ferric iron (225). Within the LOX family, 5-LOX is unique because it 
owns two distinct enzymatic activities. 5-LOX can catalyse oxygenation of AA to either 
HpETE, which later could be reduced to 5-HETE by peroxidise, or to leukotriene A4 (LTA4). 
LTA4 is an intermediate product, which can undergo enzymatic hydrolysis or be conjugated 
to glutathione to produce LTB4 and LTC4 respectively (226; 227). Another unique aspect of 
5-LOX is that it is dependent on Ca
2+ 
and ATP, and requires interaction with a novel 18 kDa 
membrane protein known as 5-LOX activating protein (FLAP) to initiate the lipoxygenation 
(228; 229). The presence of both 5-LOX and FLAP are necessary for leukotriene biosynthesis 
in cells (228). 
 
1.5.8.2 Mechanism of LOX products’ action in cancer progression 
The products of LOX metabolism – including leukotriene, HETE and lipoxin – act as 
signalling molecules. ROS is also generated during eicosanoid synthesis. Leukotriene and 
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lipoxin act through GPCR on the cell surface (230) in a paracrine fashion, while HETE may 
act at nuclear receptors, such as peroxisome proliferator activated receptors (231). Increased 
ROS may damage cellular protein and DNA content, leading to increased mutations. One 
study has demonstrated that ROS from LOX and COX alone is enough to inhibit tumour 
suppressor PTEN, leading to increased AKT activation and PC cell proliferation (83).   
 
The products of LOX metabolism may be involved in carcinogenesis by signalling for 
tumour cell proliferation, cell survival, adhesion, migration, invasion, angiogenesis and 
modulation of the immune system (232; 233). Inhibition of 5-LOX activity abrogates this 
process. For example, one study showed that 5-LOX activity is required for EGF-stimulated 
PC3 cell growth and general LOX inhibitors (NDGA and ETYA), 5-LOX inhibitors (AA861 
and Rev 5901) and FLAP inhibitor (MK886) attenuated phosphorylation of EGFR, ERK and 
AKT in these cells (234). This effect was not induced when cells were treated with 12-LOX 
inhibitor (baicalin) or COX inhibitor (indomethacin). 
 
Interestingly, PSA levels in AIPC can be reduced by inhibition of the eicosanoid pathway. In 
two clinical trials, the rate of increase of PSA following prostatectomy or radiotherapy was 
slowed in patients treated with inhibitors of eicosanoid-producing enzymes (235; 236). 
Members of the eicosanoid family can promote tumour cell proliferation in vitro and in vivo 
(201) but the long-term use of COX-2 inhibitors can lead to cardiovascular side effects (237).  
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1.6 Hypothesis and aim of this thesis 
Prostate cancer is often characterised by loss of PTEN and constitutive activation of AKT. 
The existence of a negative feedback loop on AKT, horizontal compensation of ERK and an 
increase in AR during progression to androgen independence are all factors affecting 
treatment options for prostate cancer. 
 
cPLA2α has been implicated to be important for the proliferation of prostate cancer cells. Its 
product, AA and downstream metabolites are stimulators of cancer cell proliferation. 
Inhibitors of LOX and COX, the enzymes that convert AA into eicosanoids, were used or 
considered as anti-cancer treatment but these have been associated with adverse health risks. 
Inhibition of cPLA2α, the major enzyme releasing AA, decreases substrate supply to the LOX 
and COX pathways. Thus, cPLA2α has been proposed to be a better target in treating prostate 
cancer. Inhibition of cPLA2α reduces PTEN-null prostate cancer cell proliferation but the 
underlying mechanisms have not been well examined.  
 
This thesis tested the hypothesis that cPLA2α sustains the activation and/or expression of 
AKT, ERK and AR in PTEN-null prostate cancer cells. Thus, genetic silencing or 
pharmacological blocking of cPLA2α may decrease the key oncogenic signalling leading to 
reduction in proliferation of PTEN-null prostate cancer cells.  
 
  
35 
 
The aims of this PhD thesis were: 
1. To develop an inducible cPLA2α expression system in PTEN-null prostate cancer cells and 
study the effect of cPLA2α action on AKT, ERK and AR activation and expression; 
2. To evaluate the effect of cPLA2α silencing or inhibition, by either genetic silencing or 
pharmacological agents, on AKT, ERK and AR activation and expression; 
3. To determine any possible links downstream of cPLA2α that may mediate cPLA2α action 
on oncogenic pathways.  
 
 
  
36 
 
 
 
 
CHAPTER 2 
MATERIAL AND METHODS 
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2.1 Materials, catalog numbers and manufacturers 
 
Materials  Catalog numbers and manufacturers 
 
AA  A3555, Sigma-Aldrich, Castle Hills, NSW 
ACIS III cellular imaging system Dako, Campbellfield, VIC, Australia 
Antibodies  
 α-Tubulin  ab7291 
 GAPDH ab8245 
  Abcam, Waterloo, NSW, Australia 
 ERK  9102 
 GSK3β  9315 
 pERK  9106S 
 pGSK3β  9336S 
  Cell Signaling Technology, Danvers, MA, USA 
 pAKT at Thr
308
  A00275 
  Genescript, Piscataway, NJ, USA 
 AR MS-443-P 
 Ki-67  RM-9106-S 
  Lab Vision, Kalamazoo, MI, USA 
 AKT  SC-8312 
 cPLA2α  SC-454 
 pAKT (Ser
473
) SC-7985 
 pcPLA2α  SC-34391 
  Santa Cruz Biotechnology, Santa Cruz, CA, USA 
 Anti-mouse HRP conjugate A4416 
 Anti-rabbit HRP conjugate A0545 
 BrdU  B2531 
 Cyclin D1 C7464 
 FLAG peptide  A8592 
  Sigma-Aldrich 
 Biotinylated anti-mouse BA-1000  
 Biotinylated anti-rabbit BA-9200 
  Vector Laboratories, East Brisbane, QLD, Australia  
Anti-FLAG M2 affinity gel F2426, Sigma-Aldrich 
Bacterial strain JM109  P9751, Promega, Alexandria, NSW, Australia 
Bio-Rad DC protein assay 500-0112, Bio-Rad, Gladesville, NSW, Australia  
Blasticidin  R21001, Invitrogen, Mulgrave, VIC, Australia 
Block-IT Stealth oligo 13750070, Invitrogen 
BSA   A8860, Sigma-Aldrich 
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cPLA2α sequence RC220972, Clonetech, Mountain View, CA, USA 
DAB  K346711-2, Dako 
DNA isolation kit E5038, Sigma-Aldrich 
Doxycycline D9891, Sigma-Aldrich 
DMEM powder 12100061, Invitrogen 
CellTiter 96 non-radioactive cell  
proliferation assay G4000, Promega 
Cell lines 
 LNCaP CRL-1740 
 PC-3 CRL-1435 
  ATCC, Manassas, VA, USA 
EGF  E9644, Sigma-Aldrich 
EGFP-C1 vector 632470, Clonetech, Mountain View, CA, USA  
FACSCalibur BD, North Ryde, NSW, Australia 
FBS  FBS500, AusGeneX, Arundel, QLD, Australia 
3× FLAG peptide  F4799, Sigma-Aldrich 
Flow-Jo 8.0  Tree Star Inc. Ashland, OR, USA 
FLUOstar Omega BMG Labtech, Mornington, VIC, Australia 
G418   10131035, Invitrogen 
GBox imaging system SynGene, Cambridge, England 
GeneTools software  SynGene 
HETEs 
 5-HETE 34230 
 8-HETE 34360 
 11-HETE 34510 
 12-HETE 34570  
 15-HETE 34720  
  Cayman Chemicals, Ann Arbor, MI, USA 
Igepal CA-630 I7771, Sigma-Aldrich 
Immulite 2000 third generation PSA kit 
  Siemens DPC, Bayswater, VIC, Australia 
Lipofectamine 2000 11668, Invitrogen 
MK886  M2692, Sigma-Aldrich 
NCSS (v12.0) Statistical Solutions, Saugus, MA, USA 
NE-PER™ nuclear and cytoplasmic extraction reagents  
  78833, Thermo Scientific, Scoresby, VIC, Australia 
Nitrocellulose membrane  RPN303E, Amersham Bioscience, Rydalmere,NSW  
OPTI-MEM  11058, Invitrogen 
pcDNA4 Vector V103020, Invitrogen 
pcDNA6 Vector V1025-20, Invitrogen 
pCMV6 Vector PCMV6NEO, Clonetech 
Phospholipase A2 Assay Kit E10217, Invitrogen 
PI  P4170, Sigma-Aldrich 
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Precision strep tactin-peroxidase  
Conjugate  161-0380, Bio-Rad 
Protease inhibitor cocktail 11836145001, Roche Diagnostics, Castle Hills  
Random primers 48190, Invitrogen 
REST 2009 Qiagen, Chadstone Centre, VIC, Australia 
RNase  R6513, Sigma-Aldrich 
RotorGene 6000 Qiagen 
RPMI Powder 31800022, Invitrogen 
SensiMix SYBR mastermix kit QT605, Bioline, Alexandria, NSW, Australia 
Si-cPLA2α
(Stealth)
 1299003, Invitrogen 
Si-control
(Stealth)
 12935-300, Invitrogen 
Sodium deoxycholate D6750, Sigma-Aldrich 
Sodium dodecyl sulphate L4390, Sigma-Aldrich 
SuperscriptIII 56575, Invitrogen 
SuperSignal west pico  
chemiluminescent substrate 34078, Thermo Scientific 
SYBR green I nucleic acid stain S-7563 Invitrogen 
UltraClean gelSpin DNA extraction kit 
  12400, Mo Bio Laboratories, Carlsbad, CA, USA 
UltraClean tissue & cells RNA  
isolation kit 15000, Mo Bio Laboratories 
Vectastain ABC kit  PK-4000; Vector Laboratories 
 
2.2 Cell culture 
2.2.1 Prostate cancer cell lines 
Two established cell lines used to model PTEN-null prostate cancer PC-3 (bone metastasised, 
androgen receptor negative (CRL-1435) and PTEN-deletion (75)) and LNCaP (lymph node 
metastasised, androgen receptor positive (CRL-1740) and PTEN-frame shift mutation (74)) 
were purchased from ATCC. Both cell lines were maintained in Roswell park memorial 
institute (RPMI) 1640 Medium supplemented with 3 g/L sodium bicarbonate, 20 mM L-
glutamine, penicillin at 100 units/mL, streptomycin at 100 µg/mL and 10% (v/v) FBS at 37 
o
C in 5% CO2/95% air with cells passaged prior to reaching confluence. The PC-3 and 
LNCaP cell lines used in cell culture studies described in this thesis were between passage 30 
and 40.  
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2.2.2 Generation of cell lines with Dox-controlled cPLA2α expression  
LNCaP cells were seeded in 10 cm dishes and grown to 100% confluence. Cells were then 
transfected with 24 µg pcDNA6 vector expressing TET-Repressor using lipofectamine 2000 
and then treated with media containing blasticidin (10 µg/mL) for 10 d. Successfully 
transfected colonies were picked and passaged before transfecting with pcDNA4 vector 
containing human cPLA2α cDNA sequence joined with FLAG and regulated by a promoter 
containing TRE sequence. Successfully transfected clones were selected with media 
containing G418 (300 µg/mL) for 10 d. Cells co-transfected with pCDNA6 and pcDNA4 
vectors without cPLA2α coding sequence were used as a vector control.  
 
2.2.3 Induction of cPLA2α using Dox  
For induction of cPLA2α, LNCaP TRE-cPLA2α or TRE-Vector (control) cells were seeded in 
6 or 96-well plates and grown until 70% confluency. The cells were then treated with or 
without 100 ng/mL Dox in RPMI with 10% v/v FBS for 24 h before harvest.  
 
2.2.4 Cryopreservation of cell lines 
PC-3 or LNCaP cells were prepared for cryopreservation by gently trypsinising sub-confluent 
cells with TrypLE. After centrifugation, the cell pellet was first resuspended in 20% (v/v) 
FCS RPMI and then added to an equal volume of 10% (v/v) DMSO in cell culture medium. 
Liquid nitrogen cryotanks were used for long-term storage of cells.  
 
2.2.5 Genetic silencing of cPLA2α with siRNA  
PC-3 and LNCaP cells were seeded in 6-well plates. The cells were then transfected with 10 
nM Si-cPLA2α or GC-content matched si-control mixed with lipofectamine 2000 in a 1:2 v/v 
ratio. OPTI-MEM was used as the transfection medium. The media was replenished next day 
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and cells were left to propagate for 48 or 72 h before harvesting for immunoblot. All 
experiments were performed using cells with >70% reduction in cPLA2α protein level. 
 
2.2.6 EGF, Efipladib and AA treatment 
For incubation with AA, PC-3 or LNCaP cells seeded in 6-well plates and grown to 70% 
confluency were exposed to RPMI containing 1% FBS overnight. AA was first pre-
conjugated with 5 µM fatty-acid free BSA for 3 h. Cells were then treated with 20 µM AA at 
37 
o
C for 4 h, with or without 25 µM MK886. For cells treated with Si-cPLA2α or si-control, 
AA was introduced 4 h prior to harvesting. Commercial AA was routinely assessed by HPLC 
and confirmed to contain <1% oxidation products as described previously (238). For 
incubation with EGF, cells were treated with 20 ng/mL EGF for the last 30 min prior to 
harvesting. For Efipladib, PC-3 or LNCaP cells, seeded in 6-well plates for at least 24 h 
beforehand, were treated with 20 µM Efipladib in RPMI 10% FBS for 72 h. Cells were then 
lysed or harvested for subsequent analysis.  
 
2.3 Molecular biology 
2.3.1 Cloning and sequencing 
Restriction enzyme digestions, ligations and other routine DNA procedures were done 
according to published methods (239; 240). DNA sequencing was carried out at the Sydney 
University Prince Alfred Macromolecular Analysis Centre (SUPAMAC), Department of 
Molecular and Clinical Genetics, Royal Prince Alfred Hospital, NSW Australia.  
 
2.3.1.1 DNA plasmid isolation  
JM109 E. coli cells containing plasmid vectors were inoculated into 5 mL Luria Bertani broth 
with 100 µg/mL ampicilin or kanamycin and grown overnight in a 37 
o
C incubator shaker. 
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The next day, cells were spun down and lysed. DNA plasmids were extracted from cell 
lysates using a DNA isolation kit following the manufacturers’ instructions. 
 
2.3.1.2 DNA electrophoresis and gel purification 
DNA fragments were separated in agarose gels (1%) with 1x tris-acetate-EDTA buffer (239) 
in horizontal submarine tanks. Electrophoresis was routinely performed at 100 V. DNA was 
visualised with ethidium bromide (0.5 mg/L) staining and a UV lamp according to routine 
protocols (239; 240). To purify DNA fragments, samples were first run on agarose gels. Gel 
pieces containing DNA were cut out under a UV lamp and put through purification using 
UltraClean Gelspin extraction kits according to the manufacturer’s instruction.  
 
2.3.1.3 Bacterial transformation 
Competent JM109 cells were incubated with DNA plasmid (1 µg) for 30 min on ice. The 
transformation mix was heated at 37 
o
C for 60 s and then incubated for 2 min on ice. The 
transformation mix was inoculated on a 10 cm agar plate with ampicilin or kanamycin (100 
µg/mL) for overnight selection. Successful colonies were picked for DNA plasmid isolation 
and/or sequencing.  
 
2.3.1.4 Primers 
Primers were synthesised by Geneworks (Hindmarsh, SA, Australia). Primers used in this 
study are shown in Table 2.1. 
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Table 2.1 Primers sets used to measure human cPLA2α, TBP and AR gene expression by real-time 
PCR and sequencing of cPLA2α in pcDNA4 vector.  
Primer Sequences 
cPLA2α Forward 5’-ACAGTGGGCTCACATTTAACCT 
cPLA2α Reverse 5’-CTTCCCGATCAAACACATAAGG 
TBP Forward 5’-GAACCACGGCACTGATTTTC 
TBP Reverse 5’-CCCCACCATGTTCTGAATCT 
AR Forward 5’-AATGTCAACTCCAGGATGCT 
AR Reverse 5’-CCATCCACTGGAATAATGCT 
pcDNA4 Forward 5’-GGAATAAGGGCGACACGGA 
pcDNA4 Reverse  5’-TAGAAGGCACAGTCGAGG 
 
2.3.2 Reverse transcription and quantitative real-time PCR  
Total RNA was isolated using an UltraClean Tissue & Cells RNA Isolation Kit according to 
the manufacturer’s instructions. The first strand of complementary DNA was synthesised 
from 500 ng of total RNA with random primers and SuperscriptIII. Quantitative PCR 
measurements were done with SensiMix SYBR Mastermix Kit and RotorGene 6000. 
Conditions for PCR were: one cycle of 10 min at 95 
o
C; 40 cycles of 10 s at 95 
o
C, 30 s at 65 
o
C. REST 2009 was used to calculate relative changes in cPLA2α normalised by a TBP 
housekeeping gene. Amplification efficiency was determined if 3–5 points of a dilution curve 
were within 100 ± 3% for AR, cPLA2α and TBP. 
 
2.3.3 Immunoblotting 
PC-3 and LNCaP cells were seeded in 6-well plates. Following treatment, cell lysates were 
prepared with lysis buffer (50 mM Tris-pH 8, 150 mM NaCl, 1% v/v Igepal CA-630, 0.5% 
w/v sodium deoxycholate, 0.1% w/v SDS) supplemented with 1:50 v/v dilution of protease 
inhibitor cocktail and 50 mM sodium fluoride (as phosphatase inhibitor (241; 242)). Protein 
concentration was quantified using Bio-Rad DC protein assay. Proteins were separated on 
SDS-PAGE and then transferred onto a nitrocellulose membrane. The membranes were 
blocked with 1% w/v non-fat milk in PBST for 30 min and incubated with primary antibody 
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for 1–2 d at 4 ºC. The blots were then washed in PBST, and incubated with a secondary 
antibody conjugated with peroxidase and Precision Strep Tactin-Peroxidase Conjugate for 3 h. 
Immunoreactive proteins were detected by SuperSignal West Pico Chemiluminescent 
Substrate and the signals captured by G:Box Imaging gel doc systems. The band intensity of 
digital images was measured using GeneTools software and the ratio of band intensity 
between each protein of interest and loading control was determined before expressing 
changes in protein levels as a fold-change relative to control.  
 
2.3.4 Immunocytochemistry 
Expression of Ki-67 and BrdU incorporation in cells was determined by 
immunocytochemical staining. For determining BrdU incorporation, the experimental cells in 
culture medium were added to 10 μM BrdU for 3 h prior to harvest. The treated cells in T75 
flasks were harvested with TrypLE, fixed in 10% buffered formalin solution at 4 
o
C, clotted 
in 1% w/v agarose and further processed into paraffin blocks. Sections (5 µm thickness) were 
cut and baked at 60 
o
C for 1 h, deparaffinised in xyline, re-hydrated in graded ethanol and 
distilled water, and subjected to antigen retrieval in Tris-EDTA solution (243). The sections 
were then incubated with 2 N HCl for 20 min. After being washed in TBST (50 mM Tris HCl, 
150 mM NaCl, 0.05% v/v Tween 20, pH 7.4), the sections were blocked with 10% v/v horse 
serum and then incubated with either anti-Ki-67 or anti-BrdU antibody for 20 h at 4 
o
C. After 
washing in TBST, the section was sequentially labelled with a biotinylated secondary 
antibody and Vectastain ABC kit. To detect the immunolabelling, the sections were incubated 
with DAB. Thereafter, the sections were counterstained with hematoxylin and coverslipped. 
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2.3.5 Quantification of immunocytochemically stained cells 
Digital images of the immunostained sections were obtained by using ACIS III automated 
cellular imaging system. Thereafter, two colour thresholds were chosen to distinguish 
between the positive (brown) and negative (blue) cells. Ten areas on each sample were 
randomly selected to determine the numbers of positive and negative cells. The percentage of 
positive cells of each sample was calculated using the formula: positive cells/(positive cells + 
negative cells) x 100%. 
 
2.3.6 Nuclear and cytoplasmic fractionation 
After treatment with Efipladib as in Section 2.2.6, cells were washed twice with cold PBS, 
scraped off the plate and collected into 1.5 mL microtubes. PBS was removed after 
centrifugation at 500 g for 3 min. Nuclear and cytoplasmic fractionation were performed 
using NE-PER™ Nuclear and Cytoplasmic Extraction Reagents according to manufacturer's 
instructions. All procedures including centrifugation were performed at 4 °C. The isolated 
fractions were then used for immunoblot. 
 
2.3.7 Fatty acid extraction from conditioned cell culture media and cell pellets 
Fatty acids were extracted from cell pellet and culture medium as described in detail by 
Norris and Dennis (244). Cells were trypsinised, spun down and transferred to glass test tubes. 
The cell pellets were added with 800 µL 1 N HCl/MeOH (in 1:1 ratio) and 400 µL 
chloroform before being vortexed for 1 min and then centrifuged at 1000 x g for 5 min. The 
lower phase was transferred to a new tube and the solution was evaporated using nitrogen. 
250 µL MeOH with 0.005% w/v butylated hydroxytoluene and 250 µL KOH (15% w/v) were 
added to each sample and vortexed for reconstitution. The solution was then incubated at 37 
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o
C for 30 min. 1 N HCl was added to each sample until pH < 3. Heptadecanoid acid (100 
µg/mL, 20 µL) was added before extraction by hexane as below. 
 
Briefly, media samples (2 x 250 µL from each sample) were diluted into a mixture of MeOH 
(400 µL), heptadecanoic acid (100 µg/mL, 10 µL) and HCl (1 M, 25 µL). Treated samples of 
pellet and media were then mixed with 2 mL hexane, vortexed for 30 s and centrifuged at 
1000 x g for 5 min. The upper (hexane) layer was removed from the aliquots and combined 
into a 25 mL pear-shaped flask with a ground glass joint. The hexane extraction was repeated 
and the combined fractions were then evaporated under vacuum, reconstituted with 200 µL 
isopropanol and stored at –80 oC before analysis using LC-MS. 
 
2.4 Assays 
2.4.1 Bio-Rad DC protein assay 
Reagent A (25 µL) was mixed with 5 µL protein sample (diluted) in 96-well plates. 200 µL 
of Reagent B was then added before 10 min incubation at room temperature in the dark. 
Standards of 0, 0.25, 0.5, 1, 2, 3, and 4 mg/mL were made from BSA. Absorbance was read 
at 690 nm to create a standard curve using absorbance of standard (y-axis) and concentration 
(x-axis). Sample protein concentration was then worked out based on the equation of 
trendline and their dilution factors.  
 
2.4.2 SYBR green assay for measurement of DNA synthesis 
Prostate cancer cells were seeded to 96-well plates at 2 x 10
3
 cells/ well for PC-3 cells and at 
5 x 10
3
 cells/ well for LNCaP cells. After at least 24 h seeding, Efipladib was then added at 0, 
5, 10, 15, 20 and 25 µM in fresh medium and incubated at 37 
o
C for 72 h. The same number 
of cells was aliquoted as at baseline and stored at –80 oC until use. 3 d after treatment, the 
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medium was gently removed from each well and 100 µL of lysis buffer containing SYBR 
Green I DNA gel stain at 1:10,000 v/v dilution was added. The lysis buffer consisted of 
buffer A (10 mM Tris-pH 7.5 and 2 M NaCl) and buffer B (100 mM Tris-pH 7.5, 200 mM 
EDTA and 10% v/v Triton X-100) in a 9:1 ratio. The cells were lysed in the dark for 30 min. 
Previously frozen aliquots were thawed at room temperature, lysed in the same buffer and 
transferred to the treatment plate containing samples from the same type of cells. The 
fluorescence intensity of SYBR Green was measured using a FLUOstar Omega plate reader 
and the gain in the cellular DNA content during the treatment was estimated by subtracting 
baseline fluorescence intensity from the value obtained from experimental cells. 
 
2.4.3 MTT assay for cell proliferation based on mitochondrial function 
Prostate cancer cells were seeded to 96-well plates in a similar fashion to the SYBR Green 
assay for at least 24 h before treatment. At end of treatment, culture media was aspirated and 
cells were added with RPMI (10% FBS) and dye solution from a CellTiter 96 Non-
Radioactive Cell Proliferation Assay in a 9:1 ratio. The cells were then incubated at 37 
o
C for 
30 min before being taken for absorbance reading at 414 nm.  
 
2.4.4 Determination of HETEs 
PC-3 and LNCaP cells were harvested, and the cell pellets incubated with 0.1 mM purified 
AA at 37 °C for 1 h. Total lipids were extracted into chloroform/ methanol/ water (5:1:1 v/v/v) 
and centrifuged (3600 x g, 15 min). The chloroform phase was dried and the resultant lipids 
reconstituted with methanol/water (9:1 v/v), were used for high-performance liquid 
chromatography (HPLC) separations as described previously (238). The identity of HETEs in 
the HPLC profile was confirmed by spiking with the authentic HETEs obtained commercially. 
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HPLC separation of HETE was performed by PhD student, Dr Marzieh Niknami, in the same 
Laboratory inBosch Institute, The University of Sydney, NSW, Australia. 
 
2.4.5 PSA assay 
LNCaP cells in 6-well plates were treated with 20 µM Efipladib for 72 h. Following 
treatment, 200 µL media were collected, centrifuged (300 x g, 5 min), and measured with 
Immulite 2000 Third Generation PSA kit at the Royal Prince Alfred Hospital. The intra- and 
inter-assay coefficients of variation were 5% and 7% respectively for the dose over the range 
of standard curves. Cells in each well were harvested for protein assay and the PSA value 
was normalised by protein concentration. 
 
2.4.6 Transfection efficiency testing by Block-IT Stealth oligo 
PC-3 and LNCaP cells were grown in T75 flasks until semi-confluent. Then they were 
trypsinised and seeded in 6-well plates at 500 k cells/well and transfected with or without 10 
nM Block-IT Stealth oligo mixed with lipofectamine 2000 in a 1:2 v/v ratio. OPTI-MEM was 
used as the transfection medium. The cells were incubated at 37 
o
C for 24 h before being 
trypsinised, spun down and resuspended in PBS with 5% (v/v) FBS. The cells were taken for 
flow cytometry analysis using FACSCalibur machine. Positively transfected cells showing 
intracellular fluorescence at 485 nm (245) were gated and counted by Flow-Jo 8.0. 
 
2.4.7 Transfection efficiency testing by EGFP-C1 vector 
PC-3 or LNCaP cells were seeded in 6-well plates at 100 k cells/well. Following 24 h, the 
cells in each well were transfected with or without 4 µg EGFP-C1 Vector mixed with 
lipofectamine 2000 in a 1:1, 1:2 or 1:4 ratio. OPTI-MEM was used as the transfection 
medium. The cells were then incubated at 37 
o
C for up to 72 h. After 24, 48 and 72 h, light 
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contrast and fluorescence images of cells expressing EGFP were taken under an UV 
microscope. The percentage of cells expressing EGFP was measured using flow-cytometric 
analysis or manual counting. 
 
2.4.8 Flow cytometry analysis of the cell cycle using PI 
PC-3 or LNCaP cells seeded in 6-well plates were treated with Si-cPLA2α or Efipladib and 
control according to above procedures. At the end of treatment, the cells were trypsinised, 
spun down and re-suspended in 300 µL PBS. The cells were then fixed by adding 800 µL 
ethanol drop-wise to each sample under a constant vortex and then stored at 4 
o
C for at least 
overnight. Following fixation, cells were washed in PBS and incubated in PBS containing 20 
µg/mL PI and 100 µg/mL RNase for 1 h. The cells were then washed and resuspended in 
PBS with 5% (v/v) FBS before being measured by flow cytometry analysis. Positive nuclei 
stained with PI were gated and cells in each cell cycle phase measured using Flow-Jo 8.0.  
 
2.4.9 Trypan blue exclusion assay 
At end of treatment, PC-3 or LNCaP cells in 6-well plates were trypsinised, spun down and 
resuspended in PBS. The cell suspension was then mixed with trypan blue in a 1:1 ratio and 
loaded onto a Haemacytometer. For each sample, five 0.1 x 0.1 mm squares were counted. 
Trypan blue positive cells were subtracted from total number of cells to get cell viability.  
 
2.4.10 cPLA2α immunoprecipitation and activity assay 
LNCaP cells transfected with TRE-cPLA2α or TRE-empty vector control were induced with 
Dox as described in Section 2.2.3 and then lysed with lysis buffer (50 mM Tris-pH 7.4, 150 
mM NaCl, 1% v/v Triton X-100, 1 mM EDTA, 0.1% v/v NP-40). The cell lysates were 
centrifuged at 8200 g/10 min/4 °C and the protein concentration in the supernatant was 
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quantified as in Section 2.4.1. Each sample (final protein concentration 250 μg/mL) was 
mixed with 40 μL Anti-FLAG M2 Affinity Gel in a microtube and followed by 1 mL of lysis 
buffer. The mixtures were agitated for 2 h/4 °C and then centrifuged for 30 s/8200 g before 
removing the supernatant. The bead pellets were washed three times with 500 μL TBS for 5 
min/4 °C. Bound antigens were eluted with 3× FLAG peptide and assayed using the 
Phospholipase A2 Assay Kit according to the manufacturer's specifications. 
 
2.4.11 Liquid chromatography–mass spectrometry (LC–MS)/MS analysis 
Fatty acid from the cell pellet and culture medium were extracted as in Section 2.3.7 and 
resuspended in 200 µL isopropanol. Samples were stored at –80 oC for less than one week 
before LC-MS/MS analysis as described in Hua et al. (134). MS  was performed by Leila 
Hejazi in the Mass Spectrometry Facility, University of Western Sydney, Sydney, Australia. 
 
2.5 Statistical analysis 
Statistical software NCSS (v12.0) was used for analysis. One-way analysis of variance 
(ANOVA) was used to determine differences between groups of data. Fisher’s Least 
Significant Difference Multiple-Comparison Test was used to determine the difference 
between individual groups (P value < 0.05 was considered significant). Data that failed the 
test for normal distribution or homogeneous variance were analysed with the Kruskal-Wallis 
test of ranked variable and post-hoc Kruskal-Wallis Multiple-Comparison Z-Value Test (a z-
value of > 1.96 was considered significant).  
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CHAPTER 3 
EFFECT OF OVEREXPRESSION OF 
cPLA2α ON PTEN-NULL PROSTATE 
CANCER CELLS 
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3.1 Introduction 
The mechanisms by which eicosanoids promote cancer progression include activation of the 
PI3K/AKT and Ras/Raf/MEK/ERK pathways (246). AA metabolites such as PGE2, PGF2α, 
5-HETE and 12-HETE have all been implicated to activate pAKT and/or pERK in various 
cancer types (247-250). Prostanoid receptors EP1, EP4 and FP have been shown to convey 
the eicosanoid signals to AKT and ERK pathways via transactivation of EGFR (249; 251). 
Naturally, the inhibition of eicosanoid synthesis has shown effects of cancer inhibition (237). 
Blockade of eicosanoid production by drugs, commonly termed non-steroidal anti-
inflammatory drugs (NSAIDs), decreases the levels of pAKT (234), phospho-PI3K (on p85 
subunit) (252) and pERK (251).  
 
LOX and COX, the enzymes that metabolise AA to produce eicosanoids, have been 
identified as potential targets for both chemoprevention and treatment of several cancers (85; 
253). However, the long-term use of some inhibitors such as COX-2 inhibitors can lead to 
cardiovascular side effects (237) and gastrointestinal bleeding (254). Further, a single, 
specific inhibitor alone cannot inhibit the action of all LOX and LOX enzymes. The current 
hypothesis proposed by others and us is that inhibition of cPLA2α could be a more effective 
therapeutic approach than inhibition of COX or LOX alone against prostate cancer (201; 237). 
 
cPLA2α is the rate-limiting enzyme that releases AA from membrane phospholipids for 
eicosanoid production (255). Although concentrations of free AA are maintained at low 
levels in resting cells, alterations in AA production, often resulting from dysregulation of 
cPLA2α activity, are observed in transformed cells. Studies have shown alterations in the 
levels of cPLA2α expression or functional activity in several types of cancers (256). However, 
in previous experiments conducted in our laboratory, we were first to demonstrate expression 
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of total and phospho-cPLA2α (pcPLA2α) in prostate cancer cell lines and an aberrant increase 
in pcPLA2α in hormone-refractory prostate cancer (204). 
 
This presence of total and phospho cPLA2α coincides with an aberrant increase in AKT 
signalling in advanced prostate cancer cell lines LNCaP and PC-3. Given the fact that AA 
metabolites lead to AKT and ERK activation and promote prostate cancer progression (257-
260), we examined the hypothesis that aberrantly-increased cPLA2α is required for sustaining 
AKT and ERK signalling in PTEN-null/mutated prostate cancer cells. The aim of the work 
described in this chapter was to establish a model of inducible expression of cPLA2α in 
PTEN-null LNCaP cells and investigate the role of cPLA2α in oncogenic signalling pathways 
in prostate cancer cells.  
 
3.2 Materials and methods 
3.2.1 TetOn system used in overexpression of cPLA2α 
Within tetracycline inducible system, tetracycline may induce or suppress the transcription of 
downstream gene depending on the types of tetracycline binding protein used (261). The TetR 
gene from pcDNA6 vector was originally isolated from the Tn10 transposon which confers 
resistance to tetracycline in E. coli and other enteric bacteria (262). It encodes a repressor 
protein of 207 amino acids with a calculated molecular weight of 23 kDa (262). Under 
unstimulated conditions, TetR protein binds to the 2x tetracycline operator sequence (5’-
TCCCTATCAGTGATAGAGA) (261) on the CMV promoter of pTetOn:cPLA2α vector. 
This is able to block the transcription of downstream cPLA2α gene. Addition of tetracycline 
releases this inhibition as tetracycline molecules bind to TetR, induce conformational change, 
and allow it to dissociates from the operator sequence. The transcription of downstream 
cPLA2α is highly upregulated under CMV promoter.  
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Figure 3.1 TetOn system. The TetOn system used in this study involves two vectors working 
together in presence or absence of tetracycline. TetR (repressor) is transcribed from pcDNA6 vector 
and will suppresses transcription on pTetOn:cPLA2α vector. Presence of tetracycline binding to TetR 
releases this inhibition. 
 
 
3.2.2 Vectors and DNA sequence 
For establishment of tetracycline-inducible expression of cPLA2α, three vectors were used in 
the cloning process. Ampicilin and kanamycin were used for selection during DNA isolation. 
Restriction enzyme digestion and SUPAMAC sequencing were employed to verify the 
cloned product. Transfection efficiency tests were done using an EGFP-C1 vector and 
assessed by flow cytometry and cell counting. G418 and blasticidin were used for selection of 
stably transfected clones. Successfully transfected clones (transient or stable) were induced 
with or without doxycycline (Dox) and verified by immunoblot. Effect of cPLA2α 
overexpression on oncogenic pathways was measured by immunoblot. Effect of cPLA2α 
overexpression on proliferation was measured by cell counting and MTS assay. I assessed the 
activity of induced cPLA2α using PLA2 activity assay and LC-MS.  
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Figure 3.2 pCMV6-cPLA2α vector. The vector contained human PLA2G4A (cPLA2α) cDNA 
sequence followed by Myc and DYKDDDDK (FLAG) epitope. Gene expression is driven by a CMV 
promoter and vector is selected by a neomycin resistance gene for bacterial and mammalian 
culture selection.  
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Figure 3.3 pcDNA6 vector. The pcDNA6 vector contained Tet-repressor sequence driven by a CMV 
promoter for constitutive expression. The vector contained ampicilin and blasticidin resistance genes 
for bacterial and mammalian culture selection respectively.  
 
 
Figure 3.4 pcDNA4 Vector. The pcDNA4 vector contained a CMV promoter harbouring a 2x 
tetracycline operator sequence. The vector also contained ampicilin and zeocin resistance genes for 
bacterial and mammalian culture selection respectively. 
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3.2.3 Restriction enzyme digestion 
For DNA digestion, 2 µg of vector was added with 40 U of one or two restriction enzymes to 
10% v/v BSA and 10% v/v restriction enzyme buffer. Digestion was performed at 37 
o
C. The 
result of the DNA digest was run on agarose gel (see 2.3.1.2) and visualised under UV.  
 
3.2.4 DNA ligation 
For DNA ligation, 100 ng of vector was added with 100 ng of insert to 1 U T4 DNA ligase 
and 10% v/v T4 DNA ligase buffer. Ligation was performed at 15 
o
C for 16 h. The ligation 
mix was then used for transformation (see 2.3.1.3) and plated on agar plates containing the 
corresponding antibiotic. Successful colonies were picked for DNA plasmid isolation (see 
2.3.1.1) and subsequent reconfirmation by restriction digestion. The successful product was 
then sent for sequencing (see 2.3.1).  
 
3.3 Results 
3.3.1 Creation of a pTetON:cPLA2α vector   
To achieve a pTetON:cPLA2α vector, pCMV6 cPLA2α (Figure 3.2) was used as a template 
for the majority of the plasmid backbone, as the cPLA2α coding sequence was on pCMV6 
(Figure 3.3) from the manufacturer. Additionally antibodies against FALG and myc epitope 
(attached to the cPLA2α sequence) and the antibiotics for selecting the Neo/Kan
R
 gene are all 
readily available.  
 
pCMV6 cPLA2α (Figure 3.2)  and pcDNA4 (Figure 3.4) vectors both have a single NdeI 
and Acc65I restriction site in their sequence. Cleavage by these two enzymes gave 406 bp and 
500 bp fragments respectively (Figure 3.5).  
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Figure 3.5 NdeI and Acc65I digestion of pCMV6 cPLA2α and pcDNA4 vectors. Lane 1, double 
digest of pCMV6 vector yielding 406 bp fragment; Lane 2, DNA 1 kb ladder; Lane 3, double digest 
of pcDNA4 vector yielding 500 bp fragment; Lane 4, undigested pcDNA4 vector.  
 
 
The major portion of pCMV6 (Figure 3.5 lane 1 top band) and the 500 bp product from 
pcDNA4 (Figure 3.5 lane 3 bottom band), which contains the 2x tetracycline operator 
sequence, were both isolated through purification and ligated together to create pTetOn: 
cPLA2α (Figure 3.6). The ligation mix was subsequently transformed into JM109 for plasmid 
isolation. Successfully isolated vectors (from miniprep) were digested to confirm fragment 
size (Figure 3.7). The plasmid was then sent for sequencing to check the fidelity of plasmid 
amplification on the cPLA2α coding sequence. 
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Figure 3.6 pTetOn:cPLA2α vector. The pTetON: cPLA2α vector contained cPLA2α coding sequence 
and largely pCMV6 plasmid elements. A 500 bp fragment was taken from pcDNA4 vector to replace 
the coding sequence between NdeI and Acc65I sites on pCMV6 to produce the final vector. 
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Figure 3.7 NdeI and Acc65I digestion of isolated pTetOn:cPLA2α vector. Lanes 1 and 8, DNA 1 
kb ladder; Lane 2–5, 9–10 double digest of isolated pTetOn:cPLA2α vectors from individual colonies, 
yielding 500 bp inserts; Lane 6, double digest of parental pcDNA4 (as positive control); Lane 7, 
double digest of parental pCMV6: cPLA2α. 
 
 
A pTetOn:control vector without cPLA2α cDNA was used as a vector control. This was 
created by restriction enzyme digest of XhoI and SalI sites, which flanked the cPLA2α 
sequence, and rejoining the compatible loose ends. The ligation mix was transformed and 
plated to form colonies for DNA isolation. Successfully isolated clones were tested by NdeI, 
digested and compared with a XhoI and SalI double digest of pTetOn:cPLA2α vector 
(Figure 3.8). Vector without cPLA2α sequence (sample 1 and 3, Figure 3.8) was sent for 
sequencing.  
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Figure 3.8 NdeI digestion of isolated pTetOn:control vector. Lane 1–3, NdeI digestion of purified 
vector from individual colonies; Lane 4, DNA 1 kb ladder; Lane 5, double digest of isolated 
pTetOn:cPLA2α by XhoI and SalI. 
 
 
3.3.2 Testing of transfection efficiency by EGFP   
To test transfection efficiency, LNCaP cells were seeded into 6-well plates and transfected 
with EGFC-C1 vector for constitutive expression of enchanced green fluorescence protein. 
Percentage of successfully transfected cells from different lipofectamine to DNA (µL:µg) 
ratio and different duration of transfection were examined by flow cytometry and manual 
counting (Figure 3.9). There appeared to be a positive correlation between transfection 
efficiency and vector amount or duration. The efficiency peaked at about 45% for 48 h 
transfections (Figure 3.9C). However, the percentage of cell death also rose, peaking at 1:2. 
Thus a 1:1 ratio was chosen as the optimal ratio in 48 h.  
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R1
R2
Region Statistics
File: PEI 24 h.001 Log Data Units: Linear Values
Sample ID: PEI 24 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 16108 Total Ev ents: 20000
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 16108 100.00 80.54 5.02 3.94 276.78 252.63 1, 2
R2 5 0.03 0.03 1006.42 449.10 322.80 279.99 3, 2
R1
R2
Region Statistics
File: Ratio 0.5 24 h.002 Log Data Units: Linear Values
Sample ID: Ratio 0.5 24 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 15804 Total Ev ents: 20000
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 15804 100.00 79.02 60.72 7.33 289.87 260.81 1, 2
R2 1754 11.10 8.77 495.45 160.15 371.42 333.25 3, 2
R1
R2
Region Statistics
File: Ratio 1 24 h.003 Log Data Units: Linear Values
Sample ID: Ratio 1 24 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 14185 Total Ev ents: 20000
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 14185 100.00 70.93 97.45 10.54 277.80 251.71 1, 2
R2 2430 17.13 12.15 532.54 175.66 336.43 301.75 3, 2
R1
R2
Region Statistics
File: Ratio 2 24 h.004 Log Data Units: Linear Values
Sample ID: Ratio 2 24 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 13437 Total Ev ents: 20000
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % G ted % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 13437 100.00 67.18 229.75 20.20 319.68 290.86 1, 2
R2 3696 7.51 18.48 809.24 226.88 375.77 341.27 3, 2
Control 1:1 
1:0.5 1:2 
a) 
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c)  
 
R1
R2
Region Statistics
File: PEI 48 h.007 Log Data Units: Linear Values
Sample ID: PEI 48 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 9489 Total Ev ents: 11550
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 9489 100.00 82.16 7.45 4.66 358.90 336.51 1, 2
R2 26 0.27 0.23 753.27 135.68 407.04 382.21 3, 2
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Region Statistics
File: Ratio 0.5 48 h.008 Log Data Units: Linear Values
Sample ID: Ratio 0.5 48 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 18555 Total Ev ents: 20000
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 18555 100.00 92.77 173.38 14.17 350.15 330.21 1, 2
R2 3970 21.40 19.85 779.04 207.49 412.46 389.67 3, 2
R1
R2
Region Statistics
File: Ratio 1 48 h.009 Log Data Units: Linear Values
Sample ID: Ratio 1 48 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 17970 Total Ev ents: 20000
X Parameter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
Region Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 17970 100.00 89.85 387.67 35.76 349.04 326.60 1, 2
R2 7187 39.99 35.94 951.65 248.54 388.13 364.44 3, 2
R1
R2
Region Statistics
File: Ratio 2 48 h.010 Log Data Units: Linear Values
Sample ID: Ratio 2 48 h Patient ID: LNCaP cells
Tube: Panel: 
Acquisition Date: 21-Nov -08 Gate: G1
Gated Ev ents: 8490 Total Ev ents: 10140
X Param ter: FL1-H GFP (Log) Y Parameter: SSC-H Side Scatter (Linear)
R gion Ev ents % Gated % Total X Mean X Geo Mean Y Mean Y Geo Mean Px,Py
R1 8490 100.00 83.73 571.83 51.54 351.88 326.61 1, 2
R2 66 45.54 38.13 1239.85 311.03 395.04 367.29 3, 2
Control 1:1 
1:0.5 1:2 
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d)  
 
 
 
e)  
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f)  
        
g) 
 
Figure 3.9 Testing transfection efficiency on LNCaP cells. a) 24 h and b) 48 h transfection of 
EGFP-C1 vector in LNCaP cells and measured by flow cytometry. c) Histogram of measurements by 
flow cytometry. d) Phase contrast and e) fluorescent image of LNCaP cells under microscope. f) 
Measurement of transfection efficiency by manual cell counting. g) Measurement of cell viability 
after transfection by trypan blue exclusion assay. 
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3.3.3 Transfection of pTetOn:cPLA2α and pcDNA 6 into LNCaP cells   
To produce the tetracycline inducible cell line (LNCaP TRE-cPLA2α), pcDNA6 and 
pTetOn:cPLA2α vectors were transfected into LNCaP cells (performed by Soma 
Vignarajan). For the control cell line (LNCaP TRE-Vector), pTetOn vector without the 
cPLA2α coding sequence was stably transfected into pcDNA6 containing LNCaP cells 
according to Section 2.2.2. Stably transfected LNCaP TRE-cPLA2α and TRE-Vector clones 
were then tested by immunoblot for cPLA2α expression under induced conditions. 39 clones 
of LNCaP TRE-cPLA2α were picked and screened (20 shown in Figure 3.10). Four clones 
(namely 101, 105, 117 and 119) were picked based on their elevated expression of cPLA2α 
following Dox induction. Two clones (101 and 105) showed increased pcPLA2α following 
Dox induction(Figure 3.11). LNCaP TRE-Vector clones, which also contained two stably 
transfected vectors, were cultured based on their antibiotic resistance and tested for Dox 
treatment. In TRE-Vector cells, the level of cPLA2α was comparable to parental LNCaP and 
did not increase following Dox treatment (Figure 3.12). 
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Figure 3.10 Expression of cPLA2α for LNCaP TRE-cPLA2α clones following Dox induction. a)–
d) clones of stably transfected clones (namely 101, 105, 110, 111, 116–120, 122–124, 126–128, 132, 
136–140) were induced by Dox (1 mg/ml) and screened for cPLA2α overexpression by immunoblot. 
Hela and PC-3 cells were used as controls.  
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a)  
 
b)  
 
 
Figure 3.11 Overexpression of cPLA2α in LNCaP TRE-cPLA2α clones with or without Dox. a) 
total and b) pcPLA2α levels were probed by immunoblot after the four clones were induced with or 
without Dox (1 mg/ml) for 24 h.  
 
69 
 
  
 
Figure 3.12 Expression of cPLA2α for LNCaP TRE-Vector transfected cells following Dox 
induction. LNCaP TRE-Vector cells were treated with or without Dox (1 mg/ml) for 24 h. The 
expression of cPLA2α was compared to parental LNCaP cell lines under similar treatments.  
 
 
3.3.4 Optimisation on time and dose of Dox induction 
To find out the optimal dose and time for induction of cPLA2α, LNCaP TRE-cPLA2α was 
treated with a range of Dox concentrations. The amount of induction on cPLA2α protein was 
measured by immunoblot. Dox was able to induce high levels of total and phospho cPLA2α at 
concentrations as low as 0.01 µg/mL (Figure 3.13 C and D). However, the results of Dox 
induction appeared to be more consistent at concentrations over 0.1 µg/mL. Thus 0.1 µg/mL 
was chosen as the concentration to use in subsequent experiments.  
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a) 
 
 
b) 
  
c)  
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d) 
 
 
Figure 3.13 Dose response of cPLA2α protein expression following Dox induction. a)–d) cPLA2α 
overexpression clone 105 and 117 were treated with or without Dox 0.01–2 µg/mL. The level of total 
and phospho cPLA2α protein induced were analysed by immunoblot. Hela cells treated with or 
without siRNA targeting cPLA2α and PC-3 cells were used as controls. The amount of GAPDH in d) 
for LNCaP TRE-cPLA2α (105) cells is equivalent to that of c). 
 
To find out the optimal duration of Dox induction, LNCaP TRE-cPLA2α cells were treated 
with Dox for up to 48 h (Figure 3.14). cPLA2α induction began to show following 8 h Dox 
treatment and appeared to be greatest at 24 and 48 h. As the cPLA2α level was similar 
between those two time points, 24 h was chosen as the best time for all subsequent 
experiments.  
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a) 
 
b) 
 
Figure 3.14 Time course of cPLA2α induction over 48 h. cPLA2α overexpression after a) 8 and 16 h 
and b) 24 and 48 h, compared with TRE-Vector control. AKT and GAPDH were used as loading 
controls. 
 
3.3.5 Biochemical changes in LNCaP cells following cPLA2α overexpression  
3.3.5.1 Measurement of ectopically expressed cPLA2α by FLAG tag 
Ectopically induced cPLA2α was probed by targeting its recombinant FLAG or myc epitope. 
In so doing, comparison between total cPLA2α levels and ectopically induced cPLA2α was 
made. A clear increase of ectopically expressed cPLA2α following Dox treatment was seen 
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by antibody against FLAG (Figure 3.15). Control cells showed no detectable levels of FLAG 
or any increase in total or phospho cPLA2α following induction. The ectopically expressed 
cPLA2α was also shown to be phosphorylated.  
 
 
Figure 3.15 Induction of cPLA2α in TRE-cPLA2α compared to TRE-Vector. LNCaP TRE-
cPLA2α and TRE-Vector were induced with Dox for 24 h and then analysed by immunoblot.  
 
3.3.5.2 Measurement of cPLA2α activity after overexpression and measurement of 
extracellular AA 
To determine Dox-induced cPLA2α enzyme activity, LNCaP TRE- cPLA2α and Vector were 
induced with Dox and the FLAG-tagged cPLA2α was immunoprecipitated and assayed for 
activity. Consistent with the increased levels of pcPLA2α (Figure 3.15), Dox-induced 
cPLA2α showed a ~2.5–3-fold increase in enzyme activity compared with cells in the absence 
of Dox (Figure 3.16). TRE-Vector control cells without FLAG-tagged cPLA2α showed no 
detectable cPLA2α activity. The amount of free AA released into culture medium increased 
significantly in the cells treated with Dox compared with controls (Figure 3.16). There was 
no significant change in released AA after Dox treatment in control cells. 
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Figure 3.16 Enzyme activity and AA release. LNCaP TRE-cPLA2α and TRE-Vector cell lysates 
were tested for cPLA2α enzyme activity. AA released into culture medium was analysed by LC-MS. 
The activity assay detection limit was defined as two standard deviations above the mean value of the 
blank control. Histograms are represented as mean ± SD (n=3) * P < 0.05 versus no Dox treatment by 
One-Way ANOVA. 
 
3.3.5.3 Effect of ectopic cPLA2α expression on the PI3K/AKT pathway 
The effect of cPLA2α expression positively upregulated the AKT pathway. Overexpression of 
cPLA2α caused a significant (P < 0.05) increase in pAKT (both at Ser
473
 and Thr
308
) and its 
downstream effectors, pGSK3β and cyclin D1 (Figure 3.17), whereas total AKT and GSK3β 
were not significantly (P > 0.05) altered. The same dose of Dox in cells transfected with the 
empty vector control showed no significant increase in pAKT, pGSK3β or cyclin D1 levels 
(Figure 3.17). Overall, overexpression of cPLA2α led to increased levels of pAKT and its 
downstream targets. 
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a) 
 
b)  
 
Figure 3.17 Effects of cPLA2α overexpression on AKT pathway. LNCaP TRE-clones were treated 
with or without Dox for 24 h and examined by a) immunoblot on pAKT (Ser
473
 and Thr
308), pGSK3β 
and cyclin D1. b) Quantified band intensity represented as the mean ± SD (n = 4 independent 
experiments, pAKT values are for Ser
473
. * P < 0.05 versus no Dox treatment One-Way ANOVA. 
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3.3.5.4 Effect of cPLA2α overexpression on ERK and AR 
The effect of cPLA2α expression on ERK and AR was also examined. Unlike the effect on 
the AKT pathway, cPLA2α induction did not induce a change in pERK, ERK (Figure 3.18) 
or AR (Figure 3.19) levels.  
 
  
Figure 3.18 Effect of cPLA2α overexpression on ERK. LNCaP TRE-cPLA2α clones were treated 
with or without Dox for 24 h and examined by immunoblot for pERK and ERK levels. 
 
 
Figure 3.19 Effect of cPLA2α overexpression on AR. LNCaP TRE-cPLA2α were treated with or 
without Dox for 24 h and examined by immunoblot for AR levels. 
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3.3.6. Biological changes in LNCaP cells following cPLA2α overexpression  
3.3.6.1 Measurement by cell counting 
Although cPLA2α overexpression leads to increased levels of pAKT and its downstream 
targets, this increase in signal did not ultimately translate to cell proliferation. Although there 
was significant increase in cell number between Dox induced and non-induced cells for some 
clones (e.g. 105 at 48 h, P < 0.05), no significant difference was detected at 72 h for all clones 
(Figure 3.20). LNCaP TRE-Vector cells showed no increase but rather a decrease in 
proliferation after 72 h treatment (Figure 3.21). Therefore, cPLA2α overexpression did not 
seem to increase LNCaP cell number. 
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c) 
 
 
d) 
 
Figure 3.20 Cell counting on cPLA2α overexpression clones. a-d) LNCaP TRE-cPLA2α clones 
were treated with or without Dox for up to 72 h. At end of each time point, cells were trypsinised, 
spun down and counted by haemacytometer. Cell number per well is represented as the mean ± SD (n 
= 3 independent experiments). * P < 0.05 versus no Dox treatment. 
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Figure 3.21 MTS assay on LNCaP TRE-Vector cells. LNCaP TRE-Vector cells were treated with 
or without Dox for 72 h. At end of treatment, cells’ proliferation were measured by MTS assay. Cell 
proliferation is represented as the mean ± SD relative to no Dox (n = 3 independent experiments). * P 
< 0.05 versus no Dox treatment. 
 
3.3.6.2 Measurement of cell cycle by flow cytometry  
To find out whether ectopic expression of cPLA2α affected normal cell cycle, LNCaP TRE-
cPLA2α clones were analysed by flow cytometry using PI staining. Similar to the results of 
cell counting, cPLA2α-overexpressing cells showed no significant change in percentage of 
cells in G1/G0 phase after either 24 or 48 h (Figure 3.22 A–D). Control cells that did not 
overexpress cPLA2α also did not show a change after 48 h, as expected (Figure 3.22 E).  
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e) 
 
Figure 3.22 Cell cycle distribution in LNCaP cells with or without cPLA2α overexpression. a-d) 
LNCaP TRE-cPLA2α clones were induced with or without Dox for 24 or 48 h. e) LNCaP TRE-Vector 
were induced with or without Dock for 48 h. At end of treatment, cells were harvested, fixed in 80% 
ethanol and stained with PI. Flow cytometric analysis showed cell cycle distributions and LNCaP 
TRE-Vector cells were used as control. Histograms show mean ± SD (n = 2 independent experiments). 
 
3.4 Discussion 
Previous studies have shown the importance of cPLA2α action in several cancers (204; 256; 
263). cPLA2α action leads to increased AA and eicosanoid synthesis, both of which have 
been frequently implicated in giving pro-proliferative signals in cancer (247-250). AA and 
eicosanoid regulate signalling in the AKT, ERK and AR pathways through multiple ways: (1) 
eicosanoids may transactivate EGFR through prostanoid receptors to activate PI3K/AKT and 
ERK (249; 251); (2) inactivation of PTEN through ROS produced from eicosanoid synthesis 
(83) leads to increased AKT signalling and removal of AR inhibition (101); or (3) AA 
induces de novo androgen synthesis, which is required for AR signalling, particularly to 
overcome hormone therapy (260). However, few studies have documented any mechanism or 
direct correlation between cPLA2α action and prostate cancer. 
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The importance of cPLA2α came to light when previous findings from our lab showed that 
cPLA2α is expressed in prostate cancer cells and pcPLA2α, which increases AA generation 
(264), is increased in hormone refractory cancers (204; 205; 265; 266). In addition, ANX2, 
the inhibitor of cPLA2α is also absent in late stages of prostate cancer (214). Given the 
extensive link between AA and the pro-proliferative pathways driving prostate cancer, we 
propose that cPLA2α itself plays a central role in mediating these signals. 
 
The aim of developing the current cPLA2α overexpression model was to test the importance 
of cPLA2α in PTEN-null prostate cancer, where signalling from AKT, ERK and AR 
pathways drives proliferation (20; 97; 267; 268). The mechanism of how cPLA2α influences 
cancer through these pro-proliferative pathways may also be explored. Further, this model 
manipulated cPLA2α directly, rather than as many studies did by focusing on AA, eicosanoid-
producing enzymes, or regulators of cPLA2α, then implying a cPLA2α effect on AKT or ERK.  
 
If cPLA2α action leads to the activation of proliferative pathways, its overexpression should 
show an increase of this effect. Using the LNCaP TRE-cPLA2α model, we found that cPLA2α 
can be induced by Dox at concentrations well below the concentration (> 5 µg/mL) of Dox’s 
other reported activities, such as inhibition of matrix metalloproteinases (269). This induced 
cPLA2α can be phosphorylated and is enzymatically active (Figure 3.15 and 3.16). 
Overexpression of cPLA2α led to an increase of pAKT (Ser
473
 and Thr
308
) and its immediate 
downstream effector pGSK3β. An increase in cyclin D1 expression was also observed, 
consistent with an inactivation of GSK3β by AKT phosphorylation (52). In addition, 
pharmacological blockade of cPLA2α with Efipladib was able to attenuate the pAKT increase 
induced by cPLA2α overexpression (Chapter 5). However, this increase in signalling in AKT 
(due to cPLA2α overexpression) was not accompanied by an equal increase in pERK and AR 
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(Figure 3.18 and 3.19). In accordance with findings on pERK and AR, cPLA2α 
overexpression did not stimulate an increase in cell proliferation within 72 h and cell cycle 
within 48 h (Figure 3.20–3.22).  
 
It is possible that the apparent increase in cPLA2α was limited by the amount of AA present 
in the phospholipid membrane in vitro. This speculation is in accordance with previous 
literature (252; 270), which documented significant increases in pAKT and cell proliferation 
in PTEN-null prostate cancer cells following AA treatment at micromolar concentrations. 
LNCaP TRE-cPLA2α cells showed a mere 2.5–3 fold increase in AA at nanogram 
concentrations following overexpression (Figure 3.16) and this level of AA is well below the 
concentrations inducing cell proliferation from previous reports (270). Further, findings from 
this study (AA treatment, Chapter 5) show that AA was best at increasing PTEN-null prostate 
cancer cells at ~2.5 µM and not effective below the micromolar range. This may also be the 
reason for the lack of increase in pERK and AR. 
 
In summary, work in this chapter describes a model of a cPLA2α-inducible PTEN-null 
prostate cancer cell line. This model reflects the conditions of prostate cancer in terms of 
increased AKT signalling and cPLA2α activation. Our studies here suggest while increased 
cPLA2α expression and phosphorylation do not necessarily lead to increased cell proliferation 
and ERK and AR activation over the study period, significant metabolic changes could 
already be detected in PI3K/AKT pathway. Therefore, the link between cPLA2α and 
PI3K/AKT exists and is quite active. 
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CHAPTER 4 
EFFECT OF GENETIC SILENCING 
OF cPLA2α ON PTEN-NULL 
PROSTATE CANCER CELLS 
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4.1 Introduction 
An aberrant increase in AKT signalling is a salient feature of advanced PC and can be used to 
predict disease severity and outcome (11; 30; 32; 271). Activated AKT can be increased by 
many factors as described in Chapter 1. The aberrant activation of AKT is one of the main 
sources of proliferative signalling in PC and can even affect other parallel pro-proliferative 
pathways. For example, loss of PTEN, which increases AKT activation, in PC increases AR 
nuclear localisation and reduces AR degradation (101).  
 
Few options exist to inhibit activated AKT without causing a vertical compensation, such as a 
negative feedback loop involving S6 kinase and IRS1 or a horizontal compensation in other 
oncogenic pathways (97). Under AKT inhibition, ERK activation is increased due to (i) p53-
mediated HB-EGF expression (131), (ii) removal of AKT suppression on B-Raf and c-Raf 
signalling (95) and (iii) Ras activation by the aforementioned negative feedback loop of AKT 
pathway (93; 94; 98). Therefore, inhibition of AKT signalling per se is not enough to prevent 
PC cell proliferation.  
 
The inducible cPLA2α expression model described in the last chapter, showed a positive link 
between cPLA2α and AKT signalling in PTEN-null PC cells, despite no increase in cell 
proliferation. In this chapter, the role of cPLA2α in sustaining AKT signalling is explored 
further. The hypothesis is that if increased cPLA2α expression and activity is able to 
upregulate AKT signalling, an inhibition of cPLA2α should down-regulate AKT signalling. 
Indeed, much previous literature has documented how inhibition of eicosanoid-producing 
enzymes, which are downstream of cPLA2α, reduces cell proliferation.   
 
88 
 
The limited available literature on the role of cPLA2α in cancer points to a link between 
cPLA2α expression/activity and activation of AKT. In breast tumour lysates, cPLA2α 
expression is correlated with mTORC1/2 signalling (272). Inhibition of cPLA2α in lung 
tumour cells by the non-selective inhibitor AACOCF3 prior to irradiation prevented 
radiation-induced AKT and ERK phosphorylation, suppressed tumour growth and decreased 
overall tumour blood flow and vascularity (263; 273). Further, decreases in cPLA2α activity 
have been shown to reduce AKT phosphorylation in PC cells (204).  
 
cPLA2α has also been shown to affect cancer cell proliferation. Inhibition of cPLA2α by 
pyrrolidine reduced non-small cell lung cancer cell growth and BrdU incorporation (274). 
Inhibition of cPLA2α also reduced colon cancer cell proliferation via inhibition of the PKA 
and AKT pathways (275). In in vivo settings, cPLA2α knockout mice are viable and appear 
phenotypically normal. The females are infertile and both genders have impaired eicosanoid 
generation from inflammatory cells (200). Importantly, the mice exhibited reduced small 
bowel (276; 277) and lung tumourigenesis (278). Thus, cPLA2α expression and activity is 
required for tumourigenesis and may very well be important for proliferation of PC. This 
chapter use genetic silencing for cPLA2α inhibition to further determine the role of cPLA2α in 
AKT, ERK and AR signalling. 
 
4.2 Materials and methods 
Refer to Chapter 2 for methodologies and an outline on conditions used for cell culture. All 
experiments in this Chapter were repeated at least three times, unless indicated otherwise. 
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4.2.1 siRNA transfection 
LNCaP, PC-3 or A431 cells were grown in T75 flasks until semi-confluent. Then they were 
trypsinised and seeded in 6-well plates in different cell numbers depending on duration of 
treatment (150 k cells for 2 d; 125 k cells for 3 d and 75 k cells for 4 d). Immediately after 
seeding, they were transfected with 10 nM si-cPLA2α or si-control, which was mixed with 
lipofectamine 2000 in 1:2 v/v ratio (for 20 min prior to transfection). OPTI-MEM was used 
as the transfection medium for initial dilution of si-cPLA2α, si-control or lipofectamine 2000. 
Cells were incubated overnight at 37 
o
C before the media with 10% FBS was replenished and 
the cells were left to propagate for another 48–96 h. At end of treatment cells were lysed for 
immunoblot and RNA extraction. RT-PCR analysis was done to confirm significant reduction 
of cPLA2α mRNA in si-cPLA2α versus si-control before proceeding to immunoblot.  
 
4.3 Results 
4.3.1 cPLA2α silencing by siRNA 
4.3.1.1 Measurement of transfection efficiency 
To transfect PTEN-null PC cells with siRNA against cPLA2α, we first tested the transfection 
efficiency of stealth® siRNA using fluorescent oligonucleotides made using the same 
stealth® technology. Successfully transfected cells fluoresce and were detected by flow 
cytometry using laser against fluorescein isothiocyanate. Transfection efficiency in LNCaP 
cells was significantly greater (80%) compared to control (0.17%) (Figure 4.1). 
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a) 
 
b) 
 
c) 
 
Figure 4.1 Transfection efficiency of stealth oligonucleotide in LNCaP cells. Typical plot of 
forward scatter versus side scatter of cells and side scatter versus fluorescence for a) control and b) 10 
nM fluorescent oligo-transfected LNCaP cells. c) Histogram of cells versus fluorescent transfected 
cells. Transfection efficiency represented as mean ± SD (n=3 independent experiments). 
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4.3.1.2 Changes in mRNA level 
To silence cPLA2α, LNCaP cells were treated with 10–40 nM of siRNA and changes to 
cPLA2α mRNA were measured by RT-PCR analysis (Figure 4.2 C). The cPLA2α mRNA 
level was reduced by over 91% following 10 nM siRNA (si-cPLA2α) treatment compared 
with siRNA targeting a randomly-scrambled sequence of similar GC-content (si-control).  
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a) 
 
b) 
 
c) 
 
Figure 4.2 cPLA2α mRNA level following treatment. LNCaP cells were treated with si-cPLA2α or 
si-control for 48 h. Cells were harvested for mRNA extraction and analysed by RT-PCR. a)–b) cDNA 
dilutions of cPLA2α or TBP amplification were made to create a standard curve for calculation of 
concentration. c) Histograms are mean mRNA level ± SEM (n=2 independent experiments). * P < 
0.05 versus si-control (One-Way ANOVA). 
 
 
TBP standard curve 
cPLA
2
α standard curve 
93 
 
4.3.1.3 Optimisation of treatment durations 
To choose an optimal length of siRNA treatment, LNCaP cells were treated with si-cPLA2α 
over 96 h to compare the best rate of mRNA knockdown between each time point. Results 
show cPLA2α knockdown is most effective at 48 h after treatment with over 95% reduction in 
cPLA2α mRNA (Figure 4.3). 
 
 
 
Figure 4.3 cPLA2α mRNA level following treatment. LNCaP cells were treated with si-cPLA2α or 
si-control for 48, 72 and 96 h. Cells were harvested for mRNA extraction and analysed by RT-PCR. 
Changes in mRNA level are represented as means ± SEM (n=2 independent experiments). 
 
To confirm that changes in cPLA2α mRNA lead to a decrease in cPLA2α protein level, the 
same treatment was carried out in LNCaP cells for 2, 4 or 6 d before cell lysis for 
immunoblot. The cPLA2α protein levels were reduced at all time points examined but si-
cPLA2α was most effective at 4 d after treatment (Figure 4.4). Result from the 6 d treatment 
shows that si-cPLA2α set 2 was more effective than set 1. Since there was about a 3–5 fold-
increase in cPLA2α protein levels following Dox induction, a shorter exposure time for 
imaging was used in Chapter 3. To objectively demonstrate the silencing of cPLA2α, a 
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longer exposure was used in this chapter. This explains the difference in endogenous cPLA2α 
levels between figures from the two chapters. 
 
a) 2 day treatment 
 
b) 4 day treatment 
 
c) 6 day treatment 
 
Figure 4.4 cPLA2α protein level following treatment. LNCaP cells were treated with two si-
cPLA2α targeting different sections, si-Control or lipofectamine alone for a) 2 day, b) 4 day and c) 6 
day. Amount of cPLA2α remaining after siRNA knockdown was probed by immunoblot. 
Lipofectamine alone and si-control were used as controls. Overexpression clone LNCaP TRE-cPLA2α 
105 were used as positive controls for b) and c). 
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4.3.1.4 siRNA treatment on PC-3 and LNCaP cells 
Using the time and dose calibrated from previous experiments, PC-3 and LNCaP cells were 
treated with si-cPLA2α or si-control. Total cPLA2α levels were reduced by ~70% in both cell 
lines (Figure 4.5). The reduction in cPLA2α protein levels lead to a concurrent decrease in 
pcPLA2α to over 70% and around 50% in PC-3 and LNCaP cells respectively. 
 
 
Figure 4.5 cPLA2α protein level following treatment. A decrease in total and phospho-cPLA2α in 
PC-3 and LNCaP cells following a 48 h/37 °C treatment with si-cPLA2α relative to si-control. The 
marked reduction of bands at 85 kDa by cPLA2α siRNA also verified that the bands detected by a) 
anti-total and b) phospho cPLA2α antibodies were cPLA2α. c) Histograms representing the 
densitometric analysis are mean ± SD (n=6 independent experiments). * P < 0.05 versus si-control. 
 
 
96 
 
4.3.2 Effect of cPLA2α silencing on the PI3K/AKT pathway 
Incubation with si-cPLA2α led to a significant (P < 0.05) decrease in pAKT levels relative to 
the si-control in both cell lines (Figure 4.6 and 4.7). There was a trend of decrease in cyclin 
D1 in PC-3 and pGSK3β in LNCaP after incubation with si-cPLA2α relative to the si-control 
(Figure 4.6 and 4.7), but both did not reach statistical significance (P = 0.1).  
 
To determine the role of cPLA2α in influencing the AKT response to mitogens, PC-3 and 
LNCaP cells were treated with si-cPLA2α or si-control in the presence or absence of EGF 
(Figure 4.7, 4.8 and 4.9). In these studies, incubation of PC-3 cells treated with si-
control/EGF elicited a significant (P < 0.05) increase in pAKT (Ser
473
) relative to the si-
control alone (Figure 4.7), but this stimulation was not observed in LNCaP cells (Figure 4.8). 
Both cell lines showed increased pAKT (Thr
308
) (Figure 4.9). However, in the presence of 
cPLA2α siRNA and EGF (si-cPLA2α/EGF), pAKT (both Ser
473
 and Thr
308
) levels diminished 
significantly (P < 0.05) in both cell lines relative to the si-control/EGF. In addition, relative to 
the si-control, levels of pGSK3β were significantly (P < 0.05) increased after incubation of 
PC3 or LNCaP cells with si-control/EGF (Figure 4.7 and 4.8). For cyclin D1, the increase in 
si-control/EGF was significant (P < 0.05) in both cell lines. By incubation of cells with si-
cPLA2α/EGF as opposed to si-control/EGF (Figure 4.7 and 4.8), the levels of pGSK3β and 
cyclin D1 were significantly decreased (P < 0.05) in both cell lines. Total AKT and GSK3β 
were not significantly altered between different treatments. It was noted that EGF treatment 
alone in LNCaP and PC3 cells increased endogenous pcPLA2α, but total cPLA2α was 
unchanged (Figure 4.7). Overall, these experiments show that silencing of cPLA2α leads to 
down-regulation of pAKT and its signalling in these cells. 
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Figure 4.6 Genetic silencing of cPLA2α and EGF treatment in PC-3 and LNCaP cells.  
a) PC-3 and b) LNCaP cells were treated with si-cPLA2α for 48 h. 30 min before treatment, EGF (20 
ng/mL/30 min) was used to stimulate the cells. Immunoblots are representative of 6 independent 
experiments. 
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Figure 4.7 Genetic silencing of cPLA2α in PC-3 cells diminishes AKT signalling by immunoblot. 
PC-3 cells treated with si-cPLA2α for 48 h showed reduced pAKT (Ser
473
), pGSK3β and cyclin D1 
levels under basal or EGF-stimulating (20 ng/mL/30 min) conditions. a) Immunoblots are 
representative of 4 independent experiments; b) Histograms representing densitometric analysis are 
mean ± SD (n=4). * P < 0.05 versus si-control. # P < 0.05 versus si-control/EGF. 
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Figure 4.8 Genetic silencing of cPLA2α in LNCaP cells diminishes AKT signalling by 
immunoblot. LNCaP cells treated with si-cPLA2α for 48 h showed reduced pAKT (Ser
473
), pGSK3β 
and cyclin D1 levels under either basal or EGF-stimulating (20 ng/mL/30 min) conditions. 
Immunoblots in a) are representative of 4 independent experiments, while the histograms in b) 
representing the densitometric analysis are mean ± SD (n=4 independent experiments). * P < 0.05 
versus si-control. # P < 0.05 versus si-control/EGF. 
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Figure 4.9 Genetic silencing of cPLA2α in PC-3 and LNCaP cells diminishes AKT 
phosphorylation at Thr
308
. PC-3 a) or LNCaP b) cells treated with si-cPLA2α for 48 h showed 
reduced pAKT at Thr
308
. Immunoblots in a-b) were representative of 3 independent experiments (n=3). 
 
 
4.3.3 Effect of cPLA2α silencing on ERK and AR 
It is known that blocking the PI3K/AKT pathway may induce a compensatory response in 
ERK (97), and thus could be  ineffective at reducing cell proliferation. To investigate whether 
this phenomenon exist following cPLA2α silencing (which reduces pAKT) total and phospho 
ERK were probed by immunoblot (Figure 4.10 and 4.11). In these studies, pERK 1/2 levels 
were examined under basal or EGF-stimulated conditions with or without si-cPLA2α or si-
control. The levels of pERK 1/2 were relatively low under basal culture conditions in PC-3 
cells and no significant (P > 0.05) change was noted after treatment with cPLA2α siRNA 
relative to the si-control (Figure 4.10). For LNCaP cells under basal culture conditions there 
was a marginal decrease (P = 0.07) in pERK 1/2 levels after treatment with cPLA2α siRNA 
relative to the si-control (Figure 4.11). However, after incubation with the si-control/EGF, 
there was a marked (P < 0.05) increase in pERK 1/2 levels relative to the si-control in both 
cell-types (Figure 4.10 and 4.11). The level of pERK 1/2 was significantly (P < 0.05) 
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reduced in both PC-3 and LNCaP cells upon incubation with si-cPLA2α/EGF relative to 
treatment with the si-control/EGF. Under all treatment conditions, total ERK 1/2 levels were 
not significantly altered in either cell lines (Figure 4.10 and 4.11). 
 
 
 
Figure 4.10 Genetic silencing of cPLA2α in PC-3 cells diminishes ERK signalling under EGF 
stimulated conditions. PC-3 cells transfected with cPLA2α siRNA for 48 h/37 °C show reduced 
pERK 1/2 levels relative to the scrambled control under EGF-stimulating (20 ng/mL/30 min) 
conditions. a) Immunoblots are representative of 4 independent experiments, while the histograms 
representing the densitometric analysis are mean ± SD (n = 4). * P < 0.05 versus si-control. # P < 0.05 
versus si-control/EGF. 
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Figure 4.11 Genetic silencing of cPLA2α in LNCaP cells diminishes ERK signalling under EGF 
stimulated conditions. LNCaP cells transfected with cPLA2α siRNA for 48 h/37 °C show reduced 
pERK 1/2 levels relative to the scrambled control under EGF-stimulating (20 ng/mL/30 min) 
conditions. The level of AR was reduced under basal and EGF-stimulating conditions after incubation 
of LNCaP cells with si-cPLA2α relative to the scrambled control. a) Immunoblots are representative 
of 4 independent experiments, while the histograms representing the densitometric analysis are mean 
± SD (n = 4 independent experiments). * P < 0.05 versus si-control. # P < 0.05 versus si-control/EGF. 
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An increase in AR levels is an important mechanism involved in the progression of hormone-
refractory PC (149; 176). The effect of cPLA2α silencing on AR expression was therefore 
determined next. Since PC-3 cells do not express AR (279), LNCaP cells were used to the 
examine the change in AR levels (Figure 4.10). Interestingly, although AR protein levels 
were significantly (P < 0.05) increased in response to si-control/EGF relative to the si-control, 
there was a significant (P < 0.05) reduction of AR protein level after cPLA2α siRNA 
treatment, regardless of the presence or absence of EGF (Figure 4.11). Treatment with si-
cPLA2α negated the EGF effect on AR increase. However, no significant change in AR 
mRNA level was observed under the same incubation conditions (Figure 4.12). Collectively, 
these experiments show that silencing cPLA2α does not lead to a compensatory increase in 
the oncogenic pathways mediated by pERK 1/2 or the AR, suggesting that cPLA2α may be a 
useful therapeutic target. 
 
 
 
Figure 4.12 AR mRNA levels remain unchanged after incubation with si-cPLA2α relative to si-
control. LNCaP cells were transfected with si-cPLA2α (10 nM, 48 h) in the presence or absence of 
EGF (20 ng/mL/30 min). The levels of AR mRNA were determined by RT-qPCR, normalised by 
levels of TBP and expressed relative to si-control. Histograms represent mean AR mRNA levels ± SD 
(n=3 independent experiments). 
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4.4 Effect of cPLA2α silencing on PTEN-null prostate cancer cell proliferation 
4.4.1 Measurement by cell number and DNA synthesis 
Changes in biochemical pathways underpin changes in cell proliferation. To find out whether 
the biochemical changes following cPLA2α silencing lead to inhibition of proliferation, PC-3 
and LNCaP cells were treated with si-cPLA2α or si-control and measured by cell counting 
(Figure 4.13) and/or SyBr green assay (Figure 4.14 and 4.15). cPLA2α silencing reduced 
LNCaP cell numbers by up to 24% following 4 d treatment (Figure 4.13). The decrease in 
proliferation was dose dependent for both cell lines, with reduction reaching as high as 49% 
in both cell lines (Figure 4.14 and 4.15). For LNCaP, the magnitude of this decrease 
increased over time, with highest at 5 d. For PC-3, the decrease in proliferation reduced from 
49% (3 d) to 34% (5 d) over time. Taken together, cPLA2α silencing reduced PC-3 and 
LNCaP cell proliferation over time in a dose dependent manner.  
 
 
 
 
Figure 4.13 siRNA against cPLA2α reduced LNCaP cell proliferation by cell counting. LNCaP 
cells were transfected with 10 nM or 20nM si-cPLA2α or si-control and left to propagate at 37 
o
C for 
96 h. Cells are trypsinised, spun down and counted by haemacytometer. Histograms represent average 
cell number ± SD normalised to si-control (n=3 independent experiments). * P < 0.05 versus si-
control. 
 
* 
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a) 
 
b) 
 
c) 
 
 
Figure 4.14 siRNA against cPLA2α reduces LNCaP cell proliferation by SyBr assay. LNCaP cells 
were transfected with 10, 20 or 40 nM si-cPLA2α or si-control and left to propagate at 37 
o
C for 72, 
96 or 120 h. At end of treatment, cells were added with SyBr green I DNA dye in lysis buffer. The 
amount of DNA present in each well of the culture plate was measured by fluorescence at 485 nm. 
Histograms represent mean fluorescence of each treatment ± SD and normalised to si-control (n=3 
independent experiment). * P < 0.05 versus si-control. 
* 
* 
* 
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Figure 4.15 siRNA against cPLA2α reduced PC-3 cell proliferation by SyBr assay. PC-3 cells 
were transfected with 10 nM si-cPLA2α or si-control and left to propagate at 37 
o
C for 72, 96 or 120 h. 
At end of treatment, cells were added with SyBr green I DNA dye in lysis buffer. The amount of 
DNA present in each well of the culture plate was measured by fluorescence at 485 nm. Histograms 
represent mean fluorescence of each treatment ± SD and normalised to si-control. (n=3 independent 
experiments). * P < 0.05 versus si-control. 
 
107 
 
4.4.2 Flow cytometry analysis on cell cycle 
A reduction in cell number may result from a decrease in cells undergoing the cell cycle or an 
increase in apoptosis. To investigate the underlying cause of reduction in cell numbers, 
propidium iodide (PI) staining and flow cytometry was used. PC-3 and LNCaP cells treated 
with si-cPLA2α or si-control were stained with PI before being analysed by flow cytometry. 
cPLA2α silencing in PC-3 and LNCaP cells significantly increased cells in G1/G0 phase 
(Figure 4.16 and 4.17). This was due to a significant decrease in cells in G2/M phase in both 
cell lines. There was a significant reduction in S phase for LNCaP cells treated with si-
cPLA2α compared to control, but not for PC-3. There was also an increase in Sub-G1 (2.4%) 
for PC-3 cells, but this was not observed in LNCaP cells. Overall, flow analysis showed 
cPLA2α silencing significantly reduced PC-3 and LNCaP cell proliferation through an 
increase in G1/G0 phase and a decrease in G2/M phase.  
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Figure 4.16 cPLA2α silencing increased G1/G0 in PC-3 cells. PC-3 cells treated with si-cPLA2α or 
si-control were grown for 48 h before been harvested and fixed in 80% ethanol. Cells were then added 
with PI (20 µg/mL) and RNase (100 µg/mL) for 1 h and then analysed by flow cytometry. 
Appropriate single cells were gated from multiple cell clusters and separated according to 
fluorescence intensity. Cells in each cell cycle phase were gated according to DNA content (2N for 
G1/G0, 4N for G2/M, >2N and <4N for S; those <2N were sub-G1). Histograms represent mean 
percentage of cell population ± SD (n=3 independent experiments). * P < 0.05 versus si-control. 
 
 
Figure 4.17 cPLA2α silencing increased G1/G0 in LNCaP cells. LNCaP cells treated with si-
cPLA2α or si-control were grown for 48 h before been harvested and fixed in 80% ethanol. Cells were 
then added with PI (20 µg/mL) and RNase (100 µg/mL) for 1 h and then analysed by flow cytometry. 
Appropriate single cells were gated from multiple cell clusters and separated according to 
fluorescence intensity. Cells in each cell cycle phase were gated according to DNA content (2N for 
G1/G0, 4N for G2/M, >2N and <4N for S; those <2N were sub-G1). Histograms represent mean 
percentage of cell population ± SD (n=3 independent experiments). * P < 0.05 versus si-control. 
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4.5 cPLA2α silencing reduces pEGFR signalling in A431 cells 
Previous experiments show that cPLA2α inhibition reduces activation of AKT and ERK 
pathways under basal and mitogens stimulated conditions (Chapter 4). EGFR is a RTK that 
may pass on a signal to the PI3K/AKT and ERK pathways and is likely to play a role in 
mediating cPLA2α action. Eicosanoids synthesised from AA have been shown to 
transactivate EGFR via prostanoid receptors (249; 251). LNCaP cells have very low levels of 
pEGFR, which is difficult to detect. To find out whether EGFR activation is involved in 
mediating cPLA2α signal, some pilot experiments were done using A431 cancer cells, which 
have increased EGFR due to a B-Raf mutation (280) so pEGFR can be easily detected.  
 
To show cPLA2α is indeed be reduced by siRNA, A431 cells were incubated with si-cPLA2α 
or si-control. qRT-PCR analysis showed a decrease in cPLA2α mRNA level in si-cPLA2α 
treated cells compared with si-control (Figure 4.18). Next, EGFR phosphorylation and its 
signalling were examined. Incubation with si-control/EGF increased EGFR phosphorylation 
significantly compared to si-control alone (Figure 4.19). This effect was also seen in pERK 
but not in pAKT. However, treatment of si-cPLA2α/EGF showed significant decrease in 
pEGFR and pERK compared with si-control/EGF (P < 0.05). pAKT (Ser
473
) was not 
significantly affected, and neither were total levels of AKT or ERK. Taken together, these 
results suggest that EGFR may at least partially mediate cPLA2α action on ERK signalling in 
A431 cells. Thus, similar results may be hypothesised for PTEN-null PC cells.  
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Figure 4.18 cPLA2α mRNA was reduced by si-cPLA2α in A431 cells. A431 cells were treated with 
si-cPLA2α or si-control for 48 h. Cells were harvested for RNA extraction and RT-PCR analyses. 
Histograms are mean values of mRNA ± SD corrected by values of TBP and normalised si-control 
(n=2 independent experiments). * P < 0.05 versus si-control.  
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a) 
 
b) 
 
Figure 4.19 cPLA2α reduced EGFR activation under stimulated conditions in A431 cells. A431 
cells were treated with si-cPLA2α or si-control for 48 h. Cells were lysed at the end of treatment and 
used for immunoblot. a) Immunoblots are representative of 2 independent experiments, while the 
histograms b) representing the densitometric analysis are mean ± SD (n=2). * P < 0.05 versus si-
control. # P < 0.05 versus si-control/EGF. 
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4.6 Discussion 
In this chapter, the aim was to study the effect of cPLA2α silencing on PI3K/AKT, AR and 
ERK pathways. Following cPLA2α silencing, all three pathways showed levels of down-
regulation. Further, this effect was more pronounced under mitogen-stimulated conditions. 
Importantly, while cPLA2α overexpression had no effect on PTEN-null PC cell proliferation, 
the inhibition of cPLA2α caused a significant reduction of cell proliferation (Figure 4.13–15). 
This demonstrates the vital role of cPLA2α in sustaining signalling in these cells. The effects 
of cPLA2α action were most likely due to its product AA and eicosanoids through a paracrine 
or autocrine fashion. Pilot experiments on A431 cells also suggest the possible involvement 
of EGFR in mediating cPLA2α action on ERK. The role of EGFR in mediating cPLA2α 
action on pAKT and AR is uncertain at present (Figure 4.19). 
 
Previous studies have shown an increase in pAKT together with a decrease in pERK 1/2 in 
poorly differentiated PC (30; 32; 66). This inverse relationship is likely due to AKT 
phosphorylation of B-Raf at Ser
259
 that provides a binding site for 14-3-3 protein (281) and 
other mechanisms discussed in Section 4.1. This is likely the reason for the low levels of 
endogenous pERK found in PC-3 and LNCaP cells as pAKT was aberrantly increased in 
these two PTEN-null cell lines, as well as the possible explanation for the compensational 
increase in ERK following AKT inhibition (97). However, no compensatory increase in ERK 
was observed following cPLA2α silencing in this chapter. We speculate that cPLA2α is able 
to decrease activation of EGFR in addition to the effect on AKT. Under this setting, a 
decrease in AKT signalling is also met with a concomitant reduction in signalling upstream 
ERK. Hence, the compensatory mechanism from the ERK pathway is difficult to manifest. 
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Previous literature has not documented any link between cPLA2α and AR. However, our 
study demonstrated that cPLA2α is crucial for sustaining the AR level in PTEN-null PC cells. 
Previous publications from our lab have documented a concomitant decrease in cPLA2α 
activation and AR level by Mediterranean food extracts (282), however it does not provide 
any link in between. Although cPLA2α is important in providing AA, which induces 
androgen synthesis for AR signalling (260), cPLA2α inhibition perhaps affects AR through 
some undefined mechanisms. It is possible that this mechanism is post-translational, as EGF 
treatment increases AR protein levels within 30 min (Figure 4.11) and cPLA2α silencing can 
nullify this stimulation and keep AR levels down.  
 
In conclusion, cPLA2α inhibition by genetic silencing in PTEN-null PC cells down-regulates 
activation of the PI3K/AKT, ERK and AR pathways without any compensation between each 
pathway. This finding indicates that cPLA2α is an attractive target for inhibition of PC.  
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CHAPTER 5 
PHARMACOLOGICAL INHIBITION 
OF cPLA2α AND AA ADD-BACK IN 
PTEN-NULL PROSTATE CANCER 
CELLS  
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5.1 Introduction 
Eicosanoids are synthesised from intracellular AA, which is released from membrane 
glycerophospholipids by PLA2 (283; 284). As cPLA2α is the most predominant enzyme 
responsible for AA supply to eicosanoid-producing enzymes, a better outcome may be 
achieved with cPLA2α inhibition than with a COX or LOX inhibitor alone. While inhibitors 
such as COX have cardiovascular side effects (237) and cause gastrointestinal bleeding (254), 
knocking out cPLA2α in mice was not associated with disease (199). Highly specific 
inhibition of cPLA2α may be achieved through genetic silencing using siRNA as shown in 
Chapter 4. However a pharmacological agent targeting cPLA2α is also a viable option and it 
is able to target all cPLA2α enzymes present.  
 
In Chapter 4, experimental data from cPLA2α silencing demonstrated a decrease in 
activation of PI3K/AKT, ERK and AR pathways. The aim of the studies in this Chapter were 
to demonstrate whether Efipladib, a new and potent inhibitor of cPLA2α (285), could be used 
to reduce cPLA2α activity and decrease the activation and expression of AKT, ERK, AR and 
cell proliferation. Moreover, an effort was made to verify the effect of AA and its metabolites 
in the presence or absence of Efipladib, on AKT, ERK and AR activation and expression.   
 
5.2 Materials and methods 
5.2.1 PLA2 activity assay 
In this chapter, PLA2 activity assay was performed using complete cell lysates instead of 
immunoprecipitated cPLA2α (Section 2.4.10). LNCaP cells were treated with Efipladib (15 
µM) or DMSO for 24 h and then washed twice with Hank’s balanced salt solution (5.33 mM 
KCl, 0.441 mM KH2PO4, 4.17 mM NaHCO3, 137.93 mM NaCl, 0.338 mM Na2HPO4 and 
5.56 mM D-glucose). Cells attached in monolayer were scraped off the culture plate using a 
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plastic scraper and resuspended in 400 µL Hank’s balanced salt solution. The cells in 
suspension were lysed using a probe sonicator and the protein concentration was measured by 
Bio-Rad DC protein assay (see Section 2.4.1). A 100 µL cell homogenate was used per 
sample for the PLA2 activity assay according to manufacturer’s instructions. The results 
obtained for each sample were normalised by protein concentration for that sample. 
 
5.2.2 Efipladib and LY294002 treatment 
Efipladib (in powder) was dissolved in DMSO to make 50 µM stock. LY294002 was pre-
dissolved in DMSO. Both drugs were diluted to working concentrations in 10% FBS media. 
DMSO was used as the vehicle control.  
 
5.2.3 Nuclear fractionation 
Nuclear fractionation for AR studies was done as described in Section 2.3.6. 
 
5.2.4 AA-BSA conjugation 
5 µM fatty acid-free BSA was first added to 0% FBS RPMI media. The media was stirred 
until BSA was completely dissolved then sterile filtered. 100 µM AA or ethanol (vehicle 
control) was then added to the BSA media and the mixture was incubated at 37 
o
C on a 
rocking platform for 3 h. The BSA-AA conjugated media was then added with 1% FBS and 
diluted to working concentrations using sterile 5 µM BSA 1% FBS media. For conditions of 
treatment for AA studies see Section 2.2.6. 
 
5.2.5 AA spiking and 5-HETE measurement 
Cell culture, AA spiking and HPLC measurement of HETEs were done as described in 
Section 2.4.4. 
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5.2.6 Cell growth, SyBr green assay, PSA assay and immunostaining  
Refer to Chapter 2 for details.  
All experiments in this Chapter were repeated at least three times, unless indicated otherwise. 
 
5.3 Results 
5.3.1 Inhibition of cPLA2α by Efipladib 
Efipladib is a specific inhibitor of cPLA2α. A decrease in cPLA2α activity in PC-3 cells 
following Efipladib treatment was demonstrated previously by our lab (204; 265). To repeat 
the experiment in LNCaP cells, Efipladib or control treatment was given and the cells were 
analysed by PLA2 assay. After 24 h treatment, Efipladib significantly reduced total PLA2 
activity from LNCaP cell lysates compared with control by 32% (Figure 5.1). Taken together, 
Efipladib reduced cPLA2α activity of both PC-3 and LNCaP cells.  
 
 
Figure 5.1 cPLA2α inhibition results in decreased activity. LNCaP cells treated with Efipladib (20 
µM) or control (DMSO) for 24 h/37 
o
C were lysed and assayed for PLA2α activity. Mean activity 
normalised by protein concentrations were expressed as relative to DMSO (n=3 independent 
experiments). * P < 0.05 versus DMSO by One-Way ANOVA.  
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5.3.2 Effect of cPLA2α inhibition on AKT, ERK and AR activation and/or signalling 
We have seen that genetic silencing of cPLA2α reduced activation or expression of AKT, 
ERK 1/2 and AR in Chapter 4. To evaluate the effect of Efipladib on these pathways, we 
examined the treated PC-3 and LNCaP cells by immunoblot. To understand the effect 
duration of down-regulation of cPLA2α may have on pAKT, PC-3 and LNCaP cells were 
incubated with Efipladib for 24, 48 or 72 h. pAKT (Ser
473
) was reduced at all time points 
compared with control for both cell lines while total AKT stayed the same (Figure 5.2, 5.3 
and 5.4). Moreover, Efipladib caused a significant (P < 0.05) decrease in pERK 1/2 in PC-3 
cells, but an increase in pERK 2 (42 kDa) in LNCaP cells relative to the control (Figure 5.3 
and 5.4). Notably, a significant (P < 0.05) decrease in AR protein levels was also noted in 
LNCaP cells after incubation with Efipladib relative to the control (Figure 5.3). 
 
 
Figure 5.2 Efipladib reduced pAKT (Ser
473
) in PC-3 and LNCaP cells. PC-3 and LNCaP cells 
were incubated with Efipladib (20 μM) or the vehicle control (0.04% DMSO) for 24 or 48 h/37 °C. 
Immunoblots of phospho and total AKT are representative of 3 independent experiments. The vertical 
line indicates the pictures are combined but all from the same gel. 
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Figure 5.3 Efipladib reduced AKT and ERK activation in PC-3 cells. PC-3 cells were incubated 
with Efipladib (20 μM) or the vehicle control (0.04% DMSO) for 72 h/37 °C. a) Immunoblot of 
phospho and total AKT and ERK 1/2 levels in PC-3 cells (n=3 independent experiments); b) 
histograms representing densitometric analysis are mean ± SD (n = 3 independent experiments). * P < 
0.05 versus vehicle-treated controls by One-Way ANOVA. 
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Figure 5.4 Effect of Efipladib treatment on AKT, ERK and AR in LNCaP cells. LNCaP cells 
were incubated with Efipladib (20 μM) or the vehicle control (0.04% DMSO) for 72 h/37 °C. a) 
Immunoblot of phospho and total AKT, pERK 1/2 and AR levels in LNCaP cells. Immunoblots in a) 
are representative of 3 independent experiments and the histograms in b) representing the 
densitometric analysis are mean ± SD (n = 3). * P < 0.05 versus vehicle-treated control by One-Way 
ANOVA. 
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As AKT is dephosphorylated by PHLPP at Ser
473
 (14), we investigated if PHLPP is involved 
in Efipladib action on pAKT (Ser
473
) (Figure 5.2–5.4). Levels of PHLPP phosphatase were 
analysed by immunoblot. Incubation of Efipladib on LNCaP cells for 24, 48 or 72 h showed 
reduction of PHLPP 1 (140 and 190 kDa) (37) and PHLPP 2 (150 kDa) (43) at all time-points 
(Figure 5.5). This result suggests a decrease in AKT phosphorylation after cPLA2α inhibition 
is not due to an increase in PHLPP action.  
 
 
Figure 5.5 Efipladib reduces PHLPP 1/2 LNCaP cells. LNCaP cells were incubated with Efipladib 
(20 μM) or the vehicle control (0.04% DMSO) for 24, 48 or 72 h/37 °C. Immunoblots of PHLPP 1 
and PHLPP 2 were representative of 3 independent experiments. The vertical line indicates the 
pictures are combined but all from the same gel. 
 
 
5.3.3 Combination of PI3K/AKT and cPLA2α inhibition 
Inhibition of AKT activation in PC cells is often ineffective due to processes such as the 
negative feedback loop and so-called horizontal compensation from other oncogenic 
pathways (97). As shown in Chapter 4, cPLA2α inhibition by siRNA reduces AKT 
activation as well as proliferation of PC cells. To find out how cPLA2α inhibition may help 
further decrease PC cell proliferation in addition to AKT inhibition, a combinatorial 
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treatment of Efipladib and LY294002 (a PI3K inhibitor) were used in this study. LNCaP cells 
were treated with varying doses of LY294002 and/or two dose of Efipladib (10 or 20 µM). 
After 3 d treatment, LY294002 (5, 10 or 20 µM) or Efipladib (10 and 20 µM) significantly (P 
< 0.05) reduced LNCaP cell numbers compared with control (Figure 5.6). In addition, co-
treatment with Efipladib (10 µM) significantly (P < 0.05) decreased cell numbers further than 
5, 10 or 20 µM of LY294002 alone. The same synergistic effect was observed for 20 µM 
Efipladib and 20 µM LY294002 as their co-treatment significantly (P < 0.05) reduced cell 
number than either inhibitor alone. These results suggest that combination treatment of 
LY294002 and Efipladib significantly reduced LNCaP cell proliferation more than PI3K 
inhibition alone.  
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Figure 5.6 Concomitant treatment of Efipladib and LY294002 reduced LNCaP cell numbers 
greater than either inhibitor treatment alone. LNCaP cells seeded in 96 well plates were treated 
with Efipladib (10 or 20 µM) or LY294002 (5, 10 or 20 µM) or a combination of the two inhibitors at 
varying concentrations for 72 h/37 
o
C. 0.04% DMSO was used as the vehicle control. Cells were 
subjected to SyBr green assay at the end of treatment. A standard curve based on accurately dispensed 
cells was used to work out the cell numbers based on fluorescence. Histograms represent mean cell 
numbers ± SD of 2 independent experiments. # P < 0.05 versus control, * P < 0.05 versus 10 µM 
Efipladib or 5 µM LY294002, ** P < 0.05 versus 10 µM Efipladib or 10 µM LY294002, *** P < 0.05 
versus 10 µM Efipladib or 20 µM LY294002, **** P < 0.05 versus 20 µM Efipladib or 20 µM 
LY294002 by One-Way ANOVA.  
 
5.3.4 Effect of Efipladib on AR levels, nuclear localisation and PSA 
From Figure 5.4, we saw a significant decrease in AR level in LNCaP cell following cPLA2α 
inhibition. To confirm this, we conducted immunostaining on paraffin-embedded Efipladib-
treated LNCaP cells, which showed ~50% decrease in AR staining compared to control 
(Figure 5.7). AR functions as a nuclear transcription factor and its nuclear translocation is 
crucial for its activity (137; 148). To examine the effect of cPLA2α inhibition on AR level 
inside and outside of the nucleus, we employed nuclear fractionation techniques. Cytosolic 
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and nuclear fractions were separated from LNCaP cells treated with Efipladib or control for 
72 h. GAPDH (cytosolic) and Histone deacetylase 1 (HDAC1) (nuclear) were used as 
controls for the effectiveness of fractionation technique and as loading controls in 
immunoblot (Figure 5.8a). The immunoblot showed that AR levels in both nuclear and 
cytosolic fractions were reduced significantly (P < 0.05) compared with control (Figure 
5.8b). The effect of Efipladib on PSA, a downstream target of AR (166), was then assessed. 
Relative to the control, Efipladib caused a significant (P < 0.05) decrease in PSA levels in the 
medium overlying the LNCaP cell monolayer (Figure 5.9). Taken together, these results 
indicate inhibition of AR and its signalling from cPLA2α blocking.  
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Figure 5.7 Decrease in AR staining following Efipladib treatment. LNCaP cells in T75 flasks were 
incubated with 0.04% DMSO control or Efipladib (20 µM) for 72 h/37
0
C before being harvested and 
processed for paraffin embedding (as described in Section 2.3.4). Sectioned slides were stained with 
anti-androgen receptor antibody or an isotype control. Results are typical of 3 experiments. 
Histograms are mean percentage of positive cells ± SD (n=3 independent experiments). * P < 0.05 
versus DMSO by One-Way ANOVA. Larger image can be found online in supplementary data of 
Hua et al, (2013) (134). 
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Figure 5.8 Decrease in AR level following Efipladib treatment. LNCaP cells were incubated with 
Efipladib (20 µM) for 72 h/37 
o
C. After treatment, cells were lysed and the cytosolic fractions were 
separated from the nuclear fraction. Levels of AR in each fraction were determined by immunoblot. 
Immunoblots in a) are representative of 3 independent experiments and the histograms in b) 
representing the densitometric analysis are mean ± SD (n = 3). * P < 0.05 versus vehicle-treated 
control by One-Way ANOVA). 
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Figure 5.9 Efipladib treatment lead to a reduction of PSA secretion. Media from LNCaP cells 
incubated with Efipladib or 0.04% DMSO control in 6-well plates for 72 h were taken for PSA assay. 
The values obtained from each well were normalised by total protein concentration for that well. 
Histograms represent mean PSA value ± SD (n = 3 independent experiments). * P < 0.05 versus 
vehicle-treated control by One-Way ANOVA. 
 
5.3.5 AA increases PTEN-null prostate cancer cell proliferation  
From results above we saw decreased cPLA2α action leads to decreased levels of pAKT, 
pERK and AR. Since cPLA2α produces AA, a change in AA level is likely a link in affecting 
other signalling pathways. If so, an increase in AA level should increase PC cell proliferation. 
Indeed, treatment with BSA-conjugated AA in low serum conditions significantly increased 
(P < 0.05) the proliferation of PC-3 cells at 0.3125–2.5 µM (Figure 5.10) and LNCaP cells 
at1.25–5 µM (Figure 5.11). In summary, AA is able to increase PC-3 and LNCaP cell 
proliferation.  
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Figure 5.10 AA treatment in PC-3 cells. PC-3 cells seeded in 96 well plates were put under 1% 
serum for 16 h then given BSA (5 µM) conjugated with AA at varying concentrations or BSA alone 
for 72 h/37 
o
C. Cell proliferation was analysed by SyBr green assay at the end of treatment. 
Histograms representing fluorescence intensity relative to control are mean ± SD (n = 3 independent 
experiments). * P < 0.05 versus control by One-way ANOVA. 
 
  
Figure 5.11 AA treatment in LNCaP cells. LNCaP cells seeded in 96 well plates were put under 1% 
serum for 16 h then given BSA (5 µM) conjugated with AA at varying concentrations or BSA alone 
for 72 h/37 
o
C. Cell proliferation was analysed by SyBr green assay at the end of treatment. 
Histograms representing fluorescence intensity relative to control are mean ± SD (n = 3 independent 
experiments). * P < 0.05 versus control by One-way ANOVA. 
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5.3.6 AA add-back against genetic or pharmacological inhibition of cPLA2α 
To assess if AA mediates the effect of cPLA2α action on pAKT, pERK 1/2 and AR levels, we 
next examined the effect of adding exogenous AA to PC-3 and LNCaP cells in the presence 
or absence of cPLA2α siRNA. Incubation with si-cPLA2α in the absence of AA significantly 
(P < 0.05) decreased pAKT and pERK 1/2 levels relative to the si-control in both cell lines 
(Figure 5.12 and 5.13). Addition of AA in the presence of the si-control (si-control/AA) 
significantly (P < 0.05) increased pAKT and pERK 1/2 levels in both cell lines relative to the 
si-control alone (Figure 5.12 and 5.13). The suppressive effect of si-cPLA2α on pAKT in 
both cell-types relative to the si-control was abolished following incubation with AA (si-
cPLA2α/AA). However, although si-control/AA significantly (P < 0.05) increased pERK 1/2 
levels relative to the si-control, si-cPLA2α/AA did not completely abolish the suppressive 
effect of cPLA2α siRNA alone on pERK 1/2 (Figure 5.12 and 5.13). Notably, pERK 2 (42 
kDa) relative to pERK 1 (44 kDa) was mostly affected by incubation with AA alone or 
cPLA2α siRNA plus AA. None of the treatments had any significant effect on total AKT or 
ERK 1/2. Incubation of LNCaP cells with si-control/AA also significantly (P < 0.05) 
increased AR levels relative to cells incubated with the si-control alone (Figure 5.13). 
Further, AA reduced the suppressive effect of cPLA2α siRNA on AR protein levels such that 
the effect of cPLA2α siRNA was no longer significant relative to si-control/AA (Figure 5.13). 
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b) 
 
Figure 5.12 The effect of AA on pAKT and pERK after cPLA2α siRNA treatment in PC-3 cells. 
a) PC-3 cells were treated with or without AA (20 μM) for 4 h/37 °C following a 48 h/37 °C 
incubation with si-cPLA2α relative to the si-control. Immunoblots are representative of 3 independent 
experiments, while b) the histograms representing the densitometric analysis are mean ± SD (n = 3). * 
P < 0.05 versus si-control, # P < 0.05 versus si-control/AA by One-Way ANOVA.   
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b) 
 
 
Figure 5.13 The effect of AA on pAKT, pERK and AR after cPLA2α siRNA treatment in 
LNCaP cells. a) LNCaP cells were treated with or without AA (20 μM) for 4 h/37 °C following a 48 
h/37 °C incubation with si-cPLA2α relative to the si-control. Immunoblots are representative of 3 
independent experiments, while b) the histograms representing the densitometric analysis are mean ± 
SD (n = 3). * P < 0.05 versus si-control. # P < 0.05 versus si-control/AA by One-Way ANOVA.   
 
132 
 
5.3.7 Increase in HETE levels following AA spiking 
Previously, we showed that the 5-LOX product, 5-HETE, was markedly reduced after 
blocking cPLA2α activity (265). To examine whether 5-HETE levels were increased after the 
addition of AA, we incubated PC-3 and LNCaP cells with AA and determined the levels of 
HETE products by HPLC. Indeed, 5-HETE and 15-HETE were the most markedly increased 
HETEs after treatment with AA in both PC3 and LNCaP cells (Figure 5.14).  
 
 
Figure 5.14 Efipladib treatment lead to AR degradation over time. PC-3 and LNCaP cell lysates 
were incubated with AA (0.1 mM/1 h) and the levels of HETE were then determined by HPLC and 
expressed as relative to the 12-HETE. Histograms are mean HETE levels ± SD (n=3 independent 
experiments).  
 
5.3.8 MK886 negates AA effect on pAKT, pERK and AR  
Considering that 5-HETE is decreased after inhibiting cPLA2α (265) and increased after AA 
addition we then determined whether 5-HETE mediates the effect of AA on AKT, ERK 1/2 
and AR, by incubation of cells with AA in the presence or absence of MK886, an inhibitor of 
5-HETE production (286). In these studies, AA significantly (P < 0.05) increased the levels 
of pAKT and pERK 1/2 in PC-3 and LNCaP cells relative to the control, and also AR in 
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LNCaP (Figure 5.15 and 5.16). Importantly, MK886 diminished the stimulatory effect of AA 
in both cell lines. Again, it is pERK 2 (42 kDa) relative to pERK 1 (44 kDa) that was 
typically affected by incubation with AA alone or AA plus MK886. Total AKT and ERK 1/2 
were not significantly altered by any of the treatments relative to the control (Figure 5.15 and 
5.16). Hence, these studies indicate that 5-HETE plays an important role in the effect of AA 
on pAKT, pERK 1/2 and AR expression. 
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b) 
 
Figure 5.15 The effect of AA on AKT and ERK 1/2 levels in PC-3 cells. a) PC-3 cells treated with 
AA (20 μM/4 h/37 °C) in the presence of the 5-LOX inhibitor, MK886. After treatment, cells were 
lysed and analysed by immunoblot. Immunoblots are representative of 3 independent experiments, 
while b) the histograms representing the densitometric analysis are mean ± SD (n = 3 independent 
experiments) * P < 0.05 versus vehicle-treated control, # P < 0.05 versus AA alone by One-Way 
ANOVA. 
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b) 
 
Figure 5.16 The effect of AA on AKT, ERK 1/2 and AR levels in LNCaP cells. a) LNCaP cells 
treated with AA (20 μM/4 h/37 °C) in the presence of the 5-LOX inhibitor, MK886. After treatment, 
cells were lysed and analysed by immunoblot.. Immunoblots are representative of 3 independent 
experiments, while b) the histograms representing the densitometric analysis are mean ± SD (n = 3 
independent experiments) * P < 0.05 versus vehicle-treated control. # P < 0.05 versus AA alone by 
One-Way ANOVA. 
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5.3.9 Measuring cell proliferation by cell counting and SyBr green assay 
cPLA2α silencing by siRNA reduces cell proliferation (Chapter 4). To test the same effect 
from Efipladib, PC-3 and LNCaP cells were treated with various concentrations of Efipladib 
for 72 h. Cell numbers after 72 h were significantly reduced: at 15 and 20 µM for PC-3 and at 
20 µM for both cell lines compared with DMSO control (Figure 5.17). This reduction in 
proliferation was explored further in measurement of DNA content by SyBr green assay. 
DNA content, and thereby proliferation, was significantly reduced for PC-3 cells treated with 
15 µM or higher and LNCaP cells treated with 10 µM or higher concentrations of Efipladib 
(Figure 5.18). These results indicated that Efipladib reduced PC cell proliferation in a dose-
dependent manner.  
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a) 
 
b) 
 
Figure 5.17 PC-3 and LNCaP cell numbers were reduced following Efipladib treatment. a) PC-3 
or b) LNCaP cells were seeded in 6-well plates for 48 h before being treated with various doses of 
Efipladib or 0.04% DMSO (control) and propagated for 72 h/37 
o
C. After treatment, cells were 
trypsinised and harvested for cell counting by haemacytometer. Histograms represent mean cell 
numbers ± SD (n=3 independent experiments). * P < 0.05 versus DMSO by One-way ANOVA.  
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Figure 5.18 PC-3 and LNCaP proliferations were reduced following Efipladib treatment. PC-3 
or LNCaP cells were seeded in 96-well plates for 48 h before being treated with various doses of 
Efipladib or 0.04% DMSO (control) and propagated for 72 h/37 
o
C. After treatment, cells were 
washed and added to lysis buffer and SyBr green I DNA dye. Histograms represent mean 
fluorescence intensity ± SD (n= 3 independent experiments). * P < 0.05 versus DMSO by One-Way 
ANOVA.  
 
5.3.10 Measurement of cell cycle by PI-based flow cytometry  
Efipladib treatment in PC-3 and LNCaP cells showed a decrease in proliferation. This should 
be underpinned by a decrease in proliferating cells. To confirm this, PC-3 and LNCaP cells 
treated with Efipladib (20 µM) or DMSO for 72 h were stained with PI for cell cycle analysis 
by flow cytometry. Both cell lines showed a significant increase in G1/G0 cells compared 
with DMSO control (Figure 5.19). This was accompanied by a significant decrease in cells in 
S and G2/M phase. Although there was a significant increase of Sub G1 population in 
Efipladib-treated LNCaP cells (0.22  1%), the percentage of cell death was very small. 
These results demonstrated that cPLA2α inhibition reduced PC-3 and LNCaP cells through a 
reduction in the population of dividing cells.  
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Figure 5.19 Efipladib reduced PC-3 and LNCaP in G2M and S phase population. a) PC-3 or b) 
LNCaP cells were seeded in 6-well plates for 48 h before treated with 20 µM of Efipladib or 0.04% 
DMSO for 48 h/37 
o
C. After treatment, cells were trypsinised, stained with PI (20 µg/mL) and RNase 
(100 µg/mL) for 1 h and then analysed by flow cytometry. Histograms represent mean cell population 
± SD (n=3 independent experiments). * P < 0.05 versus DMSO by One-Way ANOVA.  
 
5.3.11 Measurement of BrdU incorporation and Ki-67 staining  
Cells undergoing a specific phase during the cell cycle may be identified based on DNA 
content or by specific markers of a particular phase. To investigate further the reduction of 
proliferating cells, PC-3 and LNCaP cells treated with Efipladib or DMSO were analysed by 
BrdU incorporation and Ki-67 staining. In both cell lines, the percentage of cells undergoing 
140 
 
DNA synthesis (positive BrdU staining) was significantly reduced (P < 0.05) in Efipladib-
treated populations compared with control (Figure 5.20, 5.21 and 5.22). Next, Ki-67 revealed 
a significant (P < 0.05) decrease of cells undergoing cell cycle after Efipladib treatment 
(Figure 5.20, 5.21 and 5.22). Taken together, the results suggested that Efipladib reduced 
cells undergoing cell cycle and forced them into quiescent status. 
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Figure 5.20 Decrease in BrdU and Ki-67 staining following Efipladib treatment in PC-3 cells. 
PC-3 cells in T75 flasks were incubated with Efipladib (20 µM) for 72 h/37
0
C before being harvested 
and processed for paraffin embedding (as described in the Section 2.3.4). Sectioned slides were 
stained with anti-AR antibody or an isotype control. Results are typical representative of 3 
independent experiments. 
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Figure 5.21 Decrease in BrdU and Ki-67 staining following Efipladib treatment in LNCaP cells. 
LNCaP cells in T75 flasks were incubated with Efipladib (20 µM) for 72 h/37
0
C before being 
harvested and processed for paraffin embedding (as described in Section 2.3.4). Sectioned slides were 
stained with anti-AR antibody or an isotype control. Results are typical of 3 independent experiments. 
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Figure 5.22 Quantifications of BrdU and Ki-67 staining. The fraction of Ki-67 and BrdU positive 
cells from immunostaining experiments in Figure 5.20 and 5.21. Histograms are mean percentage of 
positive cells ± SD (n=3 independent experiments). * P < 0.05 versus vehicle-treated control by One-
Way ANOVA. 
 
5.4 Discussion 
In this chapter, Efipladib was used to inhibit cPLA2α in PC-3 and LNCaP cells and the 
subsequent biological/biochemical changes were examined. The effect of Efipladib was in 
accordance with the effects of cPLA2α siRNA. Efipladib significantly inhibited (32% 
reduction) the total PLA2α activity in LNCaP cells (Figure 5.1). The remaining 68% PLA2 
activity following Efipladib treatment was likely due to iPLA2 and sPLA2 present in LNCaP 
cells (213). As sPLA2 is very low in PC-3 cells this may explain the reason why PLA2 
activity was reduced to a greater extent (40%) (204; 265). 
 
The significant reduction in cPLA2α activity from Efipladib treatment offers support for its 
effect in subsequent experiments. We examined the biochemical changes following Efipladib 
treatment that may underlie the change in cell proliferation. Efipladib is an indole derivative 
and is thought to be highly specific for cPLA2α (285). It binds to the single site of cPLA2α 
reversibly in a 1:1 stoichiometry (285; 287). Efipladib is currently under preclinical 
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evaluation for non-cancer-related diseases (285). Previous studies have shown that Efipladib 
specifically inhibits cPLA2α enzyme activity at 5–20 μM (204; 288; 289). Consistent with 
the results obtained with cPLA2α siRNA, incubating PC-3 and LNCaP cells with Efipladib 
decreased pAKT levels (Figure 5.2–5.4). This inhibitor also reduced pERK 1/2 levels in PC-
3 cells, but unexpectedly increased pERK 2 in LNCaP cells (Figure 5.4). We interpret our 
data to indicate that Efipladib triggered a mechanism to compensate for the inhibition of AKT 
signalling by an increase in pERK1/2 in LNCaP cells. However, this compensatory 
mechanism may not operate in PC-3 cells. Hence, it is likely that in addition to cPLA2α, 
Efipladib has additional off-target effects, which need to be taken into consideration when 
contemplating further studies using Efipladib. 
 
The mechanism underlying the decrease in pAKT is not clear. Since PHLPP 
dephosphorylates pAKT, one would expect an increase in PHLPP following Efipladib 
treatment (Figure 5.5). However, to our surprise there was a decrease in PHLPP. Hence, the 
down regulation of AKT following Efipladib treatment must result from other mechanisms, 
e.g., decreased PI3K activation and PIP3 level.  
 
Notably, Efipladib also decreased AR protein expression (Figure 5.4 and 5.7) in the nucleus 
and cytosol (Figure 5.8), as well as PSA levels in culture medium (Figure 5.9). Considering 
the role AR plays in PC cell proliferation and survival (149; 176), it may explain why AR-
positive LNCaP cells are more sensitive to Efipladib treatment compared with AR-negative 
PC-3 cells (Figure 5.18).  
 
The AR is crucial for proliferation and survival of PC cells (142; 151-153) and can promote 
G1–S phase progression via enhanced translation of cyclin D1 (267). Since cPLA2α inhibition 
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had such great effect on AR, it is interesting to see its effect in AIPC cells with increased AR 
levels. As a change in AR levels via alteration of its synthesis and/or degradation can 
influence PC progression (142), it would be interesting to see if long-term blockade of 
cPLA2α leads to a population with less dependence on cPLA2α.  
 
Although we were unable to identify any studies in the literature examining the role cPLA2α 
in regulating AR expression, the available evidence implicates AA in androgen and/or AR 
signalling. In fact, AA induces androgen synthesis (260), which is required for AR stability 
(290) and inhibition of masculinisation (a manifestation of androgens) by estradiol-17β or 
cyproterone acetate can be completely corrected by AA (291). Furthermore, indomethacin (a 
non-selective COX inhibitor) blocks the corrective effect of AA on masculinisation (291), 
suggesting the involvement of eicosanoids in mediating the AA effect. Given that AA can 
influence the AKT signalling pathway as shown herein, and that AKT can up-regulate AR 
protein levels (292; 293), the effect of AA on the AR could also be via AKT.  
 
To investigate the downstream link under of cPLA2α, we tested the effect of AA in 
stimulating PC cells. AA treatment significantly stimulated PC-3 and LNCaP cell 
proliferation at low doses (Figure 5.10 and 5.11). We then examined the mechanism 
underlying the effect of cPLA2α activity on pAKT, pERK 1/2 and AR levels. We reasoned 
that if the effect of genetic silencing of cPLA2α on the aforementioned signalling pathways is 
mediated by a decrease in the pool of available AA, replenishment of AA to cPLA2α siRNA-
treated cells should rescue the suppression of pAKT, pERK 1/2 and AR levels. Consistent 
with this hypothesis, we demonstrated that incubation of PC-3 and LNCaP cell lines with AA 
alone significantly increased pAKT, pERK 1/2 and AR levels (Figure 5.12 and 5.13). 
Importantly, supplementation of cells with AA reversed the effect of cPLA2α siRNA on 
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pAKT and to some extent AR, while the rescue effect of AA on ERK 1/2 was less apparent. 
Our working hypothesis is that the AA effect on AKT is more direct compared with the effect 
on ERK 1/2 and AR. We also noted the effect of AA on pAKT is stronger in si-cPLA2α than 
si-control PC3 cells, suggesting that AA treatment unleashes a stronger pAKT response under 
conditions where cPLA2α is blocked.  
 
We then examined which metabolite of AA was likely to mediate its action. We have shown 
previously that blocking cPLA2α resulted in reduced accumulation of 5-HETE (265). To 
verify this finding, we measured the (S)-HETE products in PC-3 and LNCaP cells incubated 
with AA (Figure 5.14) and demonstrated a prominent increase in 5-HETE, a product of 5-
LOX enzymatic action on AA (201). This outcome points to a role for 5-LOX products in 
mediating the effect of AA on pAKT, pERK 1/2 and AR levels. Indeed, the stimulatory effect 
of AA on pAKT, pERK 1/2 and AR is diminished in the presence of the 5-LOX inhibitor, 
MK886, confirming that 5-LOX products can mediate the action of AA on AKT, ERK 1/2 
and AR (Figure 5.15 and 5.16). Recently, AA has been shown to up-regulate pAKT via 
mTORC2-dependent and PI3K-independent mechanisms in breast cancer cell lines (272). 
Interestingly, this effect was blocked by LOX inhibitors (272). As the increase in 15-HETE 
after addition of AA is comparable to 5-HETE, further study is needed to determine its role in 
mediating AA action on pAKT, pERK 1/2 and AR levels. In addition, it remains to be 
determined if AA can also have a direct effect independent from 5-HETE on pATK, pERK 
1/2 and AR levels. 
 
Lastly, we examined the effect of cPLA2α treatment on proliferation of PTEN-null PC cells. 
Inhibition of cPLA2α by Efipladib hampered proliferation (Figure 5.17 and 5.18) in both cell 
lines. We next examined how cPLA2α inhibition reduced the proliferation of these cells. Flow 
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cytometry showed it that was through down regulation of cells in G2/M phase (Figure 5.19). 
Further analysis showed that, in addition to decreased DNA synthesis, cPLA2α inhibition 
draws cells into the G0 quiescent state (Figure 5.20–5.22). This is in accordance with flow 
cytometric results in that the majority of change in the G2M population was to shift into G1G0 
phase and not to apoptotic Sub G1. Thus, cPLA2α inhibition was not cytotoxic and may be a 
therapeutic option in cancer. Indeed, co-targeting of cPLA2α and PI3K using two inhibitors 
significantly reduced more cell numbers than either inhibitor alone (Figure 5.6). 
 
Together, these results show that cPLA2α inhibition by Efipladib decreased PTEN-null PC 
cells through reduction of pAKT, pERK and AR. The effect of cPLA2α action is likely 
mediated by its downstream AA and 5-HETEs. Further studies, such as AA and inhibitors of 
COX or LOX, may identify other eicosanoids or downstream molecules mediating cPLA2α 
action on AKT, ERK or AR.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE 
DIRECTIONS 
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6.1 Introduction 
Cancer is a multi-step process driven by inherited and/or somatic genetic and epigenetic 
alterations. Thus, to understand cancer aetiology, progression and patients’ prognosis, it is 
necessary to identify these alterations and find their links with cancer initiation and 
progression. 
 
Our laboratory has shown in advanced prostate cancer there is an increase in the protein 
levels of sPLA2 and cPLA2α (204; 213; 266), a key enzyme cleaving membrane-bound AA 
for lipid metabolism and production of inflammatory mediators. Blocking either sPLA2 (213) 
or cPLA2α (204) inhibits proliferation of PTEN-null prostate cancer cells in vitro and in vivo. 
A patent application for using the PLA2 inhibitor to treat advanced prostate cancer was 
granted in the USA in 2011 (294) (US Patent I.D. 7919458). The importance of sPLA2 and 
cPLA2α in cancer biology is now recognised by inclusion in the 2
nd
 edition of the Cancer 
Encyclopedia (295). Moreover, our laboratory has identified natural products that are able to 
block cPLA2α action (282; 296). As part of the overarching effort to identify the mechanism 
underlying cPLA2α action on key oncogenic pathways, my PhD Project focused on the role 
of cPLA2α in activation and/or expression of AKT, ERK and AR. 
 
6.2 Effect of cPLA2α on AKT activation 
The first study in this thesis (Chapter 3) examined the effect of cPLA2α overexpression and 
activation on AKT activation and signalling in PTEN-null prostate cancer cells. It was found 
that increased cPLA2α expression and activation, with increased AA secretion, increased 
phosphorylation of AKT. This increased AKT activation was accompanied by increased 
phosphorylation of AKT targets. However, this effect could not be somehow translated into 
increased cell proliferation. 
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Both genetic silencing and pharmacological inhibition of cPLA2α (Chapter 4 and 5) led to a 
reduction of AKT phosphorylation. The phosphorylation of AKT target, GSK3β, and levels 
of cyclin D1 were also reduced. This effect was not due to the increase of PTEN, as these are 
PTEN-null cells (74; 75), and unlikely due to actions from a negative regulator of AKT, 
PHLPP 1/2, as PHLPP was reduced by Efipladib treatment. The effect of cPLA2α inhibition 
on AKT was enhanced under mitogenic stimulation. In EGF-stimulated cells, the rise in AKT 
activation and signalling was abrogated by cPLA2α silencing. However, this effect of cPLA2α 
silencing could be reverted by reintroduction of AA from an extracellular source. Indeed, AA, 
the product of cPLA2α, stimulated pAKT and increased prostate cancer cell proliferation. The 
stimulation of AA on pAKT was likely through 5-HETE because inhibition of 5-LOX by 
MK886 abrogates the AA effect. 
 
Inhibition of cPLA2α by siRNA or Efipladib significantly reduced PTEN-null prostate cancer 
cells in a dose-dependent manner. In addition, the co-inhibition of PI3K and cPLA2α 
significantly reduced cell proliferation more than either inhibitor alone. These effects likely 
resulted from decreased AKT activation and signalling as aberrant AKT activation is a 
common characteristic crucial for prostate cancer. cPLA2α inhibition not only reduced the 
amount of dividing cells and DNA synthesis, but also forced cells into a G0 quiescent state. 
 
6.3 Effect of cPLA2α on ERK activation 
Increase in cPLA2α expression and activation did not significantly change in pERK. But 
cPLA2α inhibition reduced pERK under basal and EGF-stimulated conditions. Although it 
has been suggested that ERK activation may increase following AKT inhibition (95; 97), no 
significant increase in pERK was detected when pAKT was down-regulated by cPLA2α 
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inhibition. Addition of AA significantly increased pERK, and was able to abolish the down-
regulation of pERK brought on by cPLA2α inhibition. In addition, MK886 treatment reduced 
the AA effect on pERK, suggesting the role of 5-HETE in mediating AA effect on ERK. 
Finally, there is possible involvement of EGFR in mediating cPLA2α on ERK, but more work 
is required to ascertain this link in prostate cancer. 
 
6.4 Effect of cPLA2α on AR expression 
The effect of cPLA2α or AA on AR expression has not been documented in the literature 
before. Results from this study found that there was a very clear and strong link between 
cPLA2α action and AR levels in PTEN-null prostate cancer cells. Inhibition of cPLA2α by 
genetic silencing or pharmacological agent significantly reduced AR expression. This 
reduction in AR level was significant following 24 h Efipladib treatment and existed under 
EGF-stimulated conditions. cPLA2α inhibition reduced both nuclear and cytosolic AR as well 
as the secretion of PSA, whose gene is upregulated by AR. The effect of cPLA2α inhibition 
on AR was also likely through AA and 5-HETE. Addition of AA significantly increased AR 
levels in LNCaP cells after 4 h and this was abrogated in MK886-treated cells. 
 
Collectively, I have now found an important role for cPLA2α in sustaining AKT signalling 
under basal and/or EGF-stimulating conditions in PTEN-null/mutated prostate cancer cells. 
Moreover, a reduction of pAKT levels by genetic silencing of cPLA2α caused no 
compensational increase in pERK and AR levels. The mechanism of cPLA2α action on AKT, 
ERK and AR is likely via AA and its metabolite, 5-HETE. Hence, restriction of AA supply to 
PTEN-null prostate cancer cells by inhibition of cPLA2α could have a therapeutic value by 
inhibiting constitutively activated AKT signalling. 
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Figure 6.1 Schematic diagram of cPLA2α affecting AKT, ERK 1/2 and AR levels. The studies 
herein demonstrate using genetic approaches that cPLA2α positively regulates pAKT, pERK 1/2 and 
AR levels via AA and its metabolite 5-HETE derived from the activity of 5-LOX (as confirmed with 
the 5-LOX pharmacological inhibitor, MK886) in PTEN null/mutated prostate cancer cells. 
Pharmacological inhibition of cPLA2α causes reduction in proliferation of PTEN null/mutated 
prostate cancer cells. 
 
6.5 Future directions 
This PhD project has laid foundation for the overarching goal to develop a novel strategy to 
inhibit constitutively-activated AKT signalling in PTEN-null prostate cancer. 
 
Firstly, the potential of blocking cPLA2α in preventing prostate cancer development can be 
examined by determination of the time of onset of prostate cancer after blocking cPLA2α in 
prostate specific PTEN knockout mice. This can be done by administering Efipladib to PTEN 
knock-out mice and measure the timing and frequency of prostate cancer occurrence. 
Secondly, the effect of blocking cPLA2α on cell cycle re-entry by (serum starved or contact 
inhibited) quiescent PTEN-null prostate cancer cells can be examined. These quiescent 
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cancer cells are thought to be central for cancer recurrence after cycling cancer cells are 
removed by chemo- or radiotherapy. Lastly, it is worthwhile determining if blocking cPLA2α 
concomitantly with androgen ablation therapy can delay the occurrence of resistance to 
medical castration. A mouse model of androgen ablation therapy and Efipladib treatment can 
be used in preliminary studies.  
 
The work described in this thesis has provided a new perspective in our understanding of 
cPLA2α and AA in activation of classical oncogenic pathways in PTEN-null prostate cancer 
cells. It is my hope that this work can contribute to the development of novel therapies for 
advanced prostate cancer with constitutively activated AKT signalling pathway. 
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Prostate cancerConstitutive phosphorylation of protein kinase B (AKT) is a common feature of cancer caused by genetic
alteration in the phosphatase and tensin homolog (PTEN) gene and is associated with poor prognosis. This
study determined the role of cytosolic phospholipase A2α (cPLA2α) in AKT, extracellular signal-regulated
kinase (ERK) and androgen receptor (AR) signaling in PTEN-null/mutated prostate cancer cells. Doxycycline
(Dox)-induced expression of cPLA2α led to an increase in pAKT, pGSK3β and cyclin D1 levels in LNCaP cells
that possess a PTEN frame-shift mutation. In contrast, silencing cPLA2α expression with siRNA decreased
pAKT, pGSK3β and cyclin D1 levels in both PC-3 (PTEN deletion) and LNCaP cells. Silencing of cPLA2α
decreased pERK and AR protein levels. The inhibitory effect of cPLA2α siRNA on pAKT and AR protein levels
was reduced by the addition of arachidonic acid (AA), whereas the stimulatory effect of AA on pAKT, pERK
and AR levels was decreased by an inhibitor of 5-hydroxyeicosatetraenoic acid production. Pharmacological
blockade of cPLA2α with Eﬁpladib reduced pAKT and AR levels with a concomitant inhibition of PC-3 and
LNCaP cell proliferation. These results demonstrate an important role for cPLA2α in sustaining AKT, ERK
and AR signaling in PTEN-null/mutated prostate cancer cells and provide a potential molecular target for
treating prostate cancer.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Phosphoinositide-3-kinase (PI3K) and phosphatase and tensin
homolog deleted on chromosome 10 (PTEN) are positive and negative
regulators of phosphorylation of protein kinase B (AKT), respectively
[1]. Genetic alteration of PI3K and PTEN has been found in at least six-
teen types of human cancers [2]. Nearly one-third of prostate cancer
cases have either a gain of function mutation in PI3K or loss of function
mutation or deletion in PTEN [2]. Accordingly, about 45% of prostate
cancer cases have increased levels of pAKT at Ser473, which correlates
positively with disease severity [3–5]. The loss of PTEN or increase in
pAKT, has been used as a predictor of advanced prostate cancer that
fails to respond to treatment [6,7].
Suppression of the AKT signaling pathway in cancer cells carry-
ing genetic alterations in PI3K or PTEN has proven to be a challenge.lth, The University of Western
203633; fax:+61 2 46203025.
l rights reserved.Constitutively-activated AKT renders cancer cells resistant tomanipula-
tion by insulin or insulin-like growth factor [8]. Inhibition of down-
stream effectors of AKT such as the mammalian target of rapamycin
complex 1 (mTORC1), results in AKT activation due to removal of the
negative feedback effect on pathways upstream of AKT [9]. In addition
to this vertical compensation mechanism, a horizontal compensation
mechanism is reported to involve increasing RAS/RAF/MEK/ERK activity
in the presence of inhibitors of the AKT pathway [10]. Another factor
crucial for survival and proliferation in prostate cancer cells is the
androgen receptor (AR) [11–14]. It has been shown that an increase
in AR expression alone is sufﬁcient to enable cancer cells to progress
to a hormone refractory status [15,16]. Thus, a potential impact on AR
signaling should be considered in any attempt to block an oncogenic
pathway in prostate cancer cells.
Pro-inﬂammatory eicosanoids (prostaglandins, leukotrienes or
hydroxyeicosatetraenoic acid) are produced by various types of cancer
cells as well as their surrounding tissues and are often associated with
poor prognosis [17–19]. Themechanisms bywhich eicosanoids promote
cancer progression include activation of the PI3K/AKT and RAS/ERK
pathways [19]. Inhibition of eicosanoid production in PTEN-null prostate
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subunit) [21]. In two clinical trials, the rate of increase of prostate-
speciﬁc antigen (PSA) following prostatectomy or radiotherapy was
slowed in patients treated with inhibitors of eicosanoid-producing en-
zymes [22,23]. However, members of the eicosanoid family can promote
tumor cell proliferation in vitro and in vivo [24] and the long-term use
of cyclooxygenase-2 (COX-2) inhibitors can lead to cardiovascular side
effects [25]. The current hypothesis proposed by others and us is that
inhibition of cytosolic phospholipase A2α (cPLA2α) could be amore effec-
tive therapeutic approach than inhibition of COX or lipoxygenase (LOX)
alone [26,27]. Signiﬁcantly, cPLA2α catalyzes thehydrolysis of arachidonic
acid (AA) selectively at the sn-2 position of glycerophospholipid [28].
After hydrolysis, the non-esteriﬁed AA is enzymatically converted to
eicosanoids by the action of COX or LOX [24]. Thus, blocking cPLA2α
decreases substrate supply to the COX-1, COX-2 and LOX pathways.
Moreover, we have shown that phospho-cPLA2α at Ser505 (pcPLA2α),
which enhances AA releasing activity [29], is markedly increased in
advanced prostate cancer [30].
Studies in vitro and in vivo have shown that AA promotes prostate
cancer progression. High dietary AA reduces the time required for pro-
gression to hormone refractory prostate cancer following androgen ab-
lation therapy [31]. In addition, in an animal model of prostatectomy,
mice fed a diet supplemented with AA demonstrate an earlier and
more frequent onset of tumor development, with signiﬁcantly greater
tumor recurrence than controls [32]. Dietary AA also increases tumor
growth in prostate-speciﬁc PTEN-knockout mice [33]. Treatment of
the human prostate cancer cell line (LNCaP) with AA increases cell
proliferation and induces de novo androgen synthesis, which in turn,
may stimulate AR signaling [34]. As the rate of eicosanoid synthesis is
enhanced in the presence of added AA in prostate cancer tissues com-
pared to benign tissues, it has been postulated that there is increased
utilization of AA in tumors [35]. Collectively, these studies suggest a
role for cPLA2α in prostate cancer progression or recurrence.
Based on the aforementioned studies, we propose that restriction of
AA supply to PTEN-null/mutated prostate cancer cells by inhibition of
cPLA2α would inhibit constitutively activated AKT signaling. Herein, we
use both a genetic modiﬁcation and pharmacological intervention of
cPLA2α to examine their effect on AKT/ERK signaling in two PTEN-null/
mutated prostate cancer cell lines. Moreover, our study demonstrates
a previously unrecognised link between cPLA2α and androgen re-
ceptor expression, as well as the potential metabolites mediating
cPLA2α action.
2. Materials and methods
2.1. Cell culture
The bone metastasized AR-negative prostate cancer cell line, PC-3
(Cat. #: CRL-1435; American Type Culture Collection [ATCC], Manassas,
VA), and the lymph node metastasized, AR-positive, prostate cancer
cell line, LNCaP (Cat. #: CRL-1740; ATCC), were grown in RPMI 1640
supplemented with 10% v/v fetal bovine serum (FBS; AusGeneX,
Brisbane, QLD, Australia), penicillin (100 U/mL; Invitrogen, Melbourne,
VIC, Australia) and streptomycin (100 μg/mL; Invitrogen). The cells
were cultured at 37 °C in an incubator providing a humidiﬁed environ-
ment in the presence of 5% CO2/95% air.
2.2. Treatments
For incubation with AA, PC-3 or LNCaP cells seeded in 6-well
plates and grown to 70% conﬂuency were then subsequently exposed
to RPMI in the absence of FBS overnight. Prior to use, AA (Cat.#:
A3555, Sigma-Aldrich) was pre-conjugated with 5 μM fatty acid-free
bovine serum albumin (Cat.#: A8806; Sigma-Aldrich, St. Louis, MO).
The concentration of AA over albumin is 4:1 mol/mol. Cells were then
treated with 20 μM AA at 37 °C for 4 h, with or without 25 μMMK886 (Cat.#: M692; Sigma-Aldrich). For cells treated with cPLA2α
siRNA or the GC-matched scrambled control, AA was introduced 4 h
prior to harvesting. Commercial AA was routinely assessed by HPLC
and conﬁrmed to contain b1%mol/mol oxidation products, as described
previously [36]. For incubation with epidermal growth factor (EGF),
cells were treated with 20 ng/mL EGF (Cat.#: E9644, Sigma-Aldrich)
for the last 30 min prior to harvesting in the presence of serum.
Hence, the outcome is not inﬂuenced by the effect of serum depriva-
tion. For the Eﬁpladib incubation, PC-3 or LNCaP cells were seeded in
6-well plates for at least 24 h and then treated with 20 μM Eﬁpladib
(Sanmar Chemicals, India) in RPMI/FBS (10% v/v) for 72 h before
harvesting.
2.3. Doxycycline (Dox)-controlled cPLA2α expression
LNCaP cells were seeded in 10 cm dishes and grown to 100%
conﬂuence. Cells were then transfected with 24 μg of pcDNA6
(Cat.#: V1025-20; Invitrogen) vector expressing TET-Repressor using
Lipofectamine 2000 (Cat.#: 11668; Invitrogen). These cells were then
incubated with media containing Blasticidin (10 μg/mL) for 10 days.
Successfully transfected colonies were then selected and passaged
before further transfection with the pcDNA4 (Cat. #: V1030-20;
Invitrogen) vector containing the human cPLA2α cDNA sequence with
Flag regulated by a promoter containing the tetracycline-response
element (TRE-cPLA2α). Successfully transfected clones were selected
using media containing G418 (300 μg/mL; Cat. #: 10131; Invitrogen)
for 10 days/37 °C. Cells co-transfected with the pCDNA6 and pcDNA4
vectors without the cPLA2α coding sequence were used as a vector
control (TRE-Empty). Four of the clones showing a positive increase
in cPLA2α due to doxycycline induction were chosen and two clones
were used in the present study. For induction of cPLA2α, cells were
seeded in 6-well plates and treatedwith 100 ng/mL of Dox in RPMI/FBS
(10% v/v) for 24 h/37 °C before harvest. There is a signiﬁcant increase in
cPLA2α protein level 8 h after Dox induction and it reaches a maximum
as it approaches 24 h.
2.4. cPLA2α immunoprecipitation and activity assay
LNCaP cells transfected with cPLA2α or the empty vector control
were induced with Dox and then lysed with buffer (50 mM Tris-pH 7.4,
150 mM NaCl, 1% v/v Triton X-100, 1 mM EDTA, 0.1% v/v NP-40). The
cell lysates were centrifuged at 8200 g/10 min/4 °C and the protein
concentration in the supernatant was quantiﬁed using the Bio-Rad DC
Protein Assay (Cat. #: 500-0116; Bio-Rad, Hercules, CA). Each sample
(ﬁnal protein concentration 250 μg/mL) was mixed with 40 μL ANTI-
FLAGM2Afﬁnity Gel (Cat. #: F2426; Sigma) in amicrotube and followed
by 1 mL of lysis buffer. Themixtures were agitated for 2 h/4 °C and then
centrifuged for 30 s/8200 g before removing the supernatant. The bead
pellets were washed three times with 500 μL TBS (50 mM Tris HCl,
150 mM NaCl, pH 7.4) for 5 min/4 °C. Bound antigens were eluted
with 3× FLAG peptide (Cat. #: F4799; Sigma) and assayed using the
Phospholipase A2 Assay Kit (Cat. #: E10217; Invitrogen) according to
the manufacturer's speciﬁcations.
2.5. Fatty acid extraction from conditioned cell culture media
Fatty acids were extracted from cell culture medium as described
in detail by Norris and Dennis [37]. Brieﬂy, samples of media
(2 × 250 μL from each sample) were diluted into a mixture of MeOH
(400 μL), heptadecanoic acid (100 μg/ml, 10 μL) and HCl (1 M, 25 μL).
Treated samples were then mixed with 2 mL hexane, vortexed for
30 s and centrifuged at 1000 ×g for 5 min. The upper (hexane) layer
was removed from the aliquots and combined into a 25 mL pear-
shaped ﬂask with a ground glass joint. The hexane extraction was
repeated and the combined fractions were then evaporated under
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before analysis using LC–MS.
2.6. LC–MS/MS
AXevo-Triple quadruplemass spectrometer (Waters,Micromass, UK)
coupled to a PhenomenexKinetex 1.7 μmC18100A (2.1 × 150 mm)was
used for analysis. Fatty acids (10 μL)were separated using a binary gradi-
ent program, at a ﬂow rate of 0.1 mL/min (mobile phase A: 0.2% formic
acid in water; and mobile phase B: isopropanol.) The gradient used
for separation of fatty acid analytes was as follows: 0 min, 20:80 A/B;
3 min, 0:100 A/B; 6 min, 0:100 A/B; 7 min, 20:80 A/B.Mass spectra of in-
dividual analytes was acquired in MS/MS mode under different collision
energy ranging from 5 to 40 eV. The mass spectrometer was operated
in negative ESI mode with capillary voltage of 2.30 KV, cone voltage of
25 V and desolvation temperature of 500 °C. The collision induced disso-
ciation (CID) gas used was argon. Fragments with highest intensity were
chosen at optimumcollision energy (CE) for analysis; analyteswere iden-
tiﬁed using the following mass transitions: for heptadecanoic acid, m/z
269.14→ 251.2 (CE 25 eV), for arachidonic acid m/z 303.3→ 59 (CE
20 eV), m/z 303.3→ 205 (CE 15 eV), m/z 303.3→ 259 (CE 15 eV), m/z
303.3→ 285 (CE 15 eV). Standard curves were constructed using linear
regression of the normalized peak areas of the analyte (arachidonic acid)
over internal standard (heptadecanoic acid) against the corresponding
nominal concentrations of the analyte. Solutions of authentic standards
(0.005 to 40 ng/μL of arachidonic acid with 10 ng/μL of heptadecanoic
acid in a total volume of 1 mL) were prepared in isopropanol. Reference
standards of arachidonic acid (purity ≥ 99.0%), heptadecanoic acid
(purity ≥ 98%), LC–MSgrade isopropanol and formic acid (purity ~ 98%),
were all obtained from Sigma-Aldrich (NSW, Australia).
2.7. Genetic silencing of cPLA2α with siRNA
PC-3 and LNCaP cells were seeded in 6-well plates and then
transfected with 10 nM siRNA against cPLA2α or the scrambled
control (Cat. #: 45-2001; Invitrogen) mixed with Lipofectamine
2000 in a 1:2 v/v ratio. In these studies, OPTI-MEM (Cat. #: 11058;
Invitrogen) was used as the transfection medium. The media was
then replenished the next day and the cells were left to proliferate
for 32 h/37 °C before harvesting for immunoblot. All experiments
were performed using cells with a >70% decrease in cPLA2α protein
level.
2.8. Immunoblotting
PC-3 and LNCaP cells were seeded in 6-well plates. Following
treatment, cell lysates were prepared for immunoblots as described
previously [38]. The band intensity of digital images was measured by
using GeneTools software (SynGene, Cambridge, UK) and the ratio of
band intensity between each protein of interest and the loading control
was determined before expressing changes in protein levels as a
fold-change relative to the control. Two loading controls, α-tubulin
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), were used
to avoid overlapping signals from proteins of interest which had a
similar molecular weight. Primary antibodies against: cPLA2α (Cat. #:
SC-454), phospho-cPLA2α at Ser505 (Cat. #: SC-34391), AKT (Cat. #:
SC-8312), phospho-AKT at Ser473 (Cat. #: SC-7985) and HDAC1
(Cat. #: SC-7872) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA); ERK 1/2 (Cat. #: 9102), phospho-ERK 1/2 (Cat. #:
9106S), GSK3β (Cat. #: 9315) and phospho-GSK3β (Cat. #: 9336S)
were bought from Cell Signaling Technology (Danvers, MA); androgen
receptor (Cat. #: MS-443-P) was purchased from Lab Vision (Kalamazoo,
MI); cyclin D1 (Cat. #: C7464) and FLAG-peptide (Cat. #: A8592) were
purchased from Sigma-Aldrich; and α-tubulin (Cat. #: ab7291) and
GAPDH (Cat. #: ab8245) were obtained from Abcam (Boston, MA).2.9. Reverse transcription- and quantitative real-time PCR
Total RNA was isolated using the UltraClean Tissue & Cells RNA
Isolation Kit (Mo Bio Laboratories, CA) according to the manufacturer's
instructions. The ﬁrst strand complementary DNA was synthesized
from 500 ng of total RNA with random hexamers and SuperscriptIII
(Cat. #: 48190 and P/N 56575, Invitrogen). The primers used for AR
were forward 5′-AATGTCAACTCCAGGATGCT and reverse 5′-CCATCCA
CTGGAATAATGCT. The TATA box binding protein (TBP) was used as
the housekeeper gene, forward 5′-GAACCACGGCACTGATTTTC, reverse
5′-CCCCACCATGTTCTGAATCT. Quantitative PCR measurements were
performed using a SensiMix SYBRMastermix Kit (Cat.#: QT605, Bioline,
Sydney, NSW, Australia) and a RotorGene 6000 PCR machine (Qiagen,
Santa Clarita, CA). Conditions for PCR were 1 cycle of 10 min at 95 °C;
40 cycles of 10 s at 95 °C and 30 s at 65 °C. The Relative Expression
Software Tool 2009 (Qiagen) was used to calculate relative changes in
cPLA2α normalized to the housekeeping gene. Ampliﬁcation efﬁciency
was determined using a 5-point dilution curve and was within
100% ± 3% for AR and TBP.
2.10. Nuclear and cytoplasmic fractionation
After treatment with Eﬁpladib, cells were washed twice with cold
PBS, scraped off the plate and collected into 1.5 mL microtubes and
PBS removed after centrifugation at 500 g for 3 min. Nuclear and
cytoplasmic fractionation were performed using NE-PER™ Nuclear
and Cytoplasmic Extraction Reagents (Cat. #: 78833 Thermo Scientiﬁc)
according manufacturer's instructions. All procedures including centri-
fugation were performed at 4 °C.
2.11. Immunocytochemistry
Expression of Ki-67 and BrdU incorporation were determined by
immunocytochemical staining. For assessing BrdU incorporation, cells
were addedwith 10 μMBrdU for 3 h/37 °C prior to harvest. The treated
cells in T75 ﬂaskswere harvested and processed for immunocytochem-
istry as previously described [38]. Primary antibody against Ki-67 and
BrdU were purchased from Lab Vision (Cat. #: RM-9106-S) and Sigma
(Cat. #: B2531) respectively. Digital images of the immuno-stained sec-
tions were obtained by using an automated cellular imaging system
(ACIS III; Dako). Two color thresholds were chosen on the images to
distinguish between the positive (brown) and negative (blue) cells.
Ten areas on each sample were randomly selected to determine the
numbers of positive and negative cells. The percentage of positive
cells of each sample was calculated using the following formula:
positive cells / (positive cells + negative cells) × 100%.
2.12. Determination of hydroxyeicosatetraenoic acids (HETEs)
PC-3 and LNCaP cells were harvested and the cell pellets were
incubated with 0.1 mM puriﬁed arachidonic acid for 1 h/37 °C. Total
lipids were extracted into chloroform/methanol/water (5:1:1 v/v/v) and
centrifuged (3600 g/15 min/20 °C). The chloroform phase was dried
under vacuum and the resultant lipids, reconstituted with methanol/
water (9:1 v/v) then separated by HPLC as described previously [36].
The identity of HETEs in the HPLC proﬁle was conﬁrmed by addition of
authentic HETEs obtained commercially (Cayman Chemicals, Ann Arbor,
MI). As 12-HETE level was the lowest, it was used for normalization.
2.13. Prostate speciﬁc antigen (PSA) assay
LNCaP cells in 6-well plates were treated with 20 μM Eﬁpladib
for 72 h/37 °C. Following treatment, 200 μL media were collected,
centrifuged (300 g/5 min/4 °C) and measured using an Immulite 2000
Third Generation PSA kit (Siemens DPC, Sydney, NSW, Australia). The
coefﬁcient of variation of intra-assay and inter-assay variability was
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Cells in each well were harvested for protein assay and the PSA value
was normalized by protein concentrations. The protein concentration
was quantiﬁed using the Bio-Rad DC Protein Assay.
2.14. Measurement of DNA synthesis
Prostate cancer cells were seeded into 96-well plates at 2 × 103
cells/well for PC-3 cells and at 2 × 103 cells/well for LNCaP cells.
Eﬁpladib was then added at the dose indicated in the ﬁgure legends
and incubated for 72 h/37 °C. The same number of cells was aliquoted
as a baseline and stored at−80 °C until use. Three days after treatment,
the medium was gently removed from each well. Then, 100 μL of lysis
buffer containing SYBR Green (Cat. #: S-7563, Invitrogen) was added
at a 1:10,000 v/v dilution. The lysis buffer consisted of buffer A
(10 mM Tris-pH 7.5 and 2 M NaCl) and buffer B (100 mM Tris-pH 7.5,
200 mM disodium EDTA and 10% v/v Triton X-100) in a 9:1 ratio. The
cells were lysed in the dark for 30 min/4 °C. Previously frozen aliquots
were thawed at room temperature, lysed in the same buffer and trans-
ferred to the treatment plate containing samples from the same type
of cells. The ﬂuorescence intensity of SYBR Green was measured using
a plate reader (FLUOstar Omega, BMG Labtech) and the gain in the cel-
lular DNA content during the treatment was estimated by subtracting
baseline ﬂuorescence intensity from the value obtained from experi-
mental cells.
2.15. Statistical analysis
The statistical software NCSS (v12.0; Kaysville, UT) was used for
analysis. One-WayANOVAwas implemented to determine the difference
between individual groups of data. Fisher's LSD Multiple-Comparison
Test was used to determine whether the difference between individual
groups (P b 0.05) was considered signiﬁcant.
3. Results
3.1. Dox-induced cPLA2α expression increases AKT signaling in PTEN-
mutated prostate cancer cells
To determine the effect of an increase in cPLA2α levels on AKT
signaling in PTEN-mutated prostate cancer cells, we established a
Dox-controlled cPLA2α expression system in the prostate cancer
cell line, LNCaP (PTEN frame-shift mutation; [39]). The induction of
ectopic cPLA2α by Dox was conﬁrmed by detection of the Flag-
tagged protein, which was also veriﬁed by the size of the molecule
(85 kDa; Fig. 1A). Hence, the 85 kDa band detected using anti-total
and phosphorylated cPLA2α antibodies correspond to cPLA2α (Fig. 1A).
The Dox-induced cPLA2α was phosphorylated at Ser505 (pcPLA2α;
Fig. 1A), as shown previously with endogenous cPLA2α [29]. To deter-
mine Dox-induced cPLA2α enzyme activity, LNCaP cells transfected
with cPLA2α or the empty vector control expression system were in-
duced with Dox and the Flag-tagged cPLA2α was immuno-precipitated
and assayed for activity. Consistent with the increased levels of pcPLA2α
(Fig. 1A), Dox-induced cPLA2α showed an ~2.5–3-fold increase in
enzyme activity comparedwith cells in the absence of Dox (Fig. 1B). Con-
trol cells without Flag-tagged cPLA2α showed no detectable cPLA2α
activity. The amount of free AA released into culture medium increased
signiﬁcantly in the cells treated with Dox compared to the controls
(Fig. 1B). There was no signiﬁcant change in released AA after Dox treat-
ment in control cells.
Over-expression of cPLA2α caused a signiﬁcant (P b 0.05) increase
in pAKT and its downstream effectors, glycogen synthase kinase 3β
(pGSK3B) and cyclin D1 (Fig. 1C and D), whereas total AKT and
GSK3β were not signiﬁcantly (P > 0.05) altered. The same dose of
Dox in cells transfected with the empty vector control showed no
increase in cPLA2α expression or phosphorylation (Fig. 1A), nor wasthere any signiﬁcant increase in pAKT, pGSK3β or cyclin D1 levels
(Fig. 1C and D). In conclusion, over-expression of cPLA2α leads to
increased levels of pAKT and its downstream targets.
3.2. Genetic silencing of cPLA2α decreases AKT signaling in PTEN-null/
mutated prostate cancer cells
To further determine the role of cPLA2α in AKT signaling, we
genetically silenced cPLA2α in PC-3 (with a deletion in PTEN) and
LNCaP cells (Fig. 2). Genetic silencing of cPLA2α using si-cPLA2α in
PC-3 and LNCaP cells signiﬁcantly (P b 0.05) decreased levels of
cPLA2α and pcPLA2α by ≥70% relative to the scrambled control
(si-control) in both cell lines (Fig. 2A). Since there was about 3–5
fold-increase in cPLA2α protein level following Dox induction, a
short exposure for imaging was used in Fig. 1. To objectively demon-
strate the silencing of cPLA2α, a long exposure was used in Fig. 2. This
explains the difference in endogenous cPLA2α levels between Figs. 1
and 2. Incubation with si-cPLA2α led to a signiﬁcant (P b 0.05) de-
crease in pAKT levels relative to the si-control in both cell lines
(Fig. 2B and C). There was a trend of decrease in cyclin D1 in PC-3
and pGSK3β in LNCaP after incubation with si-cPLA2α relative to
the si-control (Fig. 2B and C), but both did not reach statistical signif-
icance (P = 0.1).
To determine the role of cPLA2α in inﬂuencing the AKT response
to mitogens, we incubated PC-3 and LNCaP cells with cPLA2α siRNA
or the corresponding si-control in the presence or absence of EGF
(Fig. 2B and C). In these studies, incubation of PC-3 cells with the
si-control and EGF (si-control/EGF) elicited a signiﬁcant (P b 0.05)
increase in pAKT relative to the si-control alone (Fig. 2B), but this
stimulation was not observed in LNCaP cells (Fig. 2C). However, in
the presence of cPLA2α siRNA and EGF (si-cPLA2α/EGF), pAKT levels
diminished signiﬁcantly (P b 0.05) in both cell lines relative to the
si-control/EGF. In addition, relative to the si-control, levels of pGSK3β
were signiﬁcantly (P b 0.05) increased after incubation of PC3 or
LNCaP cells with si-control/EGF (Fig. 2B and C). For cyclin D1, the
increase was signiﬁcant (P b 0.05) in both cell lines. By incubation of
cells with si-cPLA2α/EGF relative to the si-control/EGF (Fig. 2B and C),
the levels of pGSK3β and cyclin D1 were signiﬁcantly decreased
(P b 0.05) in both cell lines. Total AKT and GSK3βwere not signiﬁcantly
altered. Itwas noted that EGF treatment alone in LNCaP and PC3 cells in-
creased endogenous phospho-cPLA2α, but total cPLA2αwas unchanged
(data not shown). Overall, these studies show that silencing of cPLA2α
leads to down-regulation of pAKT and this likely impacts on its signaling
in these cells.
3.3. Genetic silencing of cPLA2α diminishes pERK and AR in PTEN-null/
mutated prostate cancer cells
Considering the possibility that blockade of one oncogenic path-
way may induce a compensatory response [10], and thus could be
detrimental, we examined whether a decreased pAKT, after silencing
of cPLA2α, caused an increase in pERK 1/2 (Fig. 3). In these studies,
pERK 1/2 levels were examined under basal or EGF-stimulated condi-
tions with or without cPLA2α siRNA or the corresponding si-control.
The levels of pERK 1/2 were relatively low under basal culture condi-
tions in PC-3 cells and no signiﬁcant (P > 0.05) change was noted
after treatment with cPLA2α siRNA relative to the si-control (Fig. 3A).
Experiments examining LNCaP cells under basal culture conditions
demonstrated there was a marginal decrease (P = 0.07) in pERK 1/2
levels after treatment with cPLA2α siRNA relative to the si-control
(Fig. 3B). However, after incubation with the si-control/EGF, there
was a marked (P b 0.05) increase in pERK 1/2 levels relative to the
si-control in both cell-types (Fig. 3A and B). The level of pERK 1/2 was
signiﬁcantly (P b 0.05) reduced in both PC-3 and LNCaP cells upon incu-
bation with si-cPLA2α/EGF relative to treatment with the si-control/
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Fig. 1. The effect of doxycycline (Dox)-controlled expression of cPLA2α on AKT signaling. LNCaP cells transfected with Dox-controlled cPLA2α expression system (TRE-cPLA2α) or
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niﬁcantly altered in either cell lines (Fig. 3A and B).
An increase in AR levels has been shown to be an important mech-
anism involved in the progression of hormone-refractory prostate
cancer [15,16]. Therefore, we next determined whether silencing
cPLA2α had an effect on AR expression. As PC-3 cells do not express
AR [40], studies examining AR levels were conducted using the
LNCaP cell line only (Fig. 3B). Interestingly, although AR protein levels
were signiﬁcantly (P b 0.05) increased in response to si-control/EGF
relative to the si-control, there was a signiﬁcant (P b 0.05) reduction
of AR protein level after cPLA2α siRNA treatment regardless of the
presence or absence of EGF (Fig. 3B). However, no signiﬁcant change
in ARmRNA level was observed under the same incubation conditions
(Supplementary Fig. 1). Collectively, these experiments showed that
silencing cPLA2α does not lead to a compensatory increase in the
oncogenic pathways mediated by pERK 1/2 or the AR, suggesting
that cPLA2α may be a useful therapeutic target.
3.4. Arachidonic acid and 5-HETE can mediate cPLA2α action on AKT, ERK
1/2 and AR expression
To assess if AA mediates the effect of cPLA2α action on pAKT, pERK
1/2 and AR levels, we next examined the effect of adding exogenous
AA to PC-3 and LNCaP cells in the presence or absence of cPLA2α
siRNA (Fig. 4). Incubation with si-cPLA2α in the absence of AA signif-
icantly (P b 0.05) decreased pAKT and pERK 1/2 levels relative tothe si-control in both cell lines (Fig. 4A and B). Addition of AA in the
presence of the si-control (si-control/AA) signiﬁcantly (P b 0.05)
increased pAKT and pERK 1/2 levels in both cell lines relative to the
si-control alone (Fig. 4A and B). The suppressive effect of si-cPLA2α
on pAKT in both cell-types relative to the si-control was abolished
following incubation with AA (si-cPLA2α/AA). However, although
si-control/AA signiﬁcantly (P b 0.05) increased pERK 1/2 levels rela-
tive to the si-control, si-cPLA2α/AA did not completely abolish the
suppressive effect of cPLA2α siRNA alone on pERK 1/2 (Fig. 4A and
B). Notably, it is pERK 2 (42 kDa) relative to pERK 1 (44 kDa) that is
mostly affected by incubation with AA alone or cPLA2α siRNA plus
AA. None of the treatments had any signiﬁcant effect on either total
AKT or ERK 1/2. Incubation of LNCaP cells with si-control/AA also sig-
niﬁcantly (P b 0.05) increased AR levels relative to cells incubated
with the si-control alone (Fig. 4B). Further, AA reduced the suppres-
sive effect of cPLA2α siRNA on AR protein levels such that the effect
of cPLA2α siRNA was no longer signiﬁcant relative to si-control/AA
(Fig. 4B).
Previously, we showed that the 5-LOX product, 5-HETE, was
markedly reduced after blocking cPLA2α activity [41]. To examine
whether 5-HETE levels were increased after the addition of AA, we
incubated PC-3 and LNCaP cells with AA and determined the levels
of HETE products by HPLC. Indeed, 5-HETE and 15-HETE were
the most markedly increased HETEs after treatment with AA in
both PC3 and LNCaP cells (Supplementary Fig. 2). Considering that
5-HETE is decreased after inhibiting cPLA2α [41], we then determined
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Fig. 2. Genetic silencing of cPLA2α diminishes AKT signaling by immunoblot. (A) A decrease in total and phospho-cPLA2α in PC-3 and LNCaP cells following a 48 h/37 °C treatment
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(20 ng/mL/30 min) conditions. Immunoblots in (A–C) are representative of 4 independent experiments, while the histograms representing the densitometric analysis are mean ± SD
(n = 4 independent experiments). * P b 0.05 versus si-control. # P b 0.05 versus si-control/EGF.
1151S. Hua et al. / Biochimica et Biophysica Acta 1831 (2013) 1146–1157whether this eicosanoid mediates the effect of AA on AKT, ERK 1/2, and
the AR, by incubation of cells with AA in the presence or absence of
MK886, an inhibitor of 5-HETE production [42]. In these studies, AA sig-
niﬁcantly (P b 0.05) increased the levels of pAKT and pERK 1/2 in PC-3
and LNCaP cells relative to the control, and also the AR in LNCaP (Fig. 4C
and D). Importantly, MK886 diminished the stimulatory effect of AA in
both cell lines. Again, it is pERK 2 (42 kDa) relative to pERK 1 (44 kDa)
that is typically affected by incubationwith AA alone or AA plusMK886.
Total AKT and ERK 1/2were not signiﬁcantly altered by any of the treat-
ments relative to the control (Fig. 4C and D). Hence, these studies
indicate that 5-HETE plays an important role in the effect of AA on
pAKT, pERK 1/2 and AR expression.
3.5. Pharmacological inhibition of cPLA2α on AKT, ERK 1/2 and AR
expression in PTEN-null/mutated prostate cancer cells
To evaluate the potential of targeting cPLA2α using a pharmaco-
logical approach, we examined AKT, ERK 1/2 and AR signaling inPC-3 and/or LNCaP cells treated with Eﬁpladib (Fig. 5), a new and
potent inhibitor of cPLA2α [43]. Incubation with Eﬁpladib (20 μM,
72 h/37 °C), which we have previously shown to decrease cPLA2α ac-
tivity in PTEN-null cells [30,41], signiﬁcantly (P b 0.05) reduced pAKT
levels in both cell lines relative to the control samples (Fig. 5A and B).
Moreover, Eﬁpladib caused a signiﬁcant (P b 0.05) decrease in pERK
1/2 in PC-3 cells, but an increase in pERK 2 (42 kDa) in LNCaP cells
relative to the control (Fig. 5A and B). Notably, a signiﬁcant (P b 0.05)
decrease in AR protein levels was also noted in LNCaP cells after incuba-
tion with Eﬁpladib relative to the control (Fig. 5B and Supplementary
Fig. 3). The decrease in AR protein was apparent in both nuclear and
cytoplasmic fractions (Fig. 5C). The effect of Eﬁpladib on a downstream
target of the AR, namely prostate-speciﬁc antigen (PSA) [44], was
then assessed. Relative to the control, Eﬁpladib caused a signiﬁcant
(P b 0.05) decrease in PSA levels in the medium overlying the LNCaP
cell monolayer (Fig. 5D).
Eﬁpladib also reduced PC-3 and LNCaP cell proliferation in a dose-
dependent manner as judged by assessing DNA content using SYBR
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1152 S. Hua et al. / Biochimica et Biophysica Acta 1831 (2013) 1146–1157Green (Fig. 5E). Further, the percentage of Ki-67 and BrdU positive cells
was signiﬁcantly (P b 0.05) reduced after incubation with Eﬁpladib in
PC-3 cells (Fig. 5F, Supplementary Fig. 4) and LNCaP cells (Fig. 5F and
Supplementary Fig. 5). These investigations indicate that cPLA2α
could be an importantmolecular target for the development of effective
anti-tumor therapies in prostate cancer and that further pre-clinical
studies with Eﬁpladib or an active derivative are warranted.4. Discussion
An aberrant increase in AKT signaling is a salient feature of
advanced prostate cancer and can be used to predict disease severity
and outcome [2,4,6,7]. Few options exist for inhibiting activated AKT
without causing an increase in other oncogenic pathways [10]. We
previously demonstrated an aberrant increase in pcPLA2α, which
increases AA generation [29], in hormone-refractory prostate cancer
[30]. Considering this and that the cPLA2α enzymatic product, AA,
promotes prostate cancer progression [31–34], we examined the
hypothesis that aberrantly-increased cPLA2α is required for sustain-
ing AKT signaling in PTEN-null/mutated prostate cancer cells (see
schematic: Fig. 6).
The role for cPLA2αwas ﬁrst assessed using a Dox-induced cPLA2α
over-expression system. Induced cPLA2α expression resulted in a
concomitant increase in pcPLA2α protein levels, enzymatic activity
and AA release, leading to an increase of pAKT and its immediate down-
stream effector, pGSK3β. An increase in cyclin D1 expression was also
observed, consistent with an inactivation of GSK3β by AKT phosphory-
lation [45]. In addition, pharmacological blockade of cPLA2α with
Eﬁpladib is able to attenuate the pAKT increase induced by cPLA2α
over-expression (data not shown). In contrast to over-expression of
cPLA2α, genetic silencing of cPLA2α led to a decrease in pAKT and
its downstream effectors in PC3 and LNCaP cells (Fig. 2). Both these
cell lines have constitutively activated AKT due to a PTEN deletion or
frame-shift mutation [39,46]. The role of cPLA2α in the regulation of
AKT phosphorylation became more apparent after EGF-stimulation.
These results support the hypothesis that cPLA2α is required for
sustaining AKT signaling in PTEN-null/mutated prostate cancer cells.An increase in an alternative oncogenic pathway has been shown
in various types of cancer cells when one oncogenic pathway is
blocked [10]. Hence, we examined the consequence of silencing
cPLA2α on key oncogenic proteins in the context of prostate cancer,
namely ERK 1/2 and the AR [47,48]. Previous studies have shown an
increase in pAKT together with a decrease in pERK 1/2 in poorly dif-
ferentiated prostate cancer [4,6,8]. One possible mechanism underly-
ing this inverse relationship is that AKT phosphorylates RAF at Ser259
that provides a binding site for the 14-3-3 protein [49], resulting in
down regulation of RAF activity [50]. Hence, we sought to determine
whether a decrease in pAKT signaling as a result of genetic silencing
of cPLA2α leads to an increase in pERK 1/2 levels. Our experiments
examining this possibility revealed no increase in pERK 1/2, and
instead, a decrease in pERK 1/2 was noted under EGF-stimulating con-
ditions in the PTEN-null/mutated PC3 and LNCaP cell lines (Fig. 3).
This effect occurred despite the fact that pAKT levels decrease after ge-
netic silencing of cPLA2α, with parallel decreases in the immediate
downstream targets, pGSK3β and cyclin D1 (Fig. 2). Hence, inhibition
of cPLA2α is able to abrogate both AKT and ERK 1/2 activation. Notably,
it is pERK 2 (42 kDa) relative to pERK 1 (44 kDa) that is mostly affected
by incubation with AA alone, or the combination of cPLA2α siRNA with
added AA. Considering p44 (ERK1) and p42 (ERK2) are phosphorylated
by MEK1 and MEK2, respectively [51], and MEK1 has been shown to
interact with A-Raf or C-Raf whereas MEK2 interact with C-Raf only
[52], our ﬁnding suggests that the role of cPLA2α in these pathways
may be mediated through C-Raf or MEK2.
The AR is crucial for proliferation and survival of prostate cancer
cells [11–14] and can promote G1–S phase progression via enhanced
translation of cyclin D1 [53]. Studies in animals bearing a humanprostate
cancer xenograft have suggested that an increase in AR alone is sufﬁcient
to enable cancer cells to progress to hormone-refractory status [14].
Thus, a change in AR levels via alterations in its synthesis and/or degra-
dation, can inﬂuence prostate cancer progression [14]. Herein, we
showed that silencing of cPLA2α with siRNA reduced AR protein levels
with no change in ARmRNA levels, suggesting post-transcriptional regu-
lation of AR by cPLA2α. Althoughwewere unable to identify any studies
in the literature examining the role cPLA2α in regulating AR expression,
the available evidence implicates AA in androgen and/or AR signaling. In
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1154 S. Hua et al. / Biochimica et Biophysica Acta 1831 (2013) 1146–1157fact, AA induces androgen synthesis [34], which is required for
AR stability [54] and inhibition of masculinization (a manifestation
of androgens) by estradiol-17β or cyproterone acetate can be
completely corrected by AA [55]. Furthermore, indomethacin(a non-selective COX inhibitor) blocks the corrective effect of AA
on masculinization [55], suggesting the involvement of eicosanoids
in mediating the AA effect. Given that AA can inﬂuence the AKT sig-
naling pathway as shown herein and that AKT can up-regulate AR
cPLA2
5-LOX 
Increase in cell proliferation 
A A 
5-HETE 
Membrane 
MK886 
si-cPLA2
/ Efipladib 
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GSK3
Cyclin D1 AR 
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Fig. 6. Schematic diagram of cPLA2α affecting AKT, ERK 1/2 and AR levels. The studies herein demonstrate using genetic approaches that the cPLA2α positively regulates pAKT, pERK
1/2 and AR levels via AA and its metabolite 5-HETE derived from the activity of 5-LOX (as conﬁrmed with the 5-LOX pharmacological inhibitor, MK886) in PTEN null/mutated
prostate cancer cells. Pharmacological inhibition of cPLA2α causes reduction in proliferation of PTEN null/mutated prostate cancer cells.
1155S. Hua et al. / Biochimica et Biophysica Acta 1831 (2013) 1146–1157protein levels [56,57], it can be suggested that the effect of AA on the
AR can also be via AKT.
Our investigation then examined the mechanism underlying the
effect of cPLA2α activity on pAKT, pERK 1/2 and AR levels. We rea-
soned that if the effect of genetic silencing of cPLA2α on the afore-
mentioned signaling pathways is mediated by a decrease in the pool
of available AA, replenishment of AA to cPLA2α siRNA-treated cells
should rescue the suppression of pAKT, pERK 1/2 and AR levels.
Consistent with this hypothesis, we demonstrated that incubation of
PC-3 and LNCaP cell lines with AA alone signiﬁcantly increased
pAKT, pERK 1/2 and AR levels. Importantly, supplementation of cells
with AA reversed the effect of cPLA2α siRNA on pAKT and to some
extent AR, while the rescue effect of AA on ERK 1/2 was less appar-
ent. Our working hypothesis is that the AA effect on AKT is more
direct compared with the effect on ERK1/2 and AR. We also noted
the effect of AA on pAKT is stronger in si-cPLA2α than si-control
PC3 cells, suggesting that AA treatment unleashes a stronger pAKT
response under the condition when cPLA2α is blocked. The reason is
unknown and further studies aimed at understanding this response
are planned.
We then examined which metabolite of AA was likely to mediate
its action. We have shown previously that blocking cPLA2α resulted
in reduced accumulation of 5-HETE [41]. To verify this ﬁnding, we
measured the (S)-HETE products in PC-3 and LNCaP cells incubated
with AA (Supplementary Fig. 2) and demonstrated a prominent
increase is 5-HETE, a product of 5-LOX enzymatic action on AA [24].
This outcome points to a role for 5-LOX products in mediating the
effect of AA on pAKT, pERK 1/2 and AR levels. Indeed, the stimulatory
effect of AA on pAKT, pERK 1/2 and AR is diminished in the presence
of the 5-LOX inhibitor, MK886, conﬁrming that 5-LOX products can
mediate the action of AA on AKT, ERK 1/2 and AR. Recently, AA has
been shown to up-regulate pAKT via a mTOR complex 2-dependent
and PI3K-independent mechanism in breast cancer cell lines [58].
Interestingly, this effect was blocked by LOX inhibitors [58]. As the
increase in 15-HETE after addition of AA is comparable to 5-HETE,
further study is needed to determine its role in mediating AA action
on pAKT, pERK 1/2 and AR levels. In addition, it remains to bedetermined if AA can also have a direct effect independent from
5-HETE on pATK, pERK 1/2 and AR levels.
Next, we determined the effect of the cPLA2α inhibitor, Eﬁpladib, on
AKT, ERK 1/2 and AR signaling pathways. Eﬁpladib is an indole deriva-
tive and is thought to be highly speciﬁc for cPLA2α [43]. It binds to the
single site of cPLA2α reversibly in a 1:1 stoichiometry [43,59]. Eﬁpladib
is currently under preclinical evaluation for non-cancer-related diseases
[43]. Previous studies have shown that Eﬁpladib speciﬁcally inhibits
cPLA2α enzyme activity at 5–20 μM [30,60,61]. Consistent with the
results obtained with cPLA2α siRNA, incubating PC-3 and LNCaP cells
with Eﬁpladib decreased pAKT levels. This inhibitor also reduced pERK
1/2 levels in PC-3 cells, but unexpectedly, increased pERK 2 in LNCaP
cells. We interpret our data to indicate that Eﬁpladib has trigged a
mechanism to compensate for the inhibition of AKT signaling by an
increase in p-ERK1/2 in LNCaP cells. This compensatory mechanism
may not be operating in PC-3 cells. Hence, it is likely that in addition
to cPLA2α, Eﬁpladib has additional off-target effects, which need to be
taken into consideration when further studies using Eﬁpladib are con-
templated. Notably, Eﬁpladib also decreased AR protein expression, as
well as PSA levels in culture medium. Considering the role AR plays in
prostate cancer cell proliferation and survival [15,16], it may explain
why AR-positive LNCaP cells are more sensitive to Eﬁpladib treatment
compared with AR-negative PC-3 cells (Fig. 5D). Further study is
needed to determine if long-term blockade of cPLA2α will lead to a
population with less dependence on cPLA2α. Considering the effect of
cPLA2α on AR expression, it would be interesting to compare the AR
expression in, and proliferation of, cells under long-term treatment
with Eﬁpladib versus those exposed to Eﬁpladib over a short-term.
In conclusion, in this investigation we showed that cPLA2α can
sustain AKT signaling under basal culture and/or EGF-stimulating
conditions in PTEN-null/mutated prostate cancer cells. A reduction
of pAKT levels by genetic silencing of cPLA2α caused a concomitant
decrease in pERK 1/2 and AR levels. The mechanism of cPLA2α action
on AKT, ERK 1/2 and AR was via AA and its metabolite, 5-HETE. Hence,
the inhibition of cPLA2α action could be considered as an option to
inhibit activated AKT in advanced prostate cancer. Our study further
supports the case for restricting dietary AA intake in patients with
1156 S. Hua et al. / Biochimica et Biophysica Acta 1831 (2013) 1146–1157diagnosed prostate cancer and utilizing agents blocking cPLA2α as a
novel therapy for this disease.
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